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The Nuclear Export of DNA Topoisomerase IIα as a
Function of Drug Resistance in Human Myeloma Cell Lines:
Clinical Implications and Mechanisms for Overcoming Drug Resistance
Roxane Engel
ABSTRACT
The focus of this investigation is about DNA topoisomerases, the molecular
targets of clinically important chemotherapy, and mechanisms of drug resistance in
human myeloma and leukemia cell lines. The ultimate goal of this investigation was to
identify mechanism(s) of drug resistance to anticancer agents so that a strategy to
overcome drug resistance could be conceived. We established an in vitro cell model by
using human leukemia and myeloma cell lines to investigate possible mechanisms of
drug resistance that are observed in confluent cells. Plateau cell densities demonstrated
de novo drug resistance to commonly used chemotherapeutic agents that was independent
of altered drug transport. We established that cellular drug resistance in these cells is a
function of topo IIα subcellular localization and further demonstrate that topo IIα
translocates to the cytoplasm in a cell-density dependent manner. We provide
experimental data that supports the nuclear export of topo IIα as the most likely event
contributing to drug resistance to topoisomerase II inhibitors, which occurs when
transformed cells transition from log to plateau cell density. We provided a plausible
nuclear export pathway for topo IIα, by identifying two
xiv

Leptomycin B sensitive nuclear export signals, which are homologous to the binding sites
recognized by the nuclear export receptor, exportin-1. Thus, topo IIα is likely to be
exported from the nucleus at plateau cell densities when exportin-1 binds topo IIα. We
confirmed that the nuclear export signals identified in topo IIα are functional when
expressed in human myeloma cells transfected with an epitope-tagged topo IIα gene.
Furthermore we demonstrate that the nuclear export signals can be abolished by sitedirected mutagenesis of specific amino acids residues found in the nuclear export signal.
Our data may have clinical relevance because plasma cells obtained from bone marrow
aspirates of patients with multiple myeloma contain a cytoplasmic distribution of topo
IIα. The potential implications of a functioning nuclear enzyme located in the cytoplasm
of cells and theoretical mechanisms for overcoming the observed drug resistance are
considered.

xv

Chapter One
Introduction

1.1 Cancer Trends and Statistics.
Cancer is the second leading cause of death in the United States, exceeded only
by heart disease (American Cancer Society, 2005). Increased life expectancy,
environmental factors, genetics, and socio-economic issues can all contribute to the
emergence of cancer around the world (Knudson, 2002; Doll, 1996). According to the
American Cancer Society (ACS), approximately 1,368,030 new cancer cases will have
been diagnosed in the year 2004 and 563,700 Americans are expected to have died of
cancer, more than 1500 people per day. The ACS anticipates the trend in further cancer
cases to continue for the year 2005. The National Institutes of Health also estimate that
medically related cancer costs will exceed the initial 2004 projection of 200 billion
dollars (National Institute of Health, 2005). Preventive measures have been insufficient
at reducing the incidence of cancer, thus driving numerous medical researchers to seek
new drugs and drug combinations for more effective cancer treatment. The sum of these
investigations has lead to the development of new treatment strategies, promising anticancer agents, and improved quality of life for many cancer patients. Consider, for
instance, the recent advancements in the clinical management of multiple myeloma, a
mostly incurable hematologic malignancy (Morgan and Davies, 2005; Rajkumar et al.,
1

2002). For example, the administration of melphalan plus prednisone has been the
conventional chemotherapy given for the treatment of multiple myeloma (Rajkuman et
al., 2002). The overall response rate with this regimen is approximately 50%, but the
complete response rate is less than 10% and the median survival is approximately 3 years
(Rajkumar et al., 2002). High-dose therapy followed by autologous stem cell
transplantation is a newer treatment strategy for multiple myeloma with improved
response rates. Response rates with this strategy exceed 75% to 90% and complete
response rates range from 20% to 40% (Rajkuman et al., 2002). Despite these
improvements however, multiple myeloma remains to be a mostly incurable plasma cell
malignancy with a median survival of 3-4 years (Terpos et al., 2005). Even when
conventional therapy or high-dose chemotherapy is administered with autologous stem
cell transplantation, myeloma patients continue to relapse (Rajkuman et al., 2002). These
findings can be attributed in large part to unresponsive or drug resistant cellular
phenotypes at the time of diagnosis or relapse (Yang et al., 2003). In these instances, a
detailed understanding of the mechanisms of drug action and a rationale for their
effective application is required before effective cancer therapy can be delivered. Thus,
medical and scientific investigators have combined efforts to analyze the molecular basis
of cellular drug resistance in the laboratory to improve clinical outcome, often referred to
as translational or “bench-to-bedside” medicine (Horousseau et al., 2004; Goessel, 2003;
Fishman and Sullivan, 2001). A group of enzymes that regulate DNA topology, called
DNA topoisomerases (topos), are at the center of many of the translational studies that
are addressing cellular drug resistance in hematological malignancies.

2

DNA topoisomerases are a key subject in cancer research because these proteins
are the molecular targets of some of the most commonly used chemotherapy agents in the
treatment of human cancers. Topo targeted agents have been used in the effective
treatment of leukemias, lymphomas, multiple myeloma, breast cancer, and other
malignancies. However, their clinical effectiveness is often limited by acquired (after
drug exposure) or intrinsic cellular drug (before drug exposure) resistance, especially in
the treatment of multiple myeloma (Valkov and Sullivan, 1997). Thus, researchers are
investigating acquired and intrinsic mechanisms of drug resistance at the molecular level,
to circumvent drug resistance observed in myeloma patients.
The focus of this investigation is about DNA topoisomerases, their roles as
molecular targets of chemotherapy, and mechanisms of cellular drug resistance to
topoisomerase targeting agents. The ultimate goal of this investigation was to identify
mechanism(s) of drug resistance so that a strategy to overcome drug resistance could be
conceived. We established an in vitro cell model that demonstrated de novo drug
resistance to commonly used chemotherapeutic agents. We determined that the observed
drug resistance was specific to topoisomerase targeting agents. We provide experimental
data that supports the nuclear export of topo IIα as the most likely event contributing to
drug resistance in our cell model. We established a plausible nuclear export pathway for
topo IIα by identifying two Leptomycin B sensitive nuclear export signals, and then
demonstrate that these signals are functional in human myeloma cells transfected with a
FLAG tagged topo IIα gene. Hematological cell lines are used throughout this discussion
as a cell model for elucidating the role that topoisomerases impart on intrinsic cellular
drug resistance to anti-cancer agents.
3

1.2 Discussion Points.
To appreciate the mechanisms of cellular drug resistance to topo targeting
cytotoxic agents, several concepts are reviewed. First, the fundamental concepts for the
molecular basis of cancer pathogenesis are covered in chapter two followed by a review
of human DNA topoisomerases, including but not limited to, their structure, function, and
mechanisms of catalysis. Chapters four and five depicts the physical biochemistry of
commonly used anti-cancer agents with particular attention to cytotoxic agents that target
DNA topoisomerase I and II. These chapters detail how specific anti-cancer agents exert
their cytotoxic effects, a subject that is necessary to realize how cells evade drug
cytotoxicity. Chapters six and seven cover our current understanding of in vitro and in
vivo mechanisms of de novo cellular drug resistance related to multiple myeloma. These
chapters illustrate many of the challenges that clinicians must overcome for therapy to
become more effective. The mechanisms of nuclear-cytoplasmic transport of proteins are
discussed in chapter eight because the subcellular distribution of proteins between the
nuclear and cytoplasmic compartments has recently been established as another
mechanism of regulating protein function. Finally, the nuclear-cytoplasmic transport of
topo is revealed as a novel mechanism of cellular drug resistance in human myeloma cell
lines in chapters eleven through thirteen. The significance of these findings in the
clinical environment is assessed and future projections are deliberated.
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Chapter Two
Molecular Basis of Cancer Pathogenesis

2.1 What is Cancer?
Cancer is not a single disease but rather a group of diseases characterized by the
proliferation of cells that bypass regulatory checkpoints of the cell-cycle and/or escape
induction of apoptosis (reviewed in Bocchetta and Carbone, 2004; Bertram, 2000). In
general, the proteins responsible for maintaining DNA and the cell cycle can be divided
into six categories that include: (1) cytokines/growth factors; (2) growth factor receptors;
(3) intracellular signaling molecules; (4) transcription factors; (5) cell-cycle/apoptotic
regulatory proteins; and (6) proteins that regulate DNA topology and metabolism (i.e.,
DNA topoisomerases). There is a high degree of cross-talk between proteins of the same
class and between different classes of proteins, resulting in a network of highly
synchronized events often referred to as a signal transduction cascade. Malignant cells
usually acquire DNA mutations in one or more of these cell cycle or DNA regulatory
proteins, which gives them growth or proliferative advantages over other cells. Since
proteins function as part of a coordinated network with other proteins, even a single gene
mutation can result in the propagation of additional gene mutations (i.e., if a gene
mutation occurs in a DNA repair protein) or proliferative advantages (i.e., if a gene
mutation occurs in a growth factor receptor). These genetic advantages disrupt the
5

balance between cell proliferation and cell death. For example, the retinoblastoma
protein (pRb) is encoded by the RB tumor suppressor gene and regulates the cell cycle by
arresting DNA replication when DNA damage is present (Sellers, 1997). Mutations in
the RB gene occur in 30 to 40% of all human cancers, thus permitting cells with DNA
damage to divide endlessly (Merck, 2004). In addition to genetic mutations, tumor cells
can also influence their microenvironment to favor their survival. For example, tumor
cells secrete or promote the secretion of cytokines and growth factors to stimulate
angiogenesis (Sivridis et al., 2003). The new blood vessels supply nutrients and
additional cytokines that continue to activate cell signaling pathways that further tumor
sustenance. To better illustrate some of the points described above, let us take a closer
look at one type of cancer, multiple myeloma.

2.2 Cancer Biology of Multiple Myeloma:
Multiple myeloma is a type of B-cell neoplasm characterized by the slow
proliferation of well-differentiated plasma cells in the bone marrow (Bhawna, 2003; Ho
et al., 2002). Although mature plasma cells are the predominant type of cell found in
multiple myeloma, pre-B, myeloid and T-cells are coexpressed with the mature plasma
cell (Barlogie, 1989). The population of malignant cells is collectively referred to as
myeloma cells.
Multiple myeloma tumor progression is a multistep process that can be described
to occur in three distinct phases: immortalization, unchecked cell proliferation, and
dissemination of the malignant plasma cells (Pratt, 2002; Shain et al., 2000). The disease
may first present as a monoclonal gammopathy of undetermined significance (MGUS), a
6

clinical term used to describe a single plasma cell that has formed a limited number of
clones (Tricot, 2002; Dalton et al., 2001). The precise cellular origin is not well
understood, but is believed to be an immature B-cell that has been repeatedly exposed to
antigen in the germinal centers of the lymphoid tissue. The disease advances when the
transformed cells clonally expand and grow in the bone marrow (intramedullary
myeloma) (Van Riet et al., 1998). During this time, the disease is usually chemosensitive
and may enter a dormant phase (Pratt, 2002). The myeloma cells receive growth and
anti-apoptotic signals that facilitate their survival through interactions with the bone
marrow microenvironment (Dalton, 2003; Shain, et al., 2000). For example, expression
of the adhesion receptors, very late antigen-4 (VLA-4) and very late antigen-5 (VLA-5)
(Hata et al., 1993), permits myeloma cells to bind fibronectin, whereas the expression of
the β2 integrin lymphocyte function associated antigen-1 allows for cell-cell aggregation
(Asosingh et al., 2003; Kawano et al., 1991). Such interactions stimulate the secretion of
various cytokines from myeloma and stromal cells in the bone marrow microenvironment
(Klein et al., 2003). IL-6, the main plasma cell activating factor, stimulates cell
proliferation via the Ras/Mitogen-activated kinase (Ras/MAPK) signaling cascade
(Kawano et al., 1988; Ogata et al., 1997). IL-6 also induces myeloma cell migration and
angiogenesis via vascular epithelial growth factor (VEGF) induction (Dankbar et al.,
2000). Advanced disease is distinguished by independence from growth factors in the
bone marrow microenvironment and proliferation to extramedullary sites (extramedullary
myeloma) (Pratt, 2002). Throughout this time, advanced myeloma is characterized by
resistance to apoptosis and chemotoxic agents (Dalton, 2003). Understanding the bone
marrow microenvironment in multiple myeloma disease pathogenesis has had a role in
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the development of new cytotoxic agents. For example, bortezomib is the first
proteasome inhibitor to be evaluated in clinical trials for the treatment of hematological
malignancies (Adams, 2004; Adams and Kauffman, 2004).

2.3 Conclusions.
In summary, cancer is a multifaceted disease that is propagated by multiple DNA
mutations that are acquired via hereditary and natural means. The gene mutations can
result in altered cellular homeostasis and confer growth and proliferative advantages. In
turn, the collection of proteins that are involved in regulating the cell cycle and DNA
replication/topology are the frequent targets of anti-cancer drugs (Damiens, 2000). Thus,
understanding the proteins involved in the intracellular cell signaling pathways, DNA
replication/topology, and cell cycle regulation are the cornerstones of cancer research.
The focus of this investigation is about DNA topoisomerases, enzymes that
regulate DNA topology. We focus on the role of DNA topoisomerases as molecular
targets of anti-cancer agents and mechanisms of drug resistance. Although the complete
family of human DNA topoisomerases is reviewed, the focus of this work centers around
type II enzymes, topo IIα and topo IIβ, the current targets of cancer chemotherapy.
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Chapter Three
Biochemistry of DNA Topoisomerases

3.1 General Introduction to the DNA Topoisomerase Family of Enzymes.
The human genome consists of approximately 3.2 billion base pairs and would be
about 2 meters in length, if stretched out from end to end (Porter et al., 2004).
Nevertheless, DNA squeezes into the nucleus, which is approximately 6 µM in diameter
(Porter et al., 2004). For example, the smallest human chromosome is 14 mm long but is
compacted to just 2 µM in length (Ball, 2003; Greeley, 1978). Thus, DNA exists in a
tightly compacted and dense form. Conversely, DNA must also allow itself to become
accessible to numerous transcription factors and regulatory proteins to allow gene
transcription and DNA replication to occur (Khorasanizadeh, 2004). The ability of DNA
strands to separate and/or unwind, however, is limited by the torsional constraints of a
double helix. DNA topoisomerases are a family of nuclear enzymes that regulate the
topological state and relieve the torsional stress of the DNA that arise during gene
transcription, DNA replication, and cell division (Champoux, 2001; Wang, 1996). DNA
can become tangled into knots, supercoiled, and form interlocked circles that must be
resolved by topo action (Figure 1) (Pulleyblank, 1997). To regulate DNA topology, all
topo enzymes introduce single- or double strand breaks in DNA to allow another strand
of DNA or duplex DNA to pass through the newly generated gap (Champoux, 2001).
Topo activity has been shown to be important during DNA replication, transcription,
9

genetic recombination, sister chromatid segregation, and chromosome condensation and
decondensation. For example, the human type I and II topoisomerases relax positive
supercoils that are generated in front of the moving replication fork. This is significant
because RNA polymerase generates tension in the DNA that must be relieved for gene
transcription to occur. Topo II also has an essential role in the proper execution of DNA
replication and cell division. Newly synthesized DNA strands must be completely
unlinked from the parent strand and every replicated chromosome must be disentangled
from each other to allow proper segregation of the chromosomes into daughter cells.

a. Supercoiled

b. Knotted

c. Catenated DNA

Figure 1. Topological Configurations in DNA that are Resolved by Topo. (a)
Twisting of DNA about its axis results in either positive or negatively supercoiled
DNA, (b) DNA knots, and (c) catenated DNA is when two or more circles of
DNA interlock. Although the family of topoisomerase enzymes are required for
DNA replication, recombination, transcription and chromosome segregation, each
type of enzyme makes different contributions to each process. For example,
human topo I and II are able to relax supercoiled DNA, but only topo II is
proficient knotting/unknotting and catenation/decatenation reactions. This figure
was reproduced from reference Pulleyblank, 1997.

"Molecular Houdini's" and enzymes with a "double-edged sword" are two terms
that are used to describe DNA topoisomerases because the integrity of DNA is
susceptible to topo cleavage activity (Osheroff, 1998; Anderson and Berger, 1994). To
ensure the integrity of DNA, all DNA breaks generated by topo are accompanied by the
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formation of a covalent phosphotyrosine bond that tethers topo to the broken strand of
DNA while DNA strand passage occurs (Tse et al., 1980). The covalent topo-DNA
intermediate, called a "cleavage complex" or a "cleavable complex", is transient and
freely reversible (Roca and Wang, 1992). Some anticancer agents exploit the DNA
cleavage activity of topo to turn these enzymes into molecular toxins (Nitiss and Wang,
1996). Thus, there has been considerable interest in topo because they have become the
molecular targets of some clinically important anticancer agents.
In summary, DNA topoisomerase enzyme activity is essential for maintaining the
topology of DNA during many DNA processes, including DNA replication, transcription,
and chromosome segregation. DNA topoisomerases have also emerged as important
molecular targets of anti-cancer agents, especially in hematological malignancies (Wang,
1987; Zijlstra et al., 1990). The next topic to be covered describes the nomenclature and
classification system for the family of DNA topoisomerases. This will be followed by a
complete description of each type of human topoisomerases.

3.2 Classification of Mammalian DNA Topoisomerase.
To date, six different DNA topoisomerases have been identified in humans and
mice (referred to as topo I, topo II, and topo III, etc) and are classified as either type I or
II enzymes (Champoux, 2001; Wang, 1996). The human type I, type II, and type III topo
enzymes have been distinguished by differences in their gene locus, molecular weights,
catalytic requirements, mechanism of catalysis, and biological roles (table 1) (Champoux,
2001; Wang, 1996). Type I enzymes include topo III, topo I, and mitochondrial DNA
topo I (topo Imt). All type I enzymes are active as monomers and catalyze transient
11

single strand DNA breaks without ATP. The type I enzymes can be further distinguished
as IA or IB enzymes based on more specific differences in their reaction mechanisms.
For example, the type IA enzymes covalently bind to the 5’-end of the cleaved DNA
strand while type IB enzymes bind to the 3’-end of the cleaved DNA strand.
In contrast to type I enzymes, type II enzymes form dimers and couple doublestrand DNA breaks with ATP hydrolysis. Type II enzymes have two known isoforms
referred to as topo IIα and topo IIβ. Several monoclonal and polyclonal antibodies have
been used to detect the different enzymes by Western blot and immunohistochemistry.
Monoclonal antibodies are available for human topo I (Beidler and Cheng, 1995),
whereas several monoclonal (Kellner et al., 1997; Negri et al., 1993) and polyclonal
antibodies are available for human topo IIα (Sullivan et al., 1993) and topo IIβ (Austin et
al., 1995). One monoclonal antibody has been used to detect topo IIIα expression by
immunohistochemistry (Lodge, 2000).
A review covering human type I and type II enzymes ensues. The type I enzymes
(i.e., topo Imt, topo I, and topo III) are discussed first, followed by a discussion of the
type II enzymes (topo IIα and topo IIβ). The type II enzymes are the focus of the work
presented here and thus, are discussed in greater detail than the type I enzymes.
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Table 1. Characteristics of Human DNA Topoisomerases I, II, and III*
Topo I
Topo Imt**
IB
IB
Type
20q12-13.2
8q24.3
Chromosome
Molecular Weight
91
60-70
(kDa)
4.2
nda
mRNA (kb)
DNA strand
single
nda
cleavage
Covalent
3'
nda
Intermediate
no
no
ATP dependence
Cell cycle
no
nda
dependence
Knockout mouse

early embryonic lethal

nda

Active site

Tyr-723

predicted
Tyr-559

Location

nucleolus
nucleoplasm

mitochondria

b

Intracellular
Targeting Signal(s)

Inhibitors

1. basic NLS
c
2. acidic NLS
c
3. nucleolar
topotecan, karenitecin,
9-nitrocamptothecin,
camptothecin, CPT-11

1. mitochondrial*

CPT sensitive;
potential molecular
target

Topo IIα
IIA
17q21-22

Topo IIβ
IIA
3q24

Topo IIIα
IA
17p11.2-12

Topo IIIβ
IA
22q11

170

180

~110

~96

6.2

6.5

4.0-7.2

2.8-3.8

double

double

single

single

5'

5'

5'

5'

yes

yes

no

no

no

nda

nda

yes, maximal in G2/M
presumed lethal
Tyr-805

perinatal death

early embryonic lethal

Tyr-821

isoform I:
nucleoplasmee

d

nucleus
d
mitochondria

nucleoplasm
nuclear matrix

nucleoplasm
nucleolus

1. bipartite NLSf
2. LMB sensitive NESg
(in vitro/in vivo)

1. bipartite NLS
h
2. LMB sensitive NES ,
(in vitro, only)

f

VP-16, VM-26, mitoxantrone, m-AMSA, doxorubicin,
merbarone, daunomycin, ICRF-193, ICRF-187, ICRF159, and XK469 (beta specific)
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predicted
Tyr-337

shortened mean life
span
predicted
Tyr-336

isoform II:
cytoplasmee
d

1. mitochondrial ,
(in vitro/in vivo)

nda

potential molecular
target

potential molecular
target

3.3 Type IB: Human Mitochondrial DNA Topoisomerase I (Topo Imt).
There are approximately 1000 mitochondria in every mammalian cell (Zhang et
al., 2004a). Each human mitochondrion contains 5-10 copies of closed circular
mitochondrial DNA (mtDNA) that has16, 569 base pairs (Moraes, 2001; Anderson, 1981;
Bibb, 1981). Human mtDNA encodes 22 tRNAs, 13mRNAs, 12S and 16S rRNA
(Anderson, 1981). DNA topo enzyme activity resolves the topological constraints of
DNA within the mitochondria (Wang et al., 2002). The human TOP1mt gene is located
on chromosome 8q24.3 and encodes for a 601 amino acid polypeptide that is highly
homologous to DNA topo I (Zhang et al., 2001). The protein was identified as
mitochondrial DNA topo I (topo Imt) because it contains a mitochondrial targeting
sequence and lacks a nuclear localization signal (Zhang et al., 2001). Topo Imt also has
different biochemical properties from those of the nuclear enzyme, DNA topo I (Zhang et
al, 2001). A MegaBlast search of all National Library of Medicine databases was
conducted and indicated that only vertebrates contain both mitochondrial and nuclear
topo I gene (Zhang et al., 2004a). These results raise the question of how non-vertebrates
perform mitochondrial DNA metabolic functions. It is possible that one gene encodes
two polypeptides that are targeted either to the nucleus or to the mitochondria (Zhange et
al., 2004a). Current investigations are underway to elucidate gene mutations in
mitochondrial topo I that could potentiate human disease. Thus, topo Imt could evolve as
a new molecular target in the future. Unless otherwise noted, this discussion will focus
on nuclear DNA topo I, the current molecular target of anticancer drugs.
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3.4 Type IB: Human DNA Topoisomerase I (Topo I).
Eukaryotic topo I was first described in mammalian cells in 1972 (Champoux and
Dulbecco, 1972). Although topo I gene knockouts are lethal in mouse models, yeast topo
I gene knockouts are viable (Champoux, 2001). The gene for human DNA topo I was
cloned in 1988 and the complete amino acid sequence of topo I protein is shown in
Appendix A on page 270 of this manuscript (Juan et al., 1988). The structure topo I
includes four functional domains (Figure 2): a highly charged N-terminal domain, a
conserved core domain and an essential C-terminal domain (Redinbo et al., 1999; Stewart
et al, 1996). The C-terminal domain contains the active site tyrosine residue (Tyr723)
(Eng et al., 1989) and is essential for DNA binding and relaxation in vitro, whereas the

N-terminal
domain

1

Linker
domain

Core domain

215

636

C-terminal
domain

713

765
COOH

H2N

Poorly conserved
Highly charged
Protease sensitive
Nuclear Targeting

Highly conserved
DNA binding
Enzyme activity

Poorly conserved
Dispensable in vitro

Conserved
Active site Tyr-723

Figure 2. Structural Domains of Human DNA Topoisomerase I. Topo I has four
domains: an N-terminal domain ( ) (amino acids 1-215), a core domain ( ) (amino
acids 215-636), a linker domain ( ) (amino acids 636-713), and a C-terminal domain
( ) (amino acids 713-765). The most significant properties are described below each
domain. Figure reproduced from reference (Champoux, 2001).

amino terminal region may have an important role in regulating the cellular localization
of topo I because it contains the nuclear localization signal (NLS) and nucleolin binding
site. Amino acids 150-156 have been shown to be sufficient for nuclear localization
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(D’Arpa et al, 1988), but a second NLS has been identified within amino acids 117-146
(Mo et al., 2000). Topo I shows a stable expression throughout the cell cycle (Heck et
al., 1988). Topo I is post-translationally modified by phosphorylation (D’Arpa and Liu,
1995) and ubiquitination (Desai et al., 1997), which may be important for regulating its
activity, localization or degradation. Topo I has an important role in transcription, rRNA
synthesis, DNA replication and transcription initiation and is the specific target for
camptothecin (CPT) and its derivatives (topotecan and CPT-11) (D’Arpa, 1990).
DNA topo I catalyzes transient single strand DNA breaks to relax DNA supercoils
(reviewed in Wang, 2002). Topo I is capable of relaxing both negatively and positively
supercoiled DNA without the presence of a cofactor, but metal cations such as Mg2+
stimulate topo I activity (Liu and Miller, 1981). Figure 3 illustrates the catalytic cycle of
topo I. To cleave DNA, topo I catalyzes the transesterfication of the active site tyrosine
(Tyr-723) to form a 3'-phosphotyrosine covalent enzyme DNA intermediate (D'Arpa et
al., 1988). The 3'-phosphotyrosine bond is formed when the O-4 oxygen of tyrosine at
position 723 (Tyr723) completes a nucleophilic attack on the scissile phosphate in the
DNA backbone (D'Arpa e al., 1988). The formation of the 3'-phosphotryosine bond is
significant because it forms a "proteinaceous" bridge between topo I and DNA, and thus
ensures the integrity of DNA. The covalent topo-DNA intermediate is also referred to as
a "cleavage complex" (Pommier, 2003) or "cleavable complex" (Tewey et al., 1984).

16

17

After DNA unwinding, the reaction reverses when the 5' OH of the cleaved DNA strand
reattacks the phosphotyrosine residue in a secondtransesterfication reaction. Under
normal cellular conditions, topo I cleavage complexes are transient and usually
undetectable. The steady-state concentration of the covalent 3' phosphotyrosine
intermediate is kept low because the rate of DNA religation is faster than the rate of
cleavage (Pommier et al., 2003). However, topo I cleavage complexes are also produced
by other endogenous and exogenous factors, such as UV-induced base modifications,
DNA oxidation by oxygen free radicals, mismatch repair deficiencies, DNA alkylating
agents, and some anticancer agents (Pommier., 2003; Pourquier and Pommier, 2001).
Such topo I cleavage complexes can result in DNA damage and cell death, if left
unrepaired. The objective of some cancer chemotherapy, however, is to capture topo I
cleavage complexes by administering a drug (ie, a DNA topo I inhibitor) that traps topo I
on DNA in a cleaved form (Nitiss and Wang, 1996).

3.5 Type IA: DNA Topoisomerase III.
The gene for eukaryotic DNA topo III was discovered in 1989 (Wallish et al.,
1989) and later identified in humans on chromosome 17p11.2-12 (Hanai et al., 1996).
There are two topo III homologues that are expressed in mammalian cells, topo IIIα and
topo IIIβ, and each of these has isoforms generated by alternative mRNA splicing (Seki
et al., 1998). Human topo IIIα has a putative mitochondrial targeting sequence and
localizes to both the nucleolus and mitochondria (Wang et al, 2002). In contrast, human
DNA topo IIIβ is found only in the nucleus (Kobayashi and Hanai, 2001). Both topo IIIα
and IIIβ can relax negatively supercoiled DNA, but the biological functions of the
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different topo III enzymes have not been determined (Goulaouic et al., 1999). Yeast
studies demonstrate that Top3 gene mutants grow very slowly, display
hyperrecombination and have defects in meiotic recombination (Gangloff et al., 1999).
Furthermore, targeted disruption of the mouse topo IIIα gene shows that topo IIIα
expression is essential in early embryogenesis (Li and Wang, 1998). Topo III gene
expression occurs in multiple somatic tissues and is differentially regulated during
different developmental stages, which is associated with binding of the upstream
stimulatory factor-2 (USF-2) to an E-box element located in the topo III gene promoter
(Han et al., 2001). The YY1 transcription factor may also have a role as a cell type
specific topo III transcriptional activator (Park et al., 2001).
Both topo IIIα and IIIβ interact with the RecQ/SGS1 family of DNA helicases,
which has been shown to occur in yeast and Escherichia coli (Kim et al., 1998). It has
been suggested that RecQ helicases may function to recruit two molecules of topo III to
DNA structures during genetic recombination to facilitate the cleavage and passage of
double strand DNA (Park et al., 2001). Human topo IIIα is shown to associate with the
Bloom syndrome protein (BLM), another member of the RecQ family of DNA helicases,
in somatic and meiotic human cells (Shimamoto et al., 2000). A mutation in the BLM
gene is associated with Bloom’s syndrome, a rare genetic disorder that is associated with
hyperrecombination between sister chromatids and increased propensity for cancer (Ellis
et al., 1995). An association of human topo IIIα with BLM could be significant in
regulating the frequency and fidelity of recombination events by either disrupting nascent
joint molecules or by regulating the migration of Holiday structures (Harmon et al, 1999).
Thus, topo III may have a role as a tumor suppressor gene, but additional investigations
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are necessary to further elucidate its role in recombination and suppression of cancer.
Furthermore, defining the physiological roles of topo III enzymes could lead to the
development of new anti-cancer agents that specifically target these enzymes.

3.6 Conclusions to Topoisomerase I.
In summary, type I enzymes cleave single strand DNA in an ATP independent
manner. Topo Imt and topo III are two of the most recent type I enzymes to be identified
in humans and these enzymes could be the future molecular targets of anti-cancer drugs.
However, topo I is the current molecular target of chemotherapeutic agents. In chapter 4,
we will learn more about how drugs, called camptothecins, target topo I and exert their
cytotoxic effects in cancer cells. Before that, however, a discussion of the type II
enzymes must be covered because these too are the molecular targets of commonly used
anti-cancer agents.

3.7 General Introduction to the Type II Enzymes.
In the preceding section, we reviewed the type I topoisomerases that are
expressed in humans. Now, we will turn our attention to topo II, a type II enzyme. In
humans, topo II has two isoforms, topo IIα and topo IIβ that share many similar
properties. Although many difference in structure, tissue distribution, and gene
expression have been described for topo IIα and topo IIβ , differences in their functional
roles, drug action, and relative contributions to cancer chemotherapy are less clear
(Austin and Marsh, 1998). Topo IIα has been the most extensively investigated isoform,
whereas the role of topo IIβ is drug resistance is not well understood (Beck et al., 1999).
20

Immediately following in section 3.8, is a description of common principles and
biochemical properties that are generally applied to both topo IIα and topo IIβ. Then, in
section 3.9, the features that distinguish the two isoforms are given.

3.8 Type IIA: Similarities between Topo IIα and Topo IIβ.
The type II enzyme, called DNA gyrase, was isolated from Escherichia coli and
was the first type II topoisomerase to be characterized (Gellert et al., 1976). Bacterial
DNA gyrase is unique because it can introduce negative supercoils in DNA or convert
positive supercoils into negative supercoils (Wang, 1996). DNA gyrase is the target for
clinically important quinolone antimicrobial agents, such as Ciproflaxin (Hooper et al.,
1993). However, DNA gyrase should not be confused with mammalian topo II enzymes,
the current molecular targets of anticancer agents.
In contrast to bacterial DNA gyrase, eukaryotic topo II is unable to generate
supercoils in vitro (Liu et al., 1983). Topo II activity is required to separate replicated
chromosomes prior to cell division, and unlike topo I and topo III, is able to decatenate
intertwined double strand DNA molecules (Marini et al., 1980). All type II
topoisomerases form dimers (Champoux, 2001) and each topo II monomer can be
divided into three domains (Jensen et al., 1996), an N-terminal domain that contains the
ATP-binding region (Bjerbaek et al., 2000; Gardiner et al., 1998), the central domain
containing the active site tyrosine residue (Okada et al., 2000) and the C-terminal domain
that contains the nuclear localization sequences (Figure 4) (Mirski et al., 1997, 1999).
The C-terminal domain has also been shown to be important for interactions with other
proteins (Messenger et al., 2002; Kroll, 1997).
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A. Topo IIα
H2N

ATPase

B. Topo IIβ
H2N

ATPase

Active site

DNA Binding

Active site

DNA Binding

NES NLS

Carboxyl
terminus
NES

COOH
NLS

Carboxyl
terminus

COOH

Figure 4. Structural Domains Shared by DNA Topo IIα (shown in A) and topo IIβ
(shown in B). Topo IIα and topo IIβ have three domains as shown. The ATPase
domain (white box) is at the amino terminus and contains the ATP binding site. The
DNA domain (grey box) contains the active site Tyr residues and the carboxyl
terminus (dark grey box) is important for intracellular localization because it
contains the nuclear localization(NLS) and nuclear export signals (NES).

All topo II enzymes share common mechanisms for DNA-cleavage and religation
reactions (Champoux, 2001; Wang, 1996). A description of the catalytic cycle of topo II
is important in understanding how drugs target topo II. The catalytic cycle of topo II
involves several distinct stages including: DNA binding, strand cleavage, strand passage,
religation, and enzyme turnover (Figure 5) (Champoux, 2001; Wang, 1996). Topo II
dimers first bind to double strand DNA, and then each monomer cleaves opposite DNA
strands to generate a 4-base stagger. Topo II mediated DNA breaks occur through.
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1

ATP
2

6

ADP + Pi

Mg2+
3

5

4

Cleavable complex

Cleavable complex

Figure 5.Catalytic Mechanism of DNA Topo II. The "two-gate model" of topo II catalysis is
shown. According to this model, topo II has two lobes called A' (colored red) and B' (colored
blue). The DNA strand that is cleaved is called the "gate DNA" or "G-segment". The DNA
strand that is transported is called the "transport DNA" or "T-segment". (1) Topo II binds gate
DNA (orange rod) and undergoes conformational changes. (2) Topo binds ATP (yellow star) and
the transport DNA molecule (green rod). (3) The ATPase domains on topo II dimerize and topo
II cleaves the gate DNA. The presence of a metal cation is required. (4) The transport DNA is
transported through the break and into the central cavity of the B' lobe. Gate DNA is held within
the A' lobe. (5) Following DNA strand passage the transport DNA is released from the enzyme
through a gate formed in the B' lobe. The gate DNA is resealed. (6) ATP is hydrolyzed and
ADP and inorganic phosphate (Pi) are released to complete enzyme turnover. This figure was
reproduced from references Champoux, 2001 and Wang, 1996.
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transesterfication reactions, in which a DNA phosphoester bond is transferred to the
active site tyrosine residue in each monomer. Thus, each monomer remains covalently
attached to the 5' end of DNA through a phosphotyrosine bond. A conformational
change in the enzyme pulls the cleaved DNA duplex apart to create an opening that is
called, "the gated or G-segment DNA". Strand passage occurs either from the same DNA
molecule (relaxation, knotting, or unknotting) or different molecules
(catenation/decatenation). The DNA segment that is passed through the opening is called
the "transported or T-segment DNA". Enzyme turnover requires ATP hydrolysis and
divalent cations (Mg2+) (Osheroff, 1987). The mechanism of topo II enzyme catalysis is
an important concept for understanding how topo poisons and catalytic inhibitors target
topo II.
Topo II can also catenate/decatenate interlocked circles of DNA (Champoux,
2001). Topo II decatenation activity is essential at the end of DNA replication for the
proper separation of daughter chromosomes. Cells lacking topo II are unable to
decatenate sister chromatids or carry out chromosome condensation reactions prior to
mitosis, which results in non-disjunction and chromosome breakage (Holm et al., 1989).
Topo II catalytic activity is measured in vitro by the decatenation of kinetoplast DNA
(kDNA) isolated from the mitochondria of Crithidia fasiculata. kDNA consists of
numerous interlocked minicircles and maxicircles. Unlike the type I enzymes, topo II is
able to decatenate the interlocked circles to generate free mini- and maxi- circles that can
be separated from the network of kDNA by centrifugation (Sahai and Kaplan, 1986;
Marini et al., 1980). Thus, the ability to decatenate kDNA is an important distinction
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between topo I and topo II enzymes because it allows us to estimate topo II enzyme
activity independent of topo I activity in vitro.

3.9 Differences between DNA Topoisomerase IIα and Topo IIβ.
Topo II has two isozymes, topo IIα and topo IIβ, with different molecular masses
and gene loci (Lang et al., 1998; Drake et al., 1987) (Table 1, page 13). The presence of
two different gene loci suggests that these isoforms may be differentially regulated at the
level of transcription. The tissue distribution of topo IIα and topo IIβ mRNA and protein
have been determined in mouse, rat, and humans (Bauman et al., 1997). Topo IIα mRNA
is highest in many proliferating cells such as thymus, spleen, bone marrow, intestine, and
testis. Topo IIβ mRNA is detectable in a wider range of tissue types; including those
with few proliferating cells (Carpanico et al., 1992). Topo IIβ is 90 amino acids longer
than topo IIα and the two isoforms are 68% homologous in amino acids (Austin and
Marsh et al., 1998). The greatest variability in amino acids between topo II α and IIβ
occurs in the C-terminal domain, and thus the C-terminus may impart specific differences
in the functional roles of these isozymes.
Topo IIα is expressed in a cell cycle dependent manner with peaks in the S-phase
and G2/M-phase of the cell cycle and is the target of ubiquitin-mediated proteolysis
(Meyer et al., 1997; Nakajima et al., 1996). Topo IIβ protein expression is more uniform
throughout the cell cycle, suggesting that it may have a role as a "housekeeping gene"
(Drake et al., 1989). Topo IIα is also highly expressed in many rapidly proliferating
human tumors (Holden et al, 1990, Turley, et al, 1997), thus making topo IIα a frequent
molecular target of anti-cancer drugs. In contrast, topo IIβ expression is constant
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throughout the cell cycle with limited fluctuations in the amount or stability of the protein
in either highly replicating or non-replicating cells (Woessner, 1991). Topo IIβ is
emerging as a new molecular target in tumors that are refractory to cytotoxic agents that
target topo IIα (Gatto and Leo, 2003).
Both topo IIα and topo IIβ are differentially phosphorylated throughout the cell
cycle with maximal phosphorylation occurring at G2/M phase (Burden et al, 1993;
Burden and Sullivan, 1994). Thus, maximum topo II phosphorylation correlates with
chromosome condensation and segregation. As cells transition from M phase to G1 phase
of the cell cycle, 75% of topo IIβ becomes dephosphorylated, whereas 25% of topo IIα is
dephosphorylated (Wells and Hickson, 1995; Burden and Sullivan, 1994)
The kinases known to phosphorylate topo IIα in vitro include protein kinase C (PKC)
(Wells et al., 1995), casein kinase 2 (CK2) (Ishida et al., 1996; Alghisi et al., 1994), and a
proline directed kinase (Wells and Hickson, 1995). The phosphorylation of precise
amino acid residues by specific kinases have not been mapped in topo IIβ.
The expression of the different topo II isoforms seems to be necessary to fulfill
distinct physiological roles, but what those roles are remains unclear (Wang, 1991;
Wang, 2002). Both enzymes are able to unknot DNA, relax supercoiled plasmid DNA,
and catalyze ATP-dependent DNA strand passage activity in vitro (Austin and Marsh,
1998). Topo IIα has a significant role in cell proliferation, whereas topo IIβ is suggested
to have a role in cell differentiation (Aoyama et al., 1998). Topo IIα has an essential role
in chromosome condensation and segregation during mitosis (Uemura et al., 1987).
Recent findings, however, suggest that topo IIβ is able to substitute for topo IIα in
chromosome condensation and segregation, but that topo IIα has a crucial role in
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shortening of chromosome axes (Sakaguchi and Kikuchi, 2004). Distinguishing the
physiological roles of topo IIα from those of topo IIβ could lead to a better understanding
of the molecular mechanisms conferring differences in drug sensitivity. A transgenic cell
line lacking topo IIβ was recently established and may lead to a better understanding of
the differential roles between topo IIα and IIβ (Errington et al., 1999). To date, there are
no established cell lines that lack topo IIα.
I searched PubMedCentral, the U.S. National Institutes of Health free digital
archive of biomedical and life sciences journal literature, and identified several proteins
that have been reported to interact with topo IIα in vitro and/or in vivo (PubMedCentral,
2005). I have included a brief description of the protein partners that interact with topo
IIα and speculated on the potential implication(s) of such protein-protein interactions in
conferring drug resistance. The protein partners that associate with topo IIα spans a
variety of protein classes with roles in various cellular processes, including chromatin
remodeling, apoptosis, mRNA splicing, RNA export, and proteasome-mediated protein
degradation. A complete discussion of each protein interaction identified in table 2 is
beyond the scope of this investigation. Briefly however, the data presented in this
investigation suggests that the nuclear export of topo IIα may be regulated by the export
receptor, exportin-1. Our laboratory has also collaborated with other laboratories to
investigate topo IIα interactions with HDAC (Tsai et al., 2000) and 14-3-3 proteins. For
example, histone deacetylases (HDAC) modifies protein histones and has a role in
regulation of gene transcription. Topo II was shown to complex with HDAC1 and
HDAC2 in vivo (Tsai et al, 2000). Histone deacetylase activity coupled with topo II
DNA cleavage has been implicated in etoposide induced apoptosis. We also investigated
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a potential interaction between 14-3-3 epsilon with topo IIα in human myeloma and
leukemia cell lines at different cell densities because we thought that 14-3-3 may
modulate the subcellular localization of topo IIα in these cells. However, we did not
observe 14-3-3- colocalization with topo IIα by confocal microscopy (data not
published). The 14-3-3 protein, however, has been shown to interact with topo IIα in
HL-60 and CCRF human leukemia cells (Kurz et al., 2000). This interaction was shown
to abrogate topo IIα cleavable complex formation in the presence of the topo II poison,
etoposide.
Although several protein-protein interactions have been described for topo IIα,
specific protein-protein with topo IIβ have not been described. The only observation of a
protein interaction with topo IIβ has been the observation that topo IIβ can
heterodimerize with topo IIα. Although topo II usually forms homodimers, a
subpopulation of α/β heterodimers has been reported to occur, but the biological
significance of this interaction is not clearly established (Gromova et al., 1998; Biersack
et al., 1996).
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Table 2. DNA Topoisomerase IIα Protein Interactions
In vitro
Function(s) of
Name
or
Protein Partner
In vivo
Topo IIβ

In vitro

DNA topology

Function(s) of
Topo-Protein Interaction
(Observed or Predicted)

Role of Topo-Protein Interaction in
Cellular Drug Sensitivity or Resistance
(Observed or Predicted)

References

Possible role in DNA metabolism;
potential therapeutic target

Potential molecular target for new drugs that
inhibit the topo IIα/β heterodimer

Biersack et al., 1996
Gromova et al., 1998

p53 has been reported to have both pro- and antiapoptotic effects depending on the cell type and
cytotoxic agent investigated. For example, mouse
fibroblasts expressing wild-type p53 are more
sensitive to etoposide and doxorubicin, but less
sensitive to UV light and alkylating agents when
compared to p53 deficient mouse fibroblasts.
These results are in contrast to lymphoblastoid
cells that are more sensitive to UV light and
alkylating agents than their p53 mutant
counterparts.

Cowell et al., 2000
Bernd, K. 2003

In vivo
In vitro

Tumor suppressor
protein; regulation of
G2/M transition

Interaction with topo IIα protein may be
necessary for detection/repair or
activation of apoptotic response
following DNA damage. p53 mediated
topo II gene suppression blocks cells in
G2/M, allowing cells to repair damaged
DNA.

Caspase activated
DNase (CAD)

In vitro

Deoxyribonuclease
involved in apoptosis
and nuclear
disassembly

CAD enhances topo IIα decatenation
activity in vitro. CAD may initiate at or
near topo IIα binding sites to initiate
chromosomal condensation and nuclear
disassembly during apoptosis.

Could be involved in apoptotic response to druginduced DNA damage

Durrieu et al., 2000

Interleukin enhancer
binding factor 2

In vivo

Transcription factor;
also associated with
pre-mRNA splicing
complex

May be involved in regulating IL-2 gene
transcription during T-cell activation

To date, there is no literature to describe ILF2topo IIα effects on cellular drug sensitivity.

Ajuh et al., 2000
Marcoulatos et al.,
1996

In vitro

An isomerase that
interacts with several
phosphoproteins
during the cell cycle

Inhibits casein kinase II (CK2)
phosphorylation of Thr1342 on topo IIα,
but especially during G2/M; may
regulate CK2 phosphorylation of topo
during the cell cycle.

Alterations in the phosphorylation status of topo
IIα could regulate topo IIα enzyme activity,
protein degradation, or subcellular localization and
confer alterations in drug sensitivity.

Messenger et al.,
2002

p53

Peptidyl-prolyl
isomerase (Pin1)

Table 2 continued on next page.
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Table 2 continued.
Name

In vitro
or
In vivo

Function(s) of
Protein Partner

Function(s) of
Topo-Protein Interaction
(Observed or Predicted)

Role of Topo-Protein Interaction in
Cellular Drug Sensitivity or Resistance
(Observed or Predicted)

References

In vivo

Unwinds doublestranded DNA and
RNA; nuclear export
of retroviral RNA

RHA may facilitate the access of topo
IIα to chromatin and work together to
maintain chromatin structure during
transcription. RHA may be a
transcriptional co-activator
(i.e. topoIIα may activate RNA
polymerase when complexed with
RHA)

Sumoylation could signal RHA to interact with
topoIIα to initiate transcription of specific genes
in response to cellular demands (i.e. during
apoptosis or when DNA damage is present)

Lee et al., 2004
Zhou et al., 2003

SUMO1/Ubc9

In vivo
In vitro

An E2-type
ubiquitin-conjugating
enzyme involved in
sumoylation (SUMO)
and proteasome
mediated
degradation;

SUMO could regulate topo IIα
degradation, subcellular localization
and/or enzyme activity. Ubc9 is also
necessary for the assembly of RNA
helicase-A topo IIα complexes to form.

Sumoylation may alter drug sensitivity by
modifying the amount, location or activity of
topo IIα. Sumoylation may be a step in
chromosome condensation or DNA cleavage
during apoptosis. SUMO-topo IIα is observed
after teniposide induced DNA damage; SUMOtopo IIβ is observed after exposure to the catalytic
inhibitor ICRF-193.

Mao et al., 2000
Isik et al., 2003
Argasinska et al.,
2004

Histone deacetylase1 Histone
deacetylase -2

In vivo
In vitro

Chromatin
remodeling

Regulation of chromatin structure and
gene transcription.

The histone deacetylase inhibitor, sodium
butyrate (NaB) results in a 2-fold increase in topo
IIα protein and increased sensitivity to etoposide
in human leukemic cells.

Tris et al., 2000
Johnson et al., 2001
Kurz et al., 2001

14-3-3- epsilon

In vivo

Adapter molecule
involved in signal
transduction
pathways

Interaction with 14-3-3 may modulate
topo IIα protein activity or subcellular
localization.

14-3-3 epsilon abrogates topo IIα cleavable
complex formation to etoposide as a result of
reduced DNA binding activity.

Kurz et al., 2000

Exportin 1

In vivo
In vitro

Protein receptor for
nuclear export

Export topo IIα from the nucleus to the
cytoplasm

Decreased drug sensitivity to etoposide has been
associated with a subcellular distribution of topo
IIα from the nucleus to the cytoplasm in human
myeloma cell lines.

Engel and Turner et
al., 2004
Mirski et al., 2003

c-Jun

In vivo

Transcription factor;
proto-oncogene

c-Jun stimulates topo IIα decatenation
activity

Etoposide induces c-jun gene expression in HL60 and U-937 myeloid leukemia cell lines and
may be an apoptotic event in etoposide-induced
DNA damage

Kroll et al., 1993

RNA helicase A
(RHA)
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3.10 Conclusions.
Thus far, cancer pathogenesis and the family of DNA topoisomerases have been
reviewed. Some key points to remember are that topo I and topo II are the major nuclear
enzymes that regulate DNA topology during DNA replication, transcription, and cell
division. Topo I catalyzes single-strand DNA breaks in an ATP-independent manner and
is not expressed in a cell-cycle dependent manner, whereas topo II enzymes cleave
double-strand DNA in an ATP-dependent manner. Topo II has two isoforms, topo IIα
and topo IIβ. Topo IIα protein expression is cell cycle dependent, whereas topo IIβ
expression is more constant throughout the cell cycle. Topo I and topo II are the
molecular targets of clinically important chemotherapeutic agents, especially in the
treatment of hematological malignancies. Next, the drugs that target topo I and topo II
are reviewed.
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Chapter Four
DNA Topoisomerase Targeted Cytotoxic Agents

4.1 Introduction to Topo Targeting Agents.
Topo proteins are the molecular targets of commonly used anti-cancer agents
(Topcu, 2001). Cytotoxic agents that target topo can be classified as poisons, catalytic
inhibitors, or suppressors (Pommier et al., 1998; Andoh and Ishida, 1998). Some poisons
are specific to topo II (i.e., etoposide and teniposide), whereas other poisons target topo I
(i.e., topotecan and irinotecan). The poisons are further subclassified as either DNA
intercalators or non-intercalators, but several drugs have multiple mechanisms of action,
and thus do not fit discreetly into one specific drug category (Table 3) (Ross et al., 1984).
DNA intercalators are able to bind to DNA, whereas the non-intercalators do not bind to
DNA. Some drugs, such as Actinomycin D, can act as a poison against both topo I and
topo II, and yet other compounds can act as a poison against one class of topo enzymes,
but as a catalytic inhibitor of another class of topo enzymes (van Hille et al., 1999). The
mechanism of drug action of the poisons is distinctly different from that observed with
the catalytic inhibitors and suppressors. The main difference between catalytic inhibitors
and suppressors is their molecular target. Catalytic inhibitors inhibit topo II activity,
whereas the suppressors inhibit topo I activity. The topo I and topo II poisons are
described in a separate section from the catalytic inhibitors and suppressors.
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4.2 Topo I and Topo II Poisons.
To comprehend how anti-cancer agents target DNA topoisomerases, it is
important to recall that, when all topo enzymes cleave DNA, they remain bound the
cleaved DNA via a phosphotyrosine bond. In this manner, topo bridges the gap between
the cleaved DNA strands, thus ensuring that the correct strands of DNA are resealed back
together. Under normal physiological conditions, the complex between topo and the
cleaved DNA strands, called a "cleavage" or "cleavable complex", is transient and freely
reversible. Some anti-cancer agents, however, stabilize the form of topo that is bound to
cleaved DNA and are called, topoisomerase poisons. Topo II poisons include the
epipodophyllotoxins (i.e., etoposide, teniposide) and anthracyclines (i.e., doxorubicin),
whereas the topo I poisons include the camptothecins (i.e., topotecan, irinotecan). The
topo poisons act by increasing the steady-state concentration of covalently bound DNAtopo cleavage complexes by blocking the religation of cleaved DNA and stabilizing the
DNA-drug-enzyme intermediate (Osheroff et al., 1994). However, it is not clear why
cells die, since the topo II-DNA covalent complexes trapped by topo poisons are freely
reversible so that removal of the drug allows the DNA to return to an undamaged state
(Nitiss and Wang, 1996). It is possible that cells accumulate DNA damage to a point of
no return, such that apoptotic pathways are triggered and cell death occurs even if DNA
damage is repaired. It is generally believed that the drug stabilized cleavage complexes
become lethal when either DNA helicases (Howard et al., 1994) or an advancing
replication fork collides with the drug-topo-DNA ternary complex (Hsiang et al., 1989).
Such collisions are believed to be lethal because they disrupt the proteinaceous bridge
between topo and the cleaved DNA, and thus the transient single- or double- strand DNA
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break that was being held together by topo becomes a permanent double-stranded break
(Osheroff, 1995; Chen and Liu, 1994). The double-stranded DNA break becomes a
target for gene recombination and repair pathways (Osheroff, 1998), resulting in sister
chromatid exchanges, large insertions and deletions, and chromosomal translocations
(Chen and Liu, 1994; Anderson and Berger, 1994; Corbet and Osheroff, 1993).
Therefore, at least some of the double-strand breaks that are generated by collision with
the replication fork can not be repaired by the enzyme (Nitiss and Beck, 1996; Zhang et
al., 1990). So, although the covalent topo-DNA complex is transient and freely
reversible, collision with the replication fork can produce DNA lesions that persist after
the drug is removed (Nitiss and Beck, 1996). Though not well understood, these cellular
events eventually trigger cell death pathways (Gupta et al., 1995, Pommier, 1993). One
additional caveat is that generation of a lethal collision is dependent on the orientation of
the cleavable complex relative to the advancing replication fork. Collision is lethal only
if the cleavable complex is formed on the lagging-strand of DNA (Pourquier et al., 1999l
Tsao et al., 1993).

4.3 Topo I Suppressors and Topo II Catalytic Inhibitors.
In contrast to the topo poisons, the suppressors of topo I and catalytic inhibitors of
topo II do not stabilize DNA-enzyme complexes, but rather work at another step of
enzyme catalysis (Pommier et al., 1998). The catalytic inhibitors include the topo II
targeting agents, merbarone and the bisioxopiperazines (ICRF-193, ICRF-187).
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Table 3. DNA Topoisomerase I and II Inhibitors
Class

Topo II Agents

Topo I Agents

Drug

Poisons

Catalytic
Inhibitors

DNA
Intercalators

Free Radical
Formation

Epipodophyllotoxi
ns

etoposide (VP-16),
teniposide (VM-26)

+++

-

-

+

Isoflavinoids

genistein

++

-

-

-

Anthracyclines

doxorubicin, daunomycin

++

+

++

+

Actinomycins

actinomycin D

+++

-

-

-

Anthracenediones

mitoxantrone

++

+

+

-

Acridines

m-AMSA

+++

+

+

-

Miscellaneous

fostriecin, merbarone,
ICRF-193, ICRF-187,
ICRF-159

-

+++

-

-

Alkaloids

topotecan, camptothecin
(CPT), irinotecan (CPT11), 9-nirocamptothecin
(9-NC), karenitecin

+++

-

-

-
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Topo suppressors and catalytic inhibitors may inhibit binding between DNA and
topoisomerase, stabilize noncovalent DNA topoisomerase complexes, or inhibit ATP
binding (Larsen et al., 2003; Burden and Osheroff, 1998). For example, catalytic
inhibitor, called ICRF-193, has been shown to lock the enzyme in a closed form on DNA,
preventing DNA cleavage (Roca et al., 1994, Fortune et al., 1998). Recall that topo IIα
cleavage activity is described to occur in a two-gate model. The enzyme undergoes two
forms, open and closed, in the absence or presence of ATP, respectively. ATP binding
triggers a conformational change in topo II, resulting in topo II gate closure around DNA.
ATP hydrolysis results in opening of the topo II gate. Therefore, ICRF-193 stabilizes
topo II in a closed formation around DNA and prevents topo from opening again. In
general, the drugs that target topo IIα come from a range of classes with differing
structures and mechanism of action. Conversely, most of the antitumor agents that target
topo I are poisons (refer to Table 3), and thus are the focus of this investigation.
A summary of the mechanisms of drug action of topo II targeting agents are
illustrated in figure 7. In general, topoisomerase poisons can be distinguished from
catalytic inhibitors by their cytotoxic profiles (Froelich-Ammon and Osheroff, 1995
Nitiss, 1994). Increased cellular content of topo protein corresponds with cellular
hypersensitivity to topo poisons, but decreased drug sensitivity to catalytic inhibitors
(Bjornsti et al., 1989; Ishida et al., 1995). Conversely, decreased cellular content of topo
protein corresponds with decreased sensitivity to topo poisons but hypersensitivity to
catalytic inhibitors (Bjornsti et al., 1989; Ishida et al., 1995; Nitiss and Wang, 1988).
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2

1

Cleavable
Complex

Supercoiled
DNA

3

Figure 6.The Mechanism of DNA Topo I Poisons. (1) Topo I monomer
binds to supercoiled DNA (2) Topo I cleaves single strand of DNA .The
cleavable complex is stabilized in the presence of topo I poison (shown as
orange box) (3) Advancing replication fork collides with cleavage complex,
resulting in double strand DNA break.
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ATP

1
2

a.

b.
6

ADP + Pi

Catalytic
Inhibitors

c.

f.

Mg2+
3

Poisons

5

4

e.

d.

Cleavable complex

Cleavable complex

Figure 7. The Mechanism of DNA Topo II Poisons and Catalytic Inhibitors. This is the same figure
illustrated on page 23, but now the steps of enzyme inhibition by topo II poisons and catalytic inhibitors are
indicated. Briefly, (1) Topo II binds DNA (orange rod) (2) Topo II binds as second DNA strand, and then
binds ATP (yellow star) (3) The ATPase domains on topo II dimerize, and then topo II cleaves DNA.(4)
Strand passasge occrs through the gap (5) transport DNA is released, and then gate DNA is resealed. (6)
ATP is hydrolyzed and ADP and inorganic phosphate (Pi) are released to complete enzyme turnover. Topo
poisons act on the cleavable complex (forms d and e) and prevent reaction 4 from proceeding forward. The
catalytic inhibitors act on any other step of the catalytic cycle (forms a, b, c, and f). Catalytic inhibitors
prevent topo binding to DNA, ATP binding, and ATP hydrolysis. This figure was modified from references
Champoux, 2001 and Wang, 1996.
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4.3 DNA Topoisomerase I Targeting Agents.
Camptothecin (CPT) (Figure 8.) is a plant alkaloid isolated from Camptotheca

O
N

+

O

-

acuminata (Wall et al., 1986). Initial studies

O

O

O
N

N

OH
H 3C

Figure 8. Camptothecin (CPT)

showed that CPT displayed potent antitumor
activity against a wide range of tumors, but the
drug was discontinued because of toxic side
effects (Pommier, 2005). There was a

renewed interest in CPT when subsequent findings identified topo I as the main
molecular target (Hsiang et al., 1985). Since CPT was the only known drug to target topo
I, finding less toxic and more water soluble CPT derivatives became a subject of
numerous investigations
(Kollmannsberger, et al., 1999; Wani et

O
H3C
N

CH3

N

O

al., 1987, 1986; Kunimotto et al., 1987).
Topotecan (TPT) (Figure 9.) and

O
HO

N
H3C

OH

irinotecan (CPT-11) are two water
Figure 9. Topotecan (TPT)

soluble CPT derivatives that are

currently being used for the treatment of human cancers (Lackey et al., 1996; Luzzio et
al., 1995). CPT-11 has been used in the treatment of colon, breast, gastric and small-cell
lung cancers as well as leukemia (Rosen, 1998), whereas topotecan has been used against
recurrent small cell lung cancer, ovarian cancer and endometrial cancer (Treat et al.,
2004; Ahmad and Gore, 2004; Traina et al., 2004). CPT-11 must be converted to the
active compound, SN-38 (7-ethyl-10-hydroxycamptothecin B-glucuronide) by
carboxylesterase (Satoh et al., 1994). Thus, increased drug sensitivity to irinotecan
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correlates with carboxylesterase expression and activity (Wierdl et al., 2001). Cisplatin is
also a substrate of the ABC drug transport protein, multidrug resistance related protein-3
(MRP3).
CPT and its derivatives interact reversibly with a DNA-enzyme complex and
usually have no detectable binding to isolated topo I or DNA (Fan et al., 1998; Hsiang et
al., 1985). However, the x-ray crystal structure of human topo I-DNA-topotecan ternary
complex shows that topotecan can mimic a DNA base pair (Staker et al., 2002). These
findings may partially explain how topotecan can intercalate in DNA in the absence of
topo enzyme in some instances. In the presence of camptothecins, topo I is unable to
reseal nicked DNA because the drug blocks the active site of the covalently bound
enzyme (Woo et al., 2002). However, single strand DNA breaks alone are not sufficient
for cell death to occur and instead must be converted into permanent DNA double strand
breaks by collision with the moving replication fork (Mosseso, 2000). Conversely, it has
also been reported that CPT induced DNA strand-breaks can occur in unstimulated
leukocytes where little or no replication is occurring (Daza et al., 2002), and thus other
cellular events besides the collision of cleavable complexes with replication forks may
have a role in CPT induced DNA damage. The molecular basis of CPT induced cell
death is not completely understood, since topo I cleavable complexes are readily
reversible after drug removal (Pommier, 2005). It is generally accepted that collision of
the moving replication fork with the topo I cleavable complexes leads to three
biochemical events: formation of a double-strand DNA break, irreversible arrest of the
replication fork, and formation of an irreversible topo I-linked DNA break (Tsao et al.,
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1993; Hsiang et al., 1989). It is thought that one or more of these events initiates S-phase
cell death and G2 phase cell cycle arrest.

4.4 DNA Topoisomerase II Targeting Agents: Etoposide and Mitoxantrone.
In contrast to the limited number of drug classes that target topo I, topo II is the
molecular target for a number of diverse drug classes,
including the epipodophyllotoxins, isoflavinoids,
anthracyclins, actinomycins, anthracenediones and
acridines (Table 3). Etoposide (VP-16) and
teniposide (VM-26) are two semi-synthetic
epipodophyllotoxins. Etoposide and teniposide are
derived from 4'-demethylepipodophyllin benzylidene
Figure 10. Podophyllum peltatum,
also known as the May Apple
Mandrake. The plant shown here is
bearing fruit, the richest source of
podophyllotoxins. This photograph
was reproduced with written
permission from the Maryland
Conservation Council.

glucoside (DEPG), a naturally occurring compound
synthesized by Podophyllum peltatum, the North
American May Apple Mandrake (Figure 10) (Imbert,
1998; Hande, 1998; Sinkule, 1984). The May Apple

was first described in 1731 and can be found growing from the coasts of Northern Florida
to Maine (Catersby, 1731). Native American Indians and American pioneers reportedly
used the plant for medicinal purposes, such as for the treatment of skin cancer (Hande,
1998). In 1844 the first alcohol extraction of the plant was reported and the isolated resin
was called podophyllin (King, 1844). For over twenty years, numerous isolation
procedures were conducted, fronting an intense search for the active compound. These
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investigations lead to the development of VP-16 and VM-26, which were renamed,
etoposide and teniposide, respectively (Stahelin and Von Wartburg, 1989).
Unlike topo I targeting agents, topo II targeting drugs are able to kill cells at all
points in the cell cycle (Dubrez et al., 1995). Topo II inhibitors such as VP-16 (Figure 11)
and mitoxantrone (Alberts et al., 1980;

OH
H3C

O

OH

Koeller and Eble, 1988) (Figure 12) stabilize

O

the complex formed by topo II and the 5’

O
O
O
O

cleaved ends of the DNA, thus forming stable

O

protein-linked double strand DNA breaks

O

H 3C

O

O

CH 3

OH

Figure 11. Etoposide (VP-16)

(Meresse et al., 2004). VP-16 and
mitoxantrone inhibit topo II DNA religation

activity, leading to an increase in DNA scission (Liu, et al., 1983). The DNA breaks are
believed to interfere with the progress of the moving replication fork (Qiu et al., 1996).
Cells recognize drug-induced DNA damage and eliminate the damaged cells by
apoptosis, but the pathway from DNA damage to cell death remains uncertain (Valkov
and Sullivan, 2003). Etoposide mediated cell death is reported to occur when DNAdependent protein kinase (DNA-PK) recognizes an accumulation of DNA double strand
breaks and then phosphorylates p53 (Karpinich et al., 2002). Activated p53 then results
in increased transcription of the pro-apoptotic protein Bax, which then translocates into
the mitochondria and induces the release of cytochrome c.
Mitoxantrone (MTX) is a synthetic anthracenediones that was developed as an
analogue of doxorubicin (Fox, 2004). Mitoxantrone has been shown to have multiple
mechanisms of action. In addition to being a topo II inhibitor (as previously described
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above), mitoxantrone also interferes with

NH
OH

O

OH

HN

RNA synthesis, and intercalates with
DNA.(Duff, 1984; Isabella et al., 1993)
DNA intercalation results in aberrant
OH

O

HN
NH

Figure 12. Mitoxantrone (MTX)

OH

DNA-protein crosslinks and DNA strand
breaks (Hagemeister et al.,

2005). Mitoxantrone has also been shown to inhibit antigen presentation and decrease the
secretion of proinflammatory cytokines, which has important roles in modulating the
immune response (Fox, 2004). MTX has also been shown to alter prostaglandin
biosynthesis and calcium release (Ehninger et al., 1990). In summary, MTX has been
shown to have multiple biological effects but, the drug's antitumor activity is mainly
attributed to its interaction with DNA topoisomerase (Koeller and Eble, 1988). However,
it is possible that these other cellular events could contribute to drug sensitivity to MTX.
Mitoxantrone was approved by the Food and Drug Administration for the treatment of
adult acute myeloid leukemia and symptomatic hormone-refractory prostate cancer.
Mitoxantrone also has demonstrated beneficial activity in preclinical lymphoma models
and appears clinically active against both aggressive and follicular lymphomas
(Hagemeister e., 2005). Topo II targeting agents have been used effectively in the
treatment of non-Hodgkin’s lymphoma, leukemias, small-cell lung cancer and soft-tissue
sarcomas. However, cancer cells have many mechanisms for evading topo II mediated
drug cytotoxicity. Mechanisms of drug resistance to topo II targeting agents are reviewed
in chapter six. .
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4.5 Dual Inhibitors of DNA Topoisomerase.
Dual inhibitors of topo I and topo II are emerging as a new class of cytotoxic
agents with promising anti-tumor activity (Denny and Baguley, 2003). The dual topo
inhibitors have activity against both topo I and topo II enzymes and can be classified into
three groups: DNA intercalators, non-DNA intercalators, and hybrid molecules (Denny
and Baguley, 2003). The DNA intercalators physically intercalate between DNA bases,
whereas the non-DNA intercalators recognize structural motifs present in topo I and II
proteins. Two examples of dual topo I and II DNA intercalating agents include are
N-[2-(dimethylamino) ethyl] acridine-4-carboxamide dihydrochloride (DACA) and the
benzophenazine referred to as XR11576 (Mistry et al., 2002). In vitro experiments using
purified topo and DNA substrates show that DACA induces DNA breakage by both topo
I and II (Finlay et al., 1996). However, the mechanism of DACA inhibition on topo I and
II is still in question. The data suggests that DACA may act as a topo poison at a low
drug concentration (0.5-5 µM) and as catalytic inhibitor at a higher drug concentration (≥
10µM) (Spicer et al., 2000; Bridewell et al., 1999). Thus, topo-DNA cleavage complexes
are not observed at the higher drug concentrations. This may be possible, if the
intercalation of DACA into DNA at higher drug concentrations inhibits the binding of
topo to DNA. DACA has completed phase I and II clinical trials (Dittrich et al., 2003;
Caponigro et al., 2002; Twelves et al., 1999) and has been shown to overcome
mechanisms of in vitro drug resistance in several multidrug resistant cell lines that
express drug efflux pumps (i.e., P-glycoprotein, multidrug resistance protein, and
multidrug resistance related protein) (Davey et al., 1997). DACA has also been shown to
be active against solid tumors in mice (Bridewell et al., 1999).
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Four examples of non-DNA intercalating agents have been described and include
NK109, acetyl Boswellic acid, BN 80927, and F-11782. Acetyl-Boswellic acid (acetylBA) is isolated from the gum resin of Boswellia serrata, a tree that grows in Asia.
Acetyl-BA inhibits topo I and IIα by binding directly to topo enzymes, rather than DNAtopo complexes, and is believed to compete with DNA for binding sites on topo
(Syrovets et al., 2000). BN 80927 is a camptothecin analogue that has a seven-membered
β-hydroxylactone ring, in contrast to other camptothecins that have a six membered
α-hydroxylactone ring (Huchet et al., 2000, Demarquay et al., 2000). The
α-hydroxylactone ring in BN 80927 is modified by the insertion of methylene (-CH2)
group. When compared to camptothecin, topotecan, and irinotecan, BN 80927 has
improved plasma stability because the additional methylene group undergoes slow and
irreversible hydrolytic ring-opening (Demarquay et al., 2000). In vitro and in vivo
experiments show that BN 80927 inhibits topo-I mediated supercoiled-DNA relaxation
because it stabilizes topo I- cleavage complex (Lavergne et al., 1999). BN 80927 was
also shown to inhibit topo II mediated supercoiled-DNA relaxation and DNA
decatenation activity (Demarquay et al., 2000). In contrast to etoposide, BN 80927 does
not stabilize topo II-DNA cleavage complexes (Demarquay et al., 2000). Thus, BN
80927 is a topo I poison and a topo II catalytic inhibitor. The fourth example of a nonintercalating dual topo I and II inhibitor mentioned above was F11782. Treatment of
P388 murine leukemia cells with F11782 results in dose-dependent DNA fragmentation
and activation of apoptotic pathways through a caspase 3/7 dependent mechanism.
F11782 has also been shown to have improved in vivo anti-tumor activity, relative to
three other cytotoxic agents (Kruczynski et al., 2004).
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The third group of dual topo inhibitors is known as "hybrid molecules" because
they consist of a topo I inhibitor biochemcially linked with a topo II inhibitor. The
hybrid molecules are still in early stages of drug development and have not been formally
reported in the literature (Denny and Baguley, 2003). The dual topo inhibitors are
promising new drugs because they may evading toxicity by compensating one enzyme
for another enzyme.
4.6 Conclusions.
Topo I and topo II are the molecular targets of several antitumor agents used for
the treatment of hematological malignancies (Wang, 1996). Topo I is the major
molecular target of the camptothecins (i.e., topotecan and irinotecan). The camptothecins
are topo I poisons, and thus stabilize topo I-DNA cleavage complexes Topo II poisons,
such as VP-16 and VM-26, stabilize topo II cleavable complexes, whereas the catalytic
inhibitors of topo II do not stabilize cleavable complexes. The catalytic inhibitors
prevent topo binding to DNA, or trap topo II in a closed formation. Dual inhibitors of
topo I and topo II are promising new cytotoxic agents, but the focus of this investigation
is on topo I and topo II poisons and topo II catalytic inhibitors. Drugs that act on other
molecular targets besides topoisomerases are briefly described in following chapter.
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Chapter Five
Non-topoisomerase Interacting Agents
5.1 Introduction.
Although some drugs interfere with DNA metabolism, they may do so without
associating with a topoisomerase and should not be confused with the topoisomerase
interacting agents described above. Thus, the primary mechanism by which these types of
drugs exert their cytotoxic effect is independent of topo content or activity. For example,
DNA alkylating agents such as Carmustine, a lipophilic nitosourea, undergoes hydrolysis
in vivo to form reactive metabolites that produce lethal O6-chloroethylguanine DNA
interstrand crosslinks (Egyhazi et al., 1991). The non-topoisomerase interacting agents
can be used in laboratory studies to help distinguish mechanisms of cellular drug
resistance that are a result of alterations in the quality or content of topo from other nontopo related cellular events, such as alterations in drug transport. In some instances,
exposure to one type of drug can result in cross-resistance to many other drugs that are
structurally unrelated, a phenomenon known as multidrug resistance. We assessed
human myeloma cell lines for cross-resistance to taxol, ara-c, cisplatinum, and
carmustine. These cytotoxic agents were selected because of their differences in chemical
structure and mechanism of action (figure 13; table 4). To improve drug sensitivity, the
non-topoisomerase drugs are often given in combination with topo targeting cytotoxic
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agents. For example, a combination of topotecan, ara-c, and cisplatin have reached phase
II clinical studies for relapsed or primary refractory lymphomas (Coutinho et al., 2004).
Unfortunately, multidrug resistance to combination chemotherapy is a limitation that
needs to be overcome. Cisplatin, paclitaxel, ara-c, and carmustine are four examples of
non-topoisomerase targeting agents described herein.

5.2 Cisplatinum.
Cisplatin (cis-diamminedichloroplatinum; CDDP) and its synthetic analogues are
DNA crosslinking agents and platinum containing compounds that exert their cytotoxic
effects by inducing the formation of various types of DNA lesions (Crul et al., 2002;
Iikima et al., 2004). Cisplatin is a DNA crosslinking agent with potent antitumor activity
against various kinds of cancers including, non-small cell lung cancer (Wang et al.,
2004). However, acquired drug resistance to CDDP is a common observation in these
patients. The mechanisms of drug resistance to cisplatin are unknown, but enhanced
DNA repair, altered drug transport, and drug inactivation by metallothionine have all
been associated with decreased drug sensitivity to CDDP (Wang et al., 2004).
Furthermore, sensitivity to DNA-crosslinking reagents are inversely proportional to topo
levels and activity, and thus elevated levels of topo II correlate with resistance to cisplatin
(Tan et al., 1987). This has been explained by the involvement of topo IIα in processing
DNA damage induced by DNA crosslinking agents (Tan et al., 1987). A deficiency in
topo IIα activity correlates with increased drug sensitivity as a result of an increase in
drug-induced sister chromatid exchanges. These results suggest that the efficacy of
CDDP in cancer chemotherapy can be improved through inhibition of topo IIα.
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5.3 Paclitaxel.
Microtubules are intracellular organelles, formed from the protein tubulin,
involved in chromosome segregation, transport, motility, and cell structure (Jordan and
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Carmustine (BCNU). Structures of the non-topoisomerase associated agents used
in the soft agar cytotoxicity experiments (see “materials and methods”) .
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Table 4. Comparison of DNA Topoisomerase Inhibitors with Non-Topoisomerase Targeting Anticancer Agents
Topoisomerase Associated

Non-topoisomerase Associated

Topotecan
(TPT)

Etoposide
(VP-16)

Class

Alkaloid

Epipodophyllotoxins

MW*

457.9

588.6

517

853.9

Mechanism of
Action

Topo I
inhibitor

Topo II inhibitor

Topo II inhibitor

yes, S-phase

yes, late S
and G2

yes

Examples of
In vitro
Mechanisms of
Drug Resistance

Altered cellular
content or activity
of topo I; altered
drug transport

Altered cellular
content. location , or
activity of topo IIα;
altered drug
transport

Altered cellular
content , location, or
activity of topo IIα;
altered drug
transport

Altered drug
transport; gene
mutations in β
tubulin

Therapeutic Uses

Ovarian cancer,
SCLC, gliomas,
AML, CML, MM,
MDS,
neuroblastoma,

ALL, AML, Brain
tumors, Ewing’s
sarcoma,
Histiocytosis X

CML, AML, ALL,
breast cancer, NHL,
ovarian cancer

Rasheed and
Rubin, 2003

Meresse et al., 2004;
Hande, 2003

Thomas and
Archimbaud, 1997;
Center, 1993

Cell-cycle
dependent?

References

Mitoxantrone
Anthracenediones

Paclitaxel
(Taxol)

Cytarabine
(Ara-C)

Carmustine
(BCNU)

Cis-platinum
(CDDP)

Anti-metabolite

Nitrosourea
(Alkylating)

Alkylating

243.2

214.06

300

Inhibits microtubule
formation

DNA polymerase

DNA crosslinking

DNA
crosslinking

yes

yes, S-phase

some, G1 and G2/M

no

Mitotic inhibitor

Altered drug
transport

Enhanced DNA
repair

Drug inactivation;
enhanced DNA repair;
altered drug transport

breast cancer,
ovarian cancer, head
and neck cancer,
lung cancer

AML, ALL CML,
NHL

brain tumors,
Hodgkin’s
lymphoma, NonHodgkin's
lymphoma

bladder cancer,
adrenocortical cancer,
lung cancer, ovarian
cancer, testicular

Jordan and Wilson,
2004

Wills et al., 2000;
Abdel et al., 2000

Linfoot et al., 1988
Ueda-Kawamitsu, et
al., 2002;
Henderson et al.,
1987

Brabec and Kasparkova,
2005; Arbuck, 1994
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Wilson, 2004). Taxol is a tubulin-binding antimitotic agent with antitumor activity in a
variety of cancers including breast cancer (Yvon et al., 1999; Fountzillas et al., 2004).
Cells acquire drug resistance to taxol by decreasing intracellular concentration through
protein transport pumps and by gene mutations in the beta tubulin gene that alter drug
binding properties (Zhou et al., 2004; Hadfield, et al., 2003; Dumontet and Sikie, 1999).

5.4 Cytarabine (Ara-C).
Cytarabine (ara-C) is an antimetabolite and nucleoside analog of deoxycytidine
(Frei et al., 1973; Kufe and Spriggs, 1985). Ara-c differs from deoxycytidine by the
addition of a hydroxyl group on the 2' position of the sugar moiety. Once inside the cell,
ara-C is converted into an active form, cytarabine-5’-triphosphate (ara-CTP) (Frei et al.,
1973). The rate limiting step of ara-C activation is catalyzed by deoxycytidine kinase
(Coleman et al., 1975). Ara-CTP competes with deoxycytidine triphosphate for
incorporation into DNA, and thus is a competitive inhibitor of DNA polymerase (Kufe
and Spriggs, 1985; Furth and Cohen, 1968). Incorporation of ara-CTP into DNA
eventually results in inhibition of DNA synthesis and cell death (Mikita and Beardsley,
1988; Kufe et al., 1984). Incorporation of Ara-c into DNA is also associated with local
conformational changes in DNA, inhibition of DNA polymerase, and a decreased ability
of transcription factor binding to DNA binding elements (Zhang et al., 2004b; Mikita and
Beardsley, 1988). Ara-C is often used in combination therapy for different types of
leukemia (Szafraniec et al., 2004). Complete response rates in acute myelocytic leukemia
(AML) reach 65-80%; however, patients usually relapse within 2-years and are resistant
to subsequent chemotherapy (Cros et al., 2004). Resistance to ara-C has been attributed
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to overexpression of the P-glycoprotein drug efflux pump, but some patients who are
resistant to ara-C do not express P-glycoprotein (Galmarini et al., 2002a). Drug resistance
in these patients has been partially attributed to deficiency in the human equilibrative
nucleoside transporter 1 (hENT1), a transmembrane drug influx pump (Boleti et al.,
1997). A lack of hENT1 presumably results in less intracellular concentrations of ara-C
because of decreased intracellular drug import (Galamarini et al., 2002a; Lang et al.,
2001).

5.5 Carmustine (BCNU).
Carmustine (BCNU) is a nitosourea compound with DNA alkylating activity.
BCNU forms a chloroethyl adduct on the O6 position of guanine, which spontaneously
converts to N1-O6 ethanol-guanine (D’Incalci et al., 1988). The adjacent cytosine
covalently binds to the N1-O6 ethanol-guanine to form an intrastrand cross-link that
interferes with DNA replication and transcription (Erickson et al., 1980). Carmustine has
antitumor activity against leukemias and gliomas, and is currently being evaluated in
phase II clinical trials for recurrent glioblastoma (Brandes et al., 2004). A major
limitation to BCNU effectiveness is that acquired drug resistance usually occurs after the
first administration of the drug (Brandes et al., 2002). Acquired chemoresistance to
BCNU has been attributed to the expression of the DNA repair enzyme, O (6)alkylguanine-DNA- alkyltransferase (AGT), because this enzyme removes alkyl groups
from DNA (Brandes et al., 2002).
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5.6 Conclusions.
Topoisomerases are not the molecular targets of DNA crosslinking agents (i.e.,
cisplatin), anti-metabolites (i.e., ara-C), DNA alkylating agents (i.e., carmustine), or antimicrotubules (i.e., paclitaxel). Non-topoisomerase targeting agents are sometimes used
in combination with topoisomerase targeting agents in cancer chemotherapy. Cancer
cells have several molecular adaptations to evade drug induced cytotoxicity.
Mechanisms of drug resistance to topoisomerase targeting agents are the focus of this
investigation and are discussed in chapter five.
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Chapter Six
In vitro Mechanisms of Topoisomerase Associated Drug Resistance

6.1 Introduction.
In the preceding sections, the family of DNA topoisomerases and commonly used
chemotherapeutic drugs has been reviewed. The focus has been on the topoisomerase I
and II as the molecular targets of topoisomerase targeting cytotoxic agents. In this
chapter, the mechanisms of tumor cell resistance to topo targeting agents and especially
topo II mediated cellular drug resistance are explained (reviewed in Engel et al., 2003).
Although the development of new drugs and new drug combinations has resulted
in more effective treatment of cancer, a major factor limiting their usefulness is the
presence of drug-resistant cancer cells that can exist prior to (intrinsic or de novo drug
resistance) or arise during cancer therapy (acquired drug resistance) (Bellamy et al.,
1990). Whether drug resistance is intrinsic or acquired, mechanisms conferring altered
drug sensitivity may be categorized as involving a pre-target event, a drug-target
interaction, or a post-target event (Larsen and Skladanowski, 1998). Mechanisms of drug
resistance that result in a modification to the drug itself are called pre-target events
because the cellular insult occurs before the drug reaches its intended molecular target.
Drug metabolism is one example of a pre-target event because the drug becomes.
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modified before reaching its intended molecular target. Modifications to the drug's
intended target, however, can also occur and results in altered drug-target interactions.
For example, sequestration of the drug's intended target into a cellular compartment
different from the drug results in an inability of the drug to interact with its target. In
other instances, neither the drug nor the drug's target is modified. Post-target events
occur after the drug-target interaction occurs, and thus do not directly involve the drug or
the drug's target. For example, altered cell-cycle progression can be a post target event, if
the drug's target is not a cell-cycle regulatory protein. Pre-target events, drug-target
interactions, and post-target events are discussed herein as they pertain to mechanisms of
drug resistance to topoisomerase targeting agents. Figure 14 and figure 15 summarize the
pre-target events, drug-target interactions, and post-target events that can lead to altered
drug sensitivity to topo targeting agents. Each type of mechanism of drug resistance that
is illustrated in these two figures is explained separately in the following sections.
However, mechanisms of drug resistance are not mutually exclusive events and thus,
there is a fair amount of overlap between the types of drug resistance mechanisms.

6.2 Pre-target Events: Altered Drug Transport.
Alterations in drug transport can either be a result of decreased drug import or
increased drug efflux. Some hydrophilic drugs need to be transported across the plasma
membrane and into cells by specific drug transporters (Cass et al., 1998). For example,
cytarabine
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Drug

Effluxed drug

Figure 14. Alterations in Pre-target Events Associated with Drug Resistance. Mechanisms of cellular drug resistance to
topoisomerase inhibitors can be categorized as pre-target events, drug-target interactions, and post-target events (see reference Larsen
and Skladanowski, 1998). Multiple cellular factors can be involved in conferring altered drug sensitivity. Altered drug transport is
shown in (1) as the expression of drug transport protein pumps located on the plasma membrane that can result in either decreased
drug import or increased drug efflux from the cell. Once inside a cell, a drug can be sequestered into intracellular vesicles resulting in
altered drug distribution as shown in (2). Some drugs undergo metabolic modifications, illustrated in (3), that alter their mechanism of
action or result in an inactive form. Other drugs such as irinotecan are a prodrug that must be converted to an active metabolite.
Cytotoxic agents that target topoisomerase must be move into the nucleus (4) where drug-target interactions occur. Mechanisms of
drug resistance by alterted drug-target and post-target events are illustrated in figure 15.
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Drug-target Interactions

Post-target Events

1
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5
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Figure 15. Alterted Drug-target Interactions and Post-target Events Associated with Drug Resistance. Altered drug-target interactions include (1) altered
subcellular localization of nuclear enzyme that results in decreased amount of topo present in the nucleus (2) decreased amount of active enzyme in the
nucleus is associated with resistance to topo poisons (3) increased amount of active topo enzyme is usually atttirbuted to decreased drug sensitivity to
catalytic inhibitors of topo and (4) altered chromatin structure can result in altered topo-DNA binding activity. Post-target events associated with drug
resistance to topo targeting agents include (5) decreased amount of replicating cells, (6) DNA-repair of cleavable complexes, and (7) decreased ability to
initiate apoptosis. Topo is shown as yellow circles, the drug is shown as blue/grey circles, and DNA is shown as a red double helix except in (4) where
DNA is shown in a relaxed conformation. In diagrams (5-7) the area of the cytoplasm is omitted because these events occur in the nucleus. For a review of
this topic see reference (Larsen and Skladanowski, 1998).
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(ara-C) is a hydrophilic nucleoside analogue that is transported into cells by the human
equilibrative nucleoside transport protein 1 (hENT1), a drug influx pump that is
expressed in the plasma membrane of some human cells (Boleti et al., 1997). In vitro
cellular drug resistance to ara-C has been associated with lack of hENT1 mRNA
expression in human T-lymphoblast CCRF-CEM cell lines selected for resistance to araC (Lang et al., 2001). Furthermore, shorter disease-free survival correlates with the
absence hENT1 gene transcription in patients with acute myeloid leukemia (Galmarini et
al., 2002b).
Topoisomerase targeting agents must also be taken up by cells and transported to
the nucleus to be effective as cytotoxic agents. Therefore, reduced drug accumulation is
a chief mechanism conferring drug resistance topoisomerase targeting agents in several
drug-resistant cell lines (Matsumoto et al., 2005; Kamath et al., 1992; Hendricks et al.,
1992). In general, topoisomerase targeting agents are presumed to enter cells by passive
diffusion and are rarely found to be substrates of drug influx pumps. However, both
active and passive transport of camptothecin has been found to occur in human intestinal
cells (Gupta et al., 200). Influx of topotecan and SN-38 has also been suggested to occur
by active transport in ovarian cells (Ma et al., 1998). Drug resistance in these cells was
attributed to decreased drug accumulation independent of P-gp and MRP expression.
Nevertheless, topo targeting agents are more commonly shown to be substrates for
several drug efflux pumps. Therefore, tumor cells that express drug transport proteins
involved in the extrusion of topo interacting agents are found to be drug resistant. Table
5 summarizes the chemotherapy related substrates for drug transport proteins.
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Table 5. Drug Transporters and Chemotherapy Substrates
rug Name

Drug Transporters*

Member of ABC-Transporter
Superfamily?

Drug Influx or Efflux?

References

Etoposide
(VP-16)

P-gp/MDR1, MRP1, MRP2,
MRP3,

Yes

Efflux

Lorico et al., 1995
Neuhaus et al., 1995

Teniposide

P-gp/MDR1, MRP3

Yes

Efflux

Kool et al., 1999

MRP2, BCRP

Yes

Efflux

Neith and Lage, 2005

BCRP

Yes

Efflux

Yang et al., 2000

MRP2, MRP3

Yes

Mitoxantrone
Topotecan
(TPT)
Cis-platinum (CDDP)

CTR1
Sn-38
(active metabolite of
CPT-11/ irinotecan)

BCRP

MRP2 and MRP3: drug
efflux

No, CTR1 is a plasma membrane
carrier for nucleoside analogs.
Yes

CTR1: drug influx
Efflux

Kool et al., 1997
Kawabe et al., 1999
Ishida et al., 2002
Nakatomi et al., 2001

Gerloff et al., 1998
Childs et al., 1998
Reinecke et al., 2000
Boleti et al., 1997
No, hENT1is an integral membrane
Cass et al., 1998
Cytarabine
proton belonging to the equilibrative
hENT1
Influx
Lang et al., 2001
(Ara-C)
nucleoside transport protein family
Galmarini et al., 2002b
Carter et al., 1972
Not a substrate for known drug
BCNU enters the cell by
Carmustine
Balcerczyk et al., 2003
transporters
diffusion
(BCNU)
Abbreviations used in this table: ABC-Transporter, ATP-binding cassette transporter; P-gp, P-glycoprotein; MDR, multidrug resistance; MRP, multidrug
resistance-related protein; BCRP, breast cancer resistance protein; CTR1, copper transporter 1; BSEP, bile salt export pump; hENT1, human equilibrative
nucleoside transporter1.
*Reviewed in reference, Ambudkar et al., 2003
Paclitaxel (Taxol)

P-gp/MDR1, MDR2, BSEP

Yes

Efflux
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Under normal conditions, ATP-binding cassette (ABC) transport proteins pump cytotoxic
agents and xenobiotics out of the cells (van der Does and Tampe, 2004). Expression of
ABC transporters in cancer cells results in decreased intracellular levels of the
administered chemotherapeutic agent that is associated with the multi-drug resistance
(MDR) phenotype (Ling, 1997). Multi-drug resistance describes the phenomenon that
occurs when cells initially exposed to one class of cytotoxic agents become resistant to
other unrelated drugs with various structural and chemical properties (Larsen and
Skladanowski, 1998) The ABC transport proteins identified in humans include, multidrug resistance protein-1/P-glycoprotein (MDR-1/P-gp) (Hoffmann and Kroemer, et al.,
2004), multi-drug resistance-associated protein (MRP) (Hoffmann and Kroemer, et al.,
2004), and breast cancer resistance protein (BCRP) (Doyle and Ross, 2003; Allen et al.,
1999). The expression drug efflux pumps in cancer cells can reduce the intracellular
accumulation of chemotherapeutic agents.
P-gp is a 170 kDa transmembrane glycoprotein that is able to expel a structurally
heterogenous group of chemotherapeutic agents, including anthracyclines, vinca alkaloids
and epipodophyllotoxins (Shustik et al., 1995). P-gp can extrude chemotherapeutic
agents out of cells against a concentrations gradient (Lankelma et al., 1990).
Overexpression of P-gp is estimated to occur in approximately 50% of all human tumors,
and thus P-gp activity likely has a role in treatment related failure of some chemotherapy
(Gottesman, 1993; Sikic, B.I. 1993). Overexpression of P-gp has been observed in many
intrinsically drug resistant tumors derived from kidney, liver, adrenals, colon, and rectum
(Goldstein et al., 1989). However, many drug resistant cells do not express P-gp,
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suggesting a role for other drug efflux pumps in cellular drug resistance (Mirski et al.,
1987, Zijlstra et al., 1987).
Some drug resistant cell lines express the multidrug resistance-associated protein
(MRP) (Cole et al., 1992). MRP has seven family members conferring different substrate
specificities. For example, methotrexate is a substrate for MRP1, but not MRP2 (Konno
et al., 2003). Both P-gp and MRP are able to transport glutathione-S-conjugated
chemotherapeutic agents (Müller et al., 1994). MRP expression is found in a wide range
of tissues, but varies by family member. For instance, MRP1 expression is found in most
tissues, whereas MRP6 expression is limited to the liver and kidney. The breast cancer
resistance protein is another type of drug efflux pump that is found to be overexpressed in
some drug resistant cell lines (Doyle and Ross, 2003). BCRP is expressed in breast
tissue, placenta, intestine, and liver. Overexpression of BCRP results in cross-resistance
to mitoxantrone and topotecan, but not to microtubular inhibitors, such as paclitaxel
(Litman et al., 2000). The lung resistance related protein (LRP) is a major vault protein
localized on lysosomes and in the nuclear pore complexes (Scheffer et al., 1995). LRP
was initially described in drug resistant non-small cell lung cancer cell lines that were
deficient in P-gp expression (Scheper et al., 1993). LRP modulates the transport of drugs
between the nucleus and the cytoplasm. Expression of LRP is associated with the
multidrug resistance and intrinsic drug resistance to doxorubicin, vincristine, and
cisplatin (Mossink et al., 2003; Scheffer et al., 2000; Izquierdo et al., 1996). Drug uptake
of [3H-VP-16] is one method that is used in the laboratory to determine the cellular
uptake of etoposide (or other cytotoxic agents) and drug transport protein activity.
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6.3 Pre-target Events: Altered Drug Distribution.
After cellular drug uptake, cells may sequester drugs into intracellular vesicles
and thus, withhold the drug from reaching its molecular target. Drug sequestration into
cytoplasmic vesicles has been described in vitro in several drug resistant cell lines by
following fluorescently labeled compounds, such as mitoxantrone (Schuurhuis et al.,
1991; Gervasoni et al., 1991). Altered intracellular distribution of doxorubicin has also
been described in leukemic cells obtained from patients with acute myeloid leukemia
(Schuurhuis et al., 1995). Altered drug distribution is usually described as a shift in the
amount of fluorescence from the nucleus to the cytoplasm. The pattern of fluorescence in
the cytoplasm is consistent with vesicle formation. The apparent shift in fluorescently
labeled compounds from the nucleus to the cytoplasm may be a result of LRP, the major
vault protein found on the nuclear membrane that modulates nuclear-cytoplasmic drug
transport. However, vesicle formation is not well understood (Slapak et al., 1992). One
mechanism has been proposed for the sequestration of DNA topoisomerase targeting
agents inside acidic vesicles (Larsen and Skladanowski, 1998). Accordingly, the
cytoplasm of most cells is mildly alkaline, a requirement for the proper functioning of the
trans-Golgi network and endocytotic secretory pathways (Tarakoff et al., 1983). Since
some topo targeting agents such as anthracyclines, anthracenediones and amascarine act
as weak bases, they can be protonated and retained inside acidic vesicles that are present
in the cytoplasm (Larsen and Skladanowski, 1998). Drugs retained inside the lysosomes
are then extruded from the cell via exocytosis (Tartakoff et al, 1983). Protonation and
retention of topo targeting agents inside cytoplasmic lysosomes would theoretically
inhibit drug transport into the nucleus. This hypothesis is supported by adriamycin62

resistant MCF-7 cells that sequester protonated compounds within vesicles, and secrete
the drugs by endocytotic secretory pathways (Schindler et al., 1996). Hence, drug
resistant tumor cells are able to maintain a pH gradient between the acidic environment of
lysosomes and the alkaline environment of the cytoplasm, which ensures the entrapment
of toxic substances inside acidic vesicles and subsequent extrusion of drugs out of the cell
via the trans-Golgi network. Conversely, drug sensitive cells fail to establish a pH
gradient, which disrupts proper formation of acidic vesicles and functioning of the transGolgi-network (Schindler et al., 1996). In summary, sequestration of chemotherapeutic
agents inside vesicular compartments may have a role in altered drug sensitivity by
reducing the amount of drug available to interact with its molecular target.

6.4 Pre-target Event: Drug Metabolism.
Once inside a cell, some topo I and II targeting agents can be modified by
metabolic enzymes. Modifications to chemotherapeutic drugs may be necessary for
activation of a prodrug or can result in a less effective cytotoxic agent. For example,
CPT-11 is an inert drug that must be converted to the active compound SN-38 by
carboxylesterases. Thus, tumor cells expressing low levels of carboxylesterases are
resistant to CPT-11 (Danks et al., 1998). Furthermore, SN-38 can be detoxified when
modified by one of several enzymes belonging to the family of UDPglucuronosyltransferases (UGT) (Ciotti et al., 1999). The UGT enzymes can convert SN38 into SN-38 glucuronide. Glucuronidation of SN-38 is associated with increased drug
efflux from colon cancer cells and decreased drug sensitivity in colon, breast, and lung
cancer cells (Cummings et al., 2002). Modification of DNA alkylating agents has also
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been attributed to altered drug sensitivity. DNA alkylating agents can be detoxified when
modified by the enzyme glutathione S-transferase (GST). GST belongs to a family of
enzymes that catalyzes the conjugation of glutathione (GSH) to cancer drugs (Hayes and
Pulford, 1995). Chemotherapeutic agents that are conjugated to glutathione are usually
less active than their unconjugated counterparts. Glutathione conjugated drugs can also
become substrates for the drug efflux pump, multidrug resistance protein 1 (MRP), and
thereby pumped out of the cell (Paumi et al., 2001). Cellular drug resistance to
anthracyclines is also associated with the intracellular amount of glutathione present
because glutathione neutralizes free radicals. Some topo targeting agents, including the
anthracyclines, exert their cytotoxic effect at least in part by producing free radicals.
Glutathione is implicated in modulation of free radical formation by decreasing OH
production. This is significant, because some human tumor cells have significantly
higher levels of GSH. In summary, acquired drug resistance to DNA alkylating agents is
attributed to deactivation by GST and extrusion from the cell by MRP, whereas drug
resistance to anthracyclines is attributed to neutralization of free radicals by GSH.
Additional mechanisms of cellular drug resistance to topo I inhibitors has also been
associated with induction of hepatic cytochrome P-450, activation of nuclear factor kappa
B (NF-κB), and activation of DNA-tyrosine phosphodiesterase (DTP1) (Frei et al., 2002;
Yang et al., 1996; Harris and Hochhauser, 1992). DTP1 is an enzyme able to cleave the
phosphodiester linkage between DNA and the active site tyrosine of topo I (Debethune et
al., 2002). Yeast cells expressing DTP1 gene mutations are hypersensitive to CPT and
thus, DTP1 may modulate CPT activity and affect cell sensitivity to topo I inhibitors
(Cheng et al., 2002).
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6.5 . Drug-target Events: Altered Quantity of Topoisomerase I or II Protein.
Generally, topo targeting agents turn topo into a lethal DNA damaging agent, so
that the more target enzyme that is available to induce DNA damage, the more effective
the agent. Thus, the amount of cleavable complex formation should increase as a
function of increasing enzyme levels (Larsen and Skladanowski, 1998). This is
supported by findings that the cytotoxicity of topo II poisons frequently correlates with
topo II levels and the proliferative status of the cells in vitro (Sullivan et al., 1987a,
1987b; Chow and Ross, 1987). Since cancer cells often have a higher level of topo IIα
protein and activity at all stages of the cell cycle, topo II is a frequent target of
antineoplastic agents. Tumor cells that are undergoing high rates of DNA replication are
more sensitive to topo inhibitors because topo IIα is preferentially transcribed in S-phase
cells and cells that are in S and G2/M have higher levels of topo IIα enzyme than nonproliferating cells. This has been demonstrated in breast cancer cell lines that are drug
resistant to etoposide because of lower amounts of topo IIα protein relative to the parental
cell line (Potmesil et al., 1988). Colorectal tumors show a 5-35 fold increase in topo I
protein levels compared to normal colorectal cells. Topo I levels are also increased 2-10
fold in prostate tumors compared to benign prostate tissues. Alterations in the expression
of topo protein may be due to loss or gain of gene copies or due to altered gene
transcription. For example, methylation of the topo I gene may account for
downregulation of topo I protein content in resistant cells (Fujimori et al., 1996).
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6.6 Drug Target Interactions: Altered Quality of Topoisomerase I or II Protein.
The phosphorylation status may contribute to alterations in cellular drug
sensitivity. Hyper and hypophosphorylation of topo II has been associated with reduced
cleavable complex formation and decreased drug sensitivity to topo II targeting agents
(Ritke et al., 1994). Changes in topo II phosphorylation are also associated with both
increased and decreased enzyme activity and a decrease in the cellular content of topo II
protein (Kroll, 1997). For example, hyperphosphorylation of topo IIα by casein kinase II
is associated with decreased protein levels and decreased drug sensitivity to etoposide in
breast cancer cells (Matsumoto et al., 1997). However, topo II phosphorylation does not
always result in attenuation of topo II content. HL60 cells selected for resistance to
doxorubicin were found to be cross-resistant to etoposide because of a reduction in the
formation of VP-16 stabilized cleavable complexes, when compared to the parent cell
line that were sensitive to both doxorubicin and etoposide (Ganapathi et al., 1996).
However, the attenuation of cleavable complex formation was not a result of either a
reduction in the amount or activity of topo II protein in these cells. The reduction in VP16 stabilized cleavable complex formation was attributed to a 3-fold decrease in the
phosphorylation status of topo IIα. Further investigations determined that, unlike topo
IIα, there is a concomitant hyperphosphorylation of topo IIβ in the HL60 cells selected
for doxorubicin resistance (Grabowski et al., 1999). Furthermore the changes in the
phosphorylation status of both topo IIα and IIβ correlated with an increase in drug
sensitivity to m-AMSA, a DNA intercalating agent that inhibits topo II. The increased
drug sensitivity to m-AMSA was attributed to a 2-fold increase in topo IIβ stabilized
cleavable complex formation as compared to VP-16 -topo IIβ cleavable complex
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formation. These results suggest that the phosphorylation status of the different topo II
isoforms may have a role in drug sensitivity that depends on the specific mechanisms of
drug action.
Although topo I has been shown to be differentially phosphorylated during
mitosis (D'Arpa and Liu, 1995), whether the changes in topo I phosphorylation have a
role in conferring differences in drug sensitivity to topo I targeting agents has not been
established. Human purified topo I enzyme activity is inactivated by phosphatases and
can be reactivated by casein kinase II or protein kinase C, suggesting that
phosphorylation regulates topo I enzyme activity (Kaiserman et al., 1988; Pommier et al.,
1990). However, differently phosphorylated forms of topo I have been shown to cleave
chromosomal DNA and relax supercoiled DNA with about equal topo I activity (D'Arpa
and Liu, 1995). Alternatively, sumoylation followed by redistribution of topo I from the
nucleoli to the nucleoplasm in response to topotecan or camptothecin exposure has been
reported (Mo et al., 2002; Rallabhandi et al., 2002). It is not clear whether the
translocation of topo I from the nucleoli to the nucleoplasm results in altered drug
sensitivity to topotecan or camptothecin. Another cellular mechanism that could confer
cellular resistance to topo I poisons appears to be the degradation of DNA-linked topo I,
which is mediated by ubiquitination and small ubiquitin related modifiers (SUMO)
(Desai et al., 1997). Proteins modified with ubiquitin molecules are frequently destroyed
by the proteasome, whereas sumoylation has been shown to modulate gene transcription,
protein-protein interactions, subcellular localization, and protein stability. When Chinese
hamster ovary cells are treated with camptothecin, topo I-DNA cleavable complexes are
multi ubiquitinated and destroyed by the 26S proteasome mediated pathway. However,
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only 5-10% of the total amount of cellular topo I that was trapped in the cleavable
complex after CPT treatment becomes conjugated to ubiquitin. Thus, it appears that a
fraction of topo I cleavable complexes are marked for ubiquitin mediated proteolysis.
Additional investigations are needed to address whether ubiquitin modified topo I
cleavable complexes can result in altered drug sensitivity to camptothecin and whether
proteasome mediated degradation of topo I cleavable complexes is specific to CPT and
topo I. Camptothecin also induces sumoylation of topo I on Lys-117, located in the
amino terminal region of topo I (Rallabhandi et al., 2002). Sumoylation of Lys-117 is
associated with the clearing of topo I from the nucleoli to the nucleoplasm in response to
CPT treatment.
There are numerous examples found in the National Library of Medicine that
describe posttranslational modifications of topo I and II occurring in cell lines that have
been selected for resistance to topo targeting drugs (Yu et al., 2004; Matsumoto et al.,
2001, 1999; Yanase et al., 2000; Yu et al., 1997; Kasahara et al., 1992). However, it is
beyond the scope of this investigation to review the results of all of these in vitro studies.
A reasonable conclusion that can be inferred from the collective results of all of these
investigations is that post-translational modification of topo I or II likely has a role in
conferring alterations in drug sensitivity by altering the amount or activity or the enzyme,
cleavable complex formation, or the stability of cleavable complexes. In vivo drug
resistance is likely to be manifested by any one or more of these methods that is
dependent on the drug class, enzyme targeted, and cell type.
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6.7 Drug Target Interactions: Topoisomerase Gene Mutations.
In some cell lines, cellular drug resistance to topo I and II targeting agents has
been attributed to both point mutations and deletions. Mutations in the topo I gene
usually confers in vitro cellular drug resistance to one class of topo I targeting agents
(Chang et al., 2002; Yanase et al., 2000). This is in contrast to topo II gene mutations
that usually result in cells being cross-resistant to all classes of topo II targeting agents
(Larsen and Skladanowski, 1998). However, some point mutations in the topo I gene,
including tyrosine 723 to phenylalanine (T723F) and tyrosine 727 to phenylalanine
(T727F), result in cells that are resistant to CPT and the indolocarbazole derivates of the
antibiotic rebeccamycin (Woo et al., 2002). Topo I gene mutations conferring resistance
to the camptothecins have been found in drug resistant human cell lines, yeast cells, and
in tumor tissue from patients treated with irinotecan (Tsurutani et al., 2002). Mutations
in the topo I gene appear to cluster either around the active site tyrosine residue (Tyr723)
or around amino acids 361 through 364 (Larsen and Skladanowski, 1998). Gene
mutations that involve amino acids 361, 362, 363, and 364, confer drug resistance to CPT
and are believed to alter the DNA-enzyme binding properties of CPT (Rasheed and
Rubin, 2003; Larsen and Skladanowski, 1998). Point mutations that occur in the core
domain of topo I have been attributed to cellular drug resistance to camptothecin because
of a reduction in topo I-DNA interactions (Kingma et al., 1999). Camptothecin resistant
P388 murine leukemia cells contain both gene rearrangements and hypermethylation in
one allele of the topo I gene, resulting in a reduction of topo I enzyme activity and
mRNA transcripts (Tan et al., 1989).
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Mutations in the topo IIα gene that confer altered cellular drug sensitivity to topo
targeting agents have been studies in both yeast and mammalian cell lines (Larsen and
Skladanowski, 1998). Point mutations in yeast cells have been shown to confer drug
resistance to etoposide (Kingma et al., 1999). A point mutation in yeast topo II that
results in histidine 1012 changed to a tyrosine (H1012Y) residue corresponds with a 3-4
fold increase in drug resistance to etoposide as compared to yeast cells expressing nonmutated topo II enzyme (Kingma et al., 1999). The observed drug resistance in these
cells was explained by a decreased affinity of etoposide-enzyme binding as compared to
non-mutated enzyme (Kingma et al., 1999). In human cell lines, selection for drug
resistance to etoposide or teniposide has been shown to result in point mutations in the
topo IIα gene (Patel et al., 1993; Bugg et al., 1991). Mutations found in human topo IIα
in drug resistant cell lines tend to cluster either around ATP binding domain or the active
site tyrosine residue (Nitiss and Beck, 1996). Furthermore, since topo II forms dimers, it
is possible that heterodimers exist that consist of one drug-sensitive and one drug
resistant subunit. Many cell lines that have been selected for resistance to topo II poisons
in vitro have been shown to carry mutations in the gene for topo IIα, but mutations are
rarely reported in patient samples (Wessel et al., 2002). Alterations in topo gene copy
number can also occur in human cancers. For example, the topo IIα gene is coamplifed
with the HER-2/neu oncogene in breast, ovarian, and bladder cancer cells because the
two genes are in close proximity to each other (Simon et al., 2003; Hengstler et al.,
1999). This is significant because an increase in topo IIα gene copy number is associated
with cancers that have increased sensitivity to topo II poisons such as doxorubicin, while
a deletion of one copy of the topo IIα gene is associated with resistance to doxorubicin.
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The only mutation in topo IIβ that has been reported to date is derived from drug-resistant
cell lines which contain topo IIβ gene mutations that completely abate the activity of the
enzyme (Dereuddre et al., 1995). No study has been reported that assesses mutations in
topo IIβ from clinical specimens.

6.8 Drug Target Interactions: Altered Chromatin Structure.
The topological structure of DNA modulates the level of topoisomerase binding
(Zechiedrich and Osheroff, 1990; Howard et al., 1991). In general, eukaryotic
topoisomerase I and II type enzymes prefer positive and negatively supercoiled DNA
over relaxed DNA substrates (Osheroff, 1986). Modifications such as glycosylation and
methylation have been shown to influence DNA conformation; however, the molecular
mechanism leading from DNA modification to cellular drug resistance is not well
documented (Stopper and Boos, 2001; Lopez-Baena et al., 1998). In mammalian cells,
DNA methylation of cytosine in CpG islands is an important regulatory mechanism of
gene expression. DNA methylation has also been shown to influence local
conformational changes in the structure of DNA (Zacharias et al., 1988; Diekmann,
1987) DNA methylation is associated with remodeling of euchromatin to
heterochromatin, suggesting that methylated DNA somehow alters the accessibility of
DNA to transcription factors and regulatory proteins (Hori, 1983). Conformational
changes that occur in methylated DNA have been also been suggested to alter the binding
and DNA cleavage properties of topo I and II (Boos and Stopper, 2001; Leteurtre et al.,
1994). For example, topo I and II cleavage patterns are modified in vitro by CpG
methylation in c-myc gene DNA fragments (Leteurtre et al., 1994). Topo I and II
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cleavage activity is shown to be dependent on the location of the methylated cytosine on
the DNA in relation to the scissile bond. Methylated cytosine has both suppressive and
stimulatory activity on topo I, whereas topo II cleavage activity is mostly suppressed by
methylated cytosine. DNA methylation of CpG islands been proposed to have a role in
tissue selectivity and efficiency of DNA topo targeting agents (Leteurtre et al., 1994).
DNA methylation has also been shown to alter topo II decatenation activity in vitro,
which may result in genomic instability, but whether this contributes to cellular drug
resistance is not known (Zwelling et al., 1989).

6.9 Post-target Events: DNA Repair.
Both topo I and topo II have roles in DNA damage recognition and repair
processes, but how cells repair drug-stabilized DNA cleavable complexes is poorly
understood. Sensitivity to DNA-crosslinking reagents is inversely proportional to topo
levels and thus, elevated levels of topo II correlate with resistance to DNA cross-linking
agents such as melphalan and Cisplatin (Dvorakova et al., 2002; Hirota et al., 2002).
This has been explained by the involvement of topo IIα in processing DNA damage
induced by melphalan (Hirota et al., 2002). A deficiency in topo IIα activity correlates
with increased drug sensitivity because of an increase in melphalan-induced sister
chromatid exchanges (Karpinich et al., 2002). These results suggest that the efficacy of
melphalan in cancer chemotherapy can be improved through inhibition of topo IIα.
Similar observations have been reported in H69 small-cell lung cancer cells resistant to
radiation and cisplatin, in part because of an increase in topo IIα expression (Hennes et
al., 2002). The results suggest that increased topo IIα expression may confer radiation
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and drug resistance because of increased DNA repair, and that radiation followed by a
topo IIα targeting agent may be a potential strategy for overcoming resistance in small
cell lung cancer. DNA repair pathways have also been implicated in conferring
sensitivity to etoposide and camptothecin in human colorectal cancer cells (Jacob et al.,
2001; Aebi et al., 1997). DNA mismatch repair (MMR) is normally involved in
correcting base/base mismatches during DNA replication but it is also implicated in
double strand DNA break repair and for modulating the induction of apoptosis as a result
of various types of drug induced DNA damage. Cell lines defective in DNA mismatch
repair pathways show increased sensitivity to both CPT and etoposide as compared to
MMR proficient colorectal cell lines and sensitivity to these drugs does not correlate with
endogenous levels of topo I or topo II (Jacob et al., 2001). In summary, differences in the
processing and repair of DNA lesions are likely to have a role in drug sensitivity to topo
targeting agents. It is plausible that the way cells remove and repair drug-stabilized
cleavable complexes could influence cellular sensitivity to DNA damaging agents.

6.10 Post-target Events: Alterations in Cell Cycle Progression.
The cellular content of topo IIα protein is highest during G2/M and lowest during
early G1 of the cell cycle (Meyer et al., 1997; Nakajima et al., 1996). Topo IIα protein is
also markedly decreased in growth-arrested cells as compared to proliferating cells
(Holden et al, 1990, Turley, et al, 1997). In contrast, topo I and topo IIβ have a relatively
uniformed expression throughout the cell cycle as compared to topo IIα (Drake et al.,
1989). The cell-cycle and proliferation dependent fluctuations of topo IIα gene
expression may also explain why some slow growing cancers may be intrinsically
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resistant to topo inhibitors. Therefore, the application of drugs specifically directed
against topo IIβ could be useful for tumors that express a mutant form of topo IIα or have
a large fraction of cells in Go/G1. In these cases, topo IIβ could be a preferred molecular
target because unlike topo IIα, topo IIβ expression is not dependent on the cell cycle or
proliferative stage of the cell. XK469 is a new anticancer agent that is reported to
specifically target topo IIβ, although it may also have an anti-proliferative role involving
cell-cycle related proteins (Snapka et al., 2001; Gao et al., 1999). XK469 exerts its
cytotoxic effect by arresting cells in prophase as a result of an irreversible accumulation
of cyclin B1 in the G2/M phase of the cell cycle (Ding et al., 2001). XK469 has been
shown to have activity against a broad spectrum of murine solid tumors, including tumors
that express the multi-drug resistance gene (LoRusso et al., 1998-99).

6.11 Post-target Events: Altered Cell Death Pathways.
Certain cellular conditions such as glucose starvation, hypoxia, and DNA
damage, are associated with drug resistance to topo II inhibitors, such as etoposide and
adriamycin, because of a decrease in topo IIα gene expression. A decrease in
transcription of topo IIα gene correlates with increased levels of Sp-3, YB1, and p53
status. Several studies have investigated the role of p53 in response to topo mediated
DNA damage (reviewed in Valkov and Sullivan, 2003). The p53 protein has been shown
to interact with topo II in vitro and stimulates the decatenation activity of topo II (Cowell
et al., 2000). The p53 protein can arrest cell cycle progression and can commit cells to
programmed cell death (Bladosklonny, 2002). Since p53 is mutated in a large percentage
of cancers, this could suggest that a failure to induce apoptosis results in resistance to
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DNA-damaging agents (Bunz et al., 1999). Since topo-targeting agents kill cells by
inducing DNA damage, p53 deficient cells could be resistance to topo poisons. Other
alterations in the apoptotic pathway may also confer cellular drug resistance to topo
inhibitors. For example, an elevated level of the anti-apoptotic protein bcl-2 is associated
with decreased drug sensitivity in cancer cells (Real et al., 2004).

6.12 Conclusions.
In summary, cancer cells have multiple different ways to evade the cytotoxic
effects of topo targeting drugs. Tumor cells with de novo resistance fail to respond to
initial drug treatment.. In contrast, tumor cells with acquired drug resistance are initially
sensitive to drug exposure, but then become resistant with future drug exposures. The
most commonly observed mechanisms of in vitro drug resistance to topo targeting agents
usually describes alterations in drug transport or alterations in the amount or activity of
topo IIα protein that may or may not be accompanied by topo IIα gene mutations.
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Chapter Seven
In vivo Mechanisms of Topoisomerase Associated Drug Resistance

7.1 Introduction.
The mechanisms of drug resistance described for topo I and topo II inhibitors in
model human cell lines have been well established, but the actual in vivo situation in
patients with solid tumors and hematologic malignancies is still uncertain. Mechanisms
of in vivo drug resistance to topoisomerase targeting agents are usually related with
alterations in drug transport and the quantity of topo protein or mRNA in clinical
preparations. However, in vivo drug resistance to topo inhibitors is likely to be a
phenomenon influenced by a network of physiological factors, such as drug dosage,
presence of the molecular target, the tumor microenvironment, and presence or absence
of specific genetic aberrations (reviewed in Lehnert, 1996). The clinical activity of
chemotherapy is also dependent on hepatic drug metabolism, extracellular drug
concentration, intracellular drug transport, and ability of the drug to access the cancer
cells. Furthermore, antitumor agents differ in their ability to diffuse through different
tissues. For example, scar tissue from surgery or radiotherapy reduces response rates
with chemotherapy, especially in head and neck cancers (Rooney et al., 1985).
Furthermore, some tumors can be poorly vascularized and some drugs are unable to cross
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the blood brain barrier. Therefore, various in vivo factors can influence how much active
drug reaches the molecular target withincancer cells. Cellular drug resistance in humans
is complex and appears to be both multifactorial and variable amongst individual
patients.
The work presented herein definitively describes an in vitro mechanism of drug
resistance observed to topo II targeting agents in a human leukemia and myeloma cell
lines. Although clinical applications are speculated from the in vitro data presented in
this work (refer to pages 201-203 herein), a complete description of in vivo mechanisms
of cellular drug resistance in the clinical environment was outside the limits of this
investigation (reviewed in Engel et al., 2003). The focus here is to briefly describe our
current understanding of clinical drug resistance to topoisomerase targeting
chemotherapeutic agents. This chapter focuses on gene mutations, cellular content of
topo I and II, and the tumor microenvironment as mechanisms of clinical drug resistance
to topo targeting chemotherapeutic agents.

7.2. Gene Mutations.
There has been a constant search for point mutations, deletions, truncations, and
atypical isoforms of topo in a wide variety of clinical samples and diverse tumor types.
Several genetic aberrations, such as allelic inactivation, deletions, and point mutations,
have been reported to occur in the gene for topo I and II in human cell lines. However,
topo I and II gene mutations are rarely detected in patient samples. Thus far, the
bronchial aspirate of one patient with small cell lung cancer treated with either etoposidecontaining chemotherapy is the only reported case to have identified two point mutations
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in the topo IIα gene (Kubo et al., 1996). DNA sequence analysis of this tumor show two
transversions at codons 486 (G to A) and 494 (A to G), resulting in two missense
mutations (arginine to lysine and glutamate to glycine, respectively). More frequently,
chemotherapy with topo II inhibitors leads to gross genomic rearrangements, including
gene amplifications and deletions of the topo IIα gene (Järvinen and Liu, 2003). For
example, a recent clinical trial has detected topo IIα gene amplification by fluorescence
in situ hybridization (FISH) in clinical samples from primary breast cancer tumor
samples, which correlates with response to topo II inhibitors (Järvinen et al., 1999).
Breast cancer seems to be one disease where amplification or deletion of the topo IIα
gene frequently occurs (Järvinen and Liu, 2003). Furthermore, topo IIα has been shown
to be a marker of tumor aggressiveness and invasive potential in breast cancer, but the
complexity of the response of breast tumors to chemotherapy is usually determined by
evaluation of several markers (Cardoso et al., 2001; Nakopoulou et al., 2000).
There have been a limited number of clinical studies reporting topo I gene
mutations (Ohashi et al., 1996). One patient with large cell lung carcinoma who did not
respond to cisplatin or irinotecan was found to have a missense mutation at codon 737 in
the topo I gene (Tsurutani et al., 2002). However, it was not determined if the missense
mutation altered CPT induced topo I cytotoxicity. Colorectal carcinomas have a high
expression of topo I protein that is due to an increased topo I gene copy number, reaching
up to eight copies (Boonsong et al., 2002, 2000). For this reason, irinotecan, a topo I
inhibitor, is being evaluated in clinical trials for the effective treatment of colorectal
carcinoma. Additional clinical studies are needed to determine if gene mutations found
in drug resistant cell lines are clinically relevant.
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7.3 Topoisomerase I and II Gene and Protein Expression.
The amount of topo protein has been investigated as a predictive factor for
clinical response to topo I and topo II targeting chemotherapeutic agents. All studies
point to a substantial interpatient variability in the amount of topo content and often fail
to correlate the amount of topo enzymes with either the prognosis or with the clinical
response to topo I and topo II inhibitors used in different combinations (McKenna et al.,
1994). For example, in acute lymphoblastic leukemia (ALL), Western blot analysis,
polymerase chain reaction (PCR), Northern blot analysis and immunohistochemistry
demonstrate that topo I and topo II gene and protein expression are variable (Stammler et
al., 1994; McKenna et al., 1994). In these studies, a total of 60% of the blasts are shown
to be positive for topo II while the levels of topo I are in the range of 25-85% of the
control cell line. However, no correlation is found between the level of topo and clinical
response.

7.4 Tumor Microenvironment.
Additional physiological conditions exist in vivo that contribute to decreased drug
sensitivity. For example, under physiological conditions in the bone marrow, tumor cells
aggregate to form tumor cell masses that confer drug resistance. This is supported by in
vitro studies demonstrating that when cancer cells are cultured in monolayers they are
more susceptible to cytotoxic agents than when cultured as 3D aggregates, a phenomenon
referred to as multicellular drug resistance (Jianmin et al., 2002; Desoize and Jardillier,
2000)). Cell adhesion mediated drug resistance (CAM-DR) is another phenomenon
whereby tumor cells bind stromal cells or extracellular matrix proteins (Dalton, 2003).
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CAM-DR represents an intrinsic mechanism of drug resistance used by malignant cells
(Dalton, 2003). Collectively, these findings suggest that the resistance to anticancer
drugs that are often observed in the clinic is likely to be a result of many physiological
conditions that act simultaneously (Mattern and Volm, 1993). This hypothesis is
supported by in vitro findings that cells selected for drug resistance have multiple
mechanisms conferring decreased drug sensitivity (Hazlehurst et al., 1999; Harker et al.,
1995). An example of an in vitro cell model that supports this theory comes from the
mitoxantrone resistant 8226/MR4 8226/M20 myeloma cells (Hazlehurst et al., 1999).
When compared to the drug-sensitive parental cell line, the 8226/MR4 cells were 10-fold
resistant to mitoxantrone and 4-fold resistant to etoposide, whereas the 8226/M20 cells
were 37-fold resistant to mitoxantrone and 15-fold resistant to etoposide. Drug resistance
in both cell lines was associated with decreased drug accumulation in a P-gp and MRP
independent mechanism. Decreased drug accumulation in these cells was attributed to an
ATP dependent ouabain-insensitive drug transport mechanism. Drug resistance could be
reversed by the chemosensitizer, fumitrenogin C. However, drug resistance in the
8226/M20 cells was also attributed to a 70-88% reduction in topo IIα and topo IIβ protein
content and reduced topo II enzyme activity, which was not observed in the 8226/MR4
cells (Hazlehurst et al., 1999). Thus, cancer cells have numerous mechanisms for
overcoming the drug cytotoxicity.

80

7.5 Conclusions.
Resistance to chemotherapy is a common problem in patiens with cancer and a
major obstacle that must be overcome for cancer therapy to be effective. In vivo drug
resistance is likely to be a multifactorial problem. Tumor cells can manipulate their
tumor microenvironment to gain growth and proliferative advantages and some tumor
cells may have gene mutatins that contribute to altered drug sensitivity. Therefore,
clinicians must consider numerous biological variables that may differ between patients
to optimize the effectiveness of cancer chemotherapy.
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Chapter Eight
Nuclear-cytoplasmic Trafficking of Proteins

8.1 Introduction.
The separation of the nucleus from the cytoplasm plays a central role in regulating
the subcellular localization of proteins, but is also a variable in drug delivery and
cytotoxicity. Generally, topo poisons convert the enzyme into a lethal DNA damaging
agent, such that the more active enzyme that is present in the nucleus, the more effective
the poison (reviewed in Engel et al., 2003). Without the co-existence of the ternary drugDNA-topo complex, topo inhibitors are less effective as cytotoxic agents. Thus,
investigating the selective movement of macromolecules across the nuclear envelope
represents a recent area of drug development (Dean et al., 2003). The potential of the
DNA topoisomerases to shuttle between the nucleus and cytoplasm has been one area of
recent investigations (Engel et al.2004; Valkov et al., 2000).

8.2 The Nuclear Pore Complex.
Recent investigations have elucidated several molecular pathways for the nuclear
import and export of proteins across transport passageways or nuclear pore complexes
(NPCs) (Weiss, 2003). The NPCs are located in the nuclear envelope where the inner
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and outer membranes are fused, providing a link between the cytoplasm and the interior
of the nucleus (Davis, 1995; Doye and Hurt, 1997; Görlich and Mattaj, 1996). The NPC
is a large (125 MDa) (Reichelt et al., 1990) multimeric protein structure that perforates
the nuclear envelope and channels proteins greater than 40 kDa into or out of the nucleus
(Pante and Kann, 2002; Hinshaw et al., 1992). The NPC consists of a central ring-spoke
structure flanked by filaments emanating from its nuclear and cytoplasmic surfaces
(Hinshaw and Milligan, 2003; Akey and Radermacher, 1993). The pores are 25 nm in
diameter and form 9 nm long channels (Peters, 1986). The number of NPCs per nucleus
varies with the organism, cell type, and growth conditions (Maui, 1977). It is common
for cells to have between 102 and 5 X 107 NPCs present per nucleus, depending on the
metabolic or differentiation state of the cell. Mammalian cells typically have 3,000-5,000
NPCs, whereas yeast cells have approximately 120 NPC per nucleus (Winey et al., 1997).

8.3 Nucleoporins.
The NPCs are composed of approximately eight copies of 30 different proteins,
the nucleoporins (Nups) (Rabut et al., 2004). A number of membrane and nonmembrane
anchored Nups have been described in yeast and mammalian cells by mass spectroscopy
(Cronshaw et al., 2002). Nup210 and glycoprotein 121 (gp121) are believed to play
critical roles in anchoring the NPC to the nuclear envelope (Wozniak et al., 1989). The
Nups are phosphorylated in a cell-cycle dependent manner and are hyperphosphorylated
during M-phase (Favreau et al., 1996). During mitosis, the nuclear membrane
breaksdown and the NPC is disassembled. Phosphorylation of nucleoporins is associated
with the disassembly of the NPC as well as reformation of the NPC when cell division is
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complete. Nucleoporins contain characteristic domains featuring multiple repeats of
short peptide sequences ending in the amino acids phenylalanine and glycine (FG
repeats) (Bayliss et al., 2000). The FG repeats provide docking sites for protein- receptor
cargo complexes (Radu et al., 1995). Binding of transport receptors to the FG domains
on the nucleoporins triggers the pore to dilate (Shahin et al., 2005; Shulga and Goldfarb,
2003). One model suggests that multiple FG rich repeats in the NPC channel form a
meshwork through weak hydrophobic interactions, which can function as a sieve
(Ribbeck and Görlich, 2001). Hydrophobic receptor-cargo complexes can transiently
interact with the hydrophobic repeats, and thus dissolve the meshwork and translocate
thorough the NPC. In contrast, hydrophilic proteins remain excluded, explaining the high
selectivity of the NPC. Transport through the NPC machinery appears to be regulated by
mitogenic signals, phosphorylation, and Ca2+ concentrations within the endoplasmic
reticulum and nuclear lumen (Harreman et al., 2004; Greber and Gerace, 1995). For
example, Ca++ stores in the nuclear envelope of Xenopus laevis oocytes, is suggested to
regulate NPC gating (Perez-Terzie et al., 1996). In these cells, conformational changes in
the NPC require calcium, such that when the Ca++ stores are depleted, a central plug
occludes passage of nuclear transport processes. Similar results have been observed in
HeLa cells grown in the presence of the calcium pump inhibitor, thapsigargin, which
blocks signal-mediated protein import (Greber and Gerace., 1995). These results suggest
that calcium stores present in the lumen of the endoplasmic reticulum, which is
contiguous with the nuclear envelope, may have a role in regulating nuclear–cytoplasmic
trafficking.
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8.4 Nuclear and Cytoplasmic Targeting Sequences.
Since 1999, when Günter Blobel received the Noble Prize in Physiology and
Medicine for discovering that proteins have intrinsic signals that govern transport and
localization in cells, there have been significant advancements in understanding the
mechanisms of nuclear-cytoplasmic transport of proteins (Raju, 2000; Shields, 2001).
Investigative reports now describe many different types of nuclear-cytoplasmic targeting
sequences, including nuclear localization sequences (NLS), nuclear export sequences
(NES), nuclear retention sequences (NRS), cytoplasmic retention sequences (CRS), and
bi-directional shuttling sequences (Jans et al., 1998). Proteins targeted for receptormediated transport across the NPC must either contain an NLS or NES. However, some
proteins that do not contain a nuclear-targeting sequence still traverse the NPC by piggybacking with another protein containing a NLS or NES.

8.5 Nuclear Localization Signals.
The first NLS, PKKKRK was identified in the Simian Virus 40 (SV 40) large T
antigen (Kalderon et al., 1984). The NLS found in the SV40 large T antigen was later
referred to as a monopartite sequence to distinguish it from the bipartite sequence,
KRPAATKKAGQAKKKKLD, found in Xenopus nucleoplasmin (Robbins et al., 1991).
The monopartite sequence is often referred to as the “classical” NLS and consists of a
short cluster of basic amino acids, often preceded by an acidic amino acid or proline
residue. Human DNA topo I has a classical monopartite NLS between amino acids 150156 (Stewart and Champoux, 1996). The amino acid sequence of the monopartite NLS in
topo I is KKIKTED. Recently, a second non-classical monopartite signal was identified
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in topo I between amino acids 117-146 (Mo et al., 2000). In contrast to the basic amino
acid residues found in a classical NLS, this NLS is unique because it is characterized by
two clusters of acidic amino acids at amino acids 117-146 and 151-156. The first cluster
of acidic amino acids is KDEPEDDG followed by a spacer region of 16 amino acids, and
then the second cluster of acid amino acids is DEDDAD. Thus, topo I has two
independent NLS with opposite charged amino acids. The precise amino acid sequence
that targets topo IIβ to the nucleus has not been determined, but the last 116 amino acids
found in the C-terminal domain in necessary and sufficient for nuclear localization of
topo IIβ in mammalian cells (Cowell et al., 1998). The C-terminal domain is presumed
to have a bipartite NLS, which has been implied by the presence of several bipartite NLS
type motifs found in the C-terminal domain of topo IIβ.
Bipartite NLS, a second type of NLS, consists of two clusters of basic amino
acids separated by a spacer region of approximately ten amino acids, often flanked by a
neutral or acidic amino acid (Robbins, et al., 1991). Topo IIα contains a bipartite NLS
located in the carboxy-terminus between amino acids 1454-1497 that consists of a spacer
region of 21 amino acids (Mirski et al., 1997). The amino acid sequence for the NLS in
topo IIα is KPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDD
(Mirski et al., 1997). The two clusters of basic amino acids are shown in bold text.
Computer software programs are available that can scan amino acid sequences for
potential bipartite NLS (Shelagh et al., 1999). Additionally, previously described NLS
are annotated in SWISS-Prot and PIR and can be retrieved at the NLS database located at
the Predict NLS server (Nair et al., 2003).
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8.6 Nuclear Export Signals.
Classic protein NES are hydrophobic rich sequences that have a characteristic
spacing of leucine, isoleucine, valine, and/or phenylalanine amino acid residues (Elfgang
et al., 1999). The Center for Biological Sequence Analysis at the Technical University of
Denmark has prepared an NES predictor, called the NetNes 1.1 server, accessible to the
public and found on the worldwide web (la Cour et al., 2004). The NetNes 1.1 server
uses a prediction algorithm based on previously described NES, but also uses a “hidden
Mark model” to identify non-hydrophobic residue that are not included in the consensus
sequences for classical NES. To date, approximately 80 experimentally validated proteinNES have been identified and compiled on the NESbase version 1.0 database, which is
also accessible on the worldwide web (la Cour et al., 2003). NES have been identified
based on the fact that mutation or deletion of the NES renders it inactive in mediating
nuclear export of the protein carrying it, or that the NES is active in effecting export from
the nucleus of a carrier protein such as beta-galactosidase (Jans et al., 1998).

8.7 Retention Signals.
Some proteins contain nuclear retention or cytoplasmic retention signals, which
do not specifically target a protein to the nuclear or cytoplasmic compartments, but
assures their retention once there (Jans et al., 1998). The nuclear retention signals usually
consist of an arginine rich motif and may include an arginine rich α-helical structure.
One example of a NRS has been described in an SR protein. The SR proteins are RNA
splicing factors that contain RNA recognition motifs and a C-terminal domain rich in
alternating serine (S) and arginine (R) amino acids, known as the RS domain. The RS
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domain can become phosphorylated and direct the subcellular localization and
nucleocytoplasmic shuttling of individual SR proteins (Cazalla et al., 2002). The human
SC35 SR protein, however, contains a dominant nuclear retention signal located in the
RS domain, and thus is not shuttled between the nucleus and cytoplasm. The nuclear
retention signal for the SC35 SR protein is, PPPVSKRESKSRSRSKSPPKSPEEEGAVSS
(Cazalla et al., 2002). The adenovirus E4orf6 protein also contains an amphipathic
arginine rich α-helical region with the amino acid sequence ARRTRRLMLRAVRIIAE,
which has been associated with E4orf6 nuclear retention. The cytoplasmic retention
signals are less well characterized (Satoshi et al., 2003). For example, cyclin B1 contains
a cytoplasmic retention signal that consists of a stretch of 45 amino acids located in the
amino terminus (Pines and Hunter, 1994). The CRS is situated within a CRM1
dependent NES of cyclin B1 (Yang et al., 1998). During interphase, cyclin B1 is
exported to the cytoplasm via the NES and is retained in the cytoplasm through its
cytoplasmic retention signal. Cyclin B1 is then imported back into the nucleus by NLS
phosphorylation (Hagting et al., 1999; Li et al., 1997). Cytoplasmic retention signals
have been identified in human and Xenopus cyclin B1 and Xenopus cyclin B2
(Yoshitome et al., 2003; Pines and Hunter, 1994). The amino acid sequence alignments
for CRS and NES for human and Xenopus cyclin B are shown in Figure 16.
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Human cyclin B1
Xenopus cyclin B1
Xenopus cyclin B2

142 PVKEEKLSPEPI LVDTASPSPMETSGCAPAEEDLCQAFSDVILAVN
154
91
EP
SSPSPMETSGCLPDE LCQAFSDVLIHVKDVDADD 126
89
PSPVPMDVSLKEEE LCQAFSDALTSVEDIDADD 121

Figure 16. Cytoplasmic Retention Signals and Nuclear Export Sequences for Cyclin B. The CRS in human
cyclin B1 consists of a stretch of 45 amino acids (residues 142-154) and a NES between amino acids 142151. The CRS for Xenopus cyclin B1 and B2 contains amino acid residues 91-126 and 89-121,
respectively. All of the NES (shown in bold text) that have been found in either cyclin B1 or B2 are nested
within the CRS. (Yoshitome et al., 2003; Pines and Hunter, 1994).

8.8 Bi-directional Shuttling Signals.
Another type of shuttling signal is characterized by the M9 sequence of
heterogeneous nuclear ribonucleoprotein A1, which consists of a 38-amino acid stretch
that is enriched in aromatic residues and glycine (Pollard et al., 1996). The M9 sequence
functions in both nuclear import and nuclear export and is now referred to as a “shuttling
sequence” to distinguish it from the unidirectional targeting sequences (NLS and NES).

8.9 Signal-mediated Nuclear Transport.
Active transport between the nucleus and cytoplasm involves primarily three
classes of macromolecules: substrates, adaptors, and receptors. In general, protein import
occurs when the transport receptors, importin-α and importin-β, form a complex with the
protein-NLS and escort the protein cargo across the NPC into the nucleus (Figure 17)
(Nigg, 1997; Görlich and Mattaj, 1996; Moroianu et al., 1996). The protein cargo is
released into the nucleus when the guanine nucleotide exchange factor, RCC1/RanGEF,
replaces Ran bound GDP with GTP. In the presence of GTP. importin-α binds the export
receptor, cellular apoptosis susceptibility protein (CAS), and is transported back into the
cytoplasm. Importin-β remains bound to GTP and is recycled back to the cytoplasm.
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Once in the cytoplasm, RanBP1 and RanGAP1 hydrolyze the bound GTP to GDP
(Gasiorowski and Dean, 2003).
Protein export occurs when Ran-GTP and the nuclear export receptor,
chromosome region maintenance-1 (Crm-1 or exportin-1), bind to a protein bearing an
NES and transports the protein cargo into the cytosol (Figure 18) (Fukuda et al., 1997).
The protein cargo is released into the cytoplasm when Ran-GTP is hydrolyzed by
RanBP1 and RanGAP1, small GTPase activating proteins (Yamada et al., 2004; Görlich
et al., 2003). In this manner, continued nuclear-cytoplasmic shuttling occurs by
maintaining a gradient of Ran-GTP in the nucleus and Ran-GDP in the cytoplasm
(Görlich et al., 1996).
Several notable exceptions to this general mechanism have been reported
(Miyamoto, 2002). For example, HIV-1 Rev proteins are recognized by importin-β rather
than the importin-α/importin-β heterodimer (Tiganis et al., 1996). Moreover, the
accessory protein Tat of HIV-1 Rev is not recognized by either importin α or β
(Efthymiadis et al., 1998), but rather, by other receptors related to importin β. At least 21
different importin β family members have been identified in humans. Furthermore, Crm1 belongs to the growing Kapβ family of proteins (table 6) (Moroianu, 1998). Crm-1 was
identified as a general receptor for proteins bearing hydrophobic rich NES, but table 6
establishes that receptor mediated nuclear export may be more specific (Jans et al., 2000).
Many more import and export receptors are believed to exist, so it is possible that nuclear
import and export pathways show sufficient specificity to be considered targets for
therapeutic intervention. The precise nuclear transport pathways for topo enzymes has not
been elucidated (Engel and Turner et al., 2004; Mirski et al., 2003).
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Figure 17. Nuclear Import Pathway. Protein cargo containing a nuclear localization signal binds to the nuclear import receptor, importin α. Importin
β-bound to Ran-GDP forms a complex with the importin-α protein cargo and escorts the entire complex across the nuclear pore complex. Once inside
the nucleus, the nucleotide exchange factor, RCC1, replaces Ran-GDP with Ran-GTP. Importin-β-Ran-GTP is transported back to the
cytoplasm.where GTPases recycle Ran-GTP back to Ran-GDP. Importin-α is exported from the nucleus by the export receptor, cellular apoptosis susceptibility protein
(CAS).
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Cargo

RCC1/RanGEF
CRM-1

Ran-GTP

CRM-1

Ran-GTP

Nucleus

Cytoplasm

CRM-1 Ran-GDP

Cargo

Recycled CRM-1

CRM-1
Recycled Ran-GDP

Ran-GDP

RanGAP
RanBP1

Cargo

Ran-GDP

Figure 18. Nuclear Export Pathway. The presence of guanine nucleotide exchange factors in the nucleus maintains a
high concentration of Ran-GTP in the nucleus and Ran-GDP in the cytoplasm. In the nucleu, Ran-GTP binds the export
receptor, Crm-1 and a NES-containing protein cargo. Crm-1 escorts the complex across the nuclear por complex. In the
cytoplasm, Ran-GTPases hydrolyze GTP to GDP. Crm-1 and Ran-GDP are recycled.
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Table 6 . Nuclear Export Receptors.
Mammalian Kapβ Family Export Receptors
Protein Receptor

Export Cargo

CRM-1 (exportin-1)

general export receptor for leucine rich export sequences

CAS

importin-α

Importin-13

eukaryotic translation factor-5A

Exportin-4

hypusine-modified eukaryote translation factor-5A*

Exportin-5

dsRNA binding proteins

Exportin-6

actin export

Exportin-7

p50RhoGAP
Non-Kapβ Family Nuclear Export Receptors

Mex67p (yeast)

mRNA

TAP/NXF (metazoans) mRNA
*hypusine, [N(epsilon)-(4 amino-2-hydroxybutyl)lysine], is a rare amino acid. Hypusine
is formed when a lysine residue is post-translationally modified by the transfer of a
butylamine from spermidine followed by hydroxylation reaction (Mehta et al., 1994;
Shiba et al., 1971).

8.10 Regulating Nuclear-cytoplasmic Transport.
Signal mediated transport has been shown to be regulated by several cellular
processes that are summarized in Figure 19. Phosphorylation (Engel et al., 1998),
ubiquitination (Lohrum et al., 2001), and sumoylation (Salinas et al., 2004) are the most
widely reported mechanisms of transport regulation. Like ubiquitination, sumoylation is
a three-step process involving an EI-activating enzyme heterodimer Aos/Uba2, the E2conjugating enzyme Ubc9 and substrate-specific E3 ligases (Gill, 2004). The
nucleoporin Nup358 (or RanBP2) is an example of an E3 ligase involved in modifying
nucleo-cytoplasmic shuttling proteins with small ubiquitin-like modifiers (SUMO)
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(Azumo and Daso, 2002). This finding illustrates the intimate association of SUMO
modification in regulating nuclear-cytoplasmic protein transport.
Several drugs and molecular agents have been used to decipher transport
processes in the laboratory (Table 15 appearing on page 213). LMB is an unsaturated
branched-chain fatty acid isolated from Streptomyces pombe (Hamamoto et al, 1983a).
LMB is an antifungal antibacterial agent with anti-tumor activity (Hamamoto et al.,
1983b) and was

also shown to be an inhibitor of the nuclear export receptor,

chromosome region maintenance protein-1 (Crm-1) (Kudo et al., 1998). LMB attacks the
sulfydryl groups on cysteine-529 of Crm-1 in a Michael-type reaction (Kudo et al., 1999).
In this way, LMB blocks all Crm-1-mediated nuclear export. The ratjadones represent a
new class of natural compounds which inhibit proliferation in eukaryotes by blocking
nuclear export (Meissner et al., 2004). Like LMB, the ratjadones covalently bind to Crm1. Additional compounds are being screened for their ability to block nuclear-export of
proteins at different points in the export pathway.

8.11 Conclusions.
The nuclear-cytoplasmic trafficking proteins have potential applications in drug
delivery and drug-target interactions. The nuclear pore complexes are the gateway
between the nuclear anc cytoplasmic compartments. Protein transport across the NPC
requires the presence of nuclear localization or nuclear export signals. Crm-1 has been
identified as the major export receptor that transports NES containing proteins out of the
nucleus. Leptomycin B specifically inhibits Crm-1 mediated nuclear export of proteins
and is being investigated for its therapeutic potential in the treatment of cancer.
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Figure 19. Mechanisms of Nuclear-cytoplasmic Transport Regulation. NLS,
nuclear localization signal; NES, nuclear export signal; NRS, nuclear retention
signal; CRS, cytoplasmic retention signal; FKHR, fork head transcription
factor; Ub, ubiquitin; and SUMO, small ubiquitin-like modifier (reviewed in
Jans et al., 2000).
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Chapter Nine
Experimental Objectives and Rationale

In vitro experiments demonstrate that cancer cells may exhibit multiple different
mechanisms to evade drug cytotoxicity. We were interested in identifying mechanisms
of cellular drug resistance to DNA topoisomerase targeting agents. Altered drug
transport and alterations in the quantity or quality of topo protein, which may or may not
be a result of topo gene mutations, have already been described in cell lines selected for
drug resistance. In culture, most cell lines also display a differential sensitivity to topo II
inhibitors, which depends on cell density (Sullivan et al., 1986, 1987; Chow and Ross,
1987; Markovits, 1987). It is well established that when cell lines become confluent and
maintain extensive cell-cell interactions they become intrinsically drug resistant (Croix
and Kerbel, 1997). How cell adhesion controls cell growth, apoptotic signal, cell cycle
progression and drug resistance remains to be elucidated. One mechanism of in vitro
drug resistance to topo II inhibitors has been described to occur when cells transition
from log to plateau cell density. For example, in non-transformed cell lines, the
transition from log to plateau density may lead to an attenuation of cellular topo IIα
amount and activity, with concomitant drug resistance (Sullivan et al., 1987). However,
tumor cell lines do not necessarily downregulate topo protein content at plateau cell
density, yet the cells are resistant (Sullivan et al., 1986, 1987). Therefore, tumor cell
lines must have other ways besides the degradation of topo II protein for evading drug
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cytotoxicity. Thus, we investigated the differences in drug sensitivity of several leukemia
and myeloma cell lines at three levels of increased cell densities, called log, plateau, and
accelerated-plateau, and then explained any observed drug resistance experimentally.
Therefore, we investigated possible alterations in the cell cycle, drug transport, topo II
enzyme activity, cleavable complex formation, and subcellular distribution of topo I, topo
IIα, and topo IIβ.
Much of our current understanding of drug resistance is derived from cell lines
that have been selected for drug resistance by applying a continuous drug pressure, and
then correlating the total cellular content of topo or expression of drug efflux pumps with
drug resistance (Davis et al., 1998). Our data establish a novel mechanism of drug
resistance in human myeloma cell lines that is detectable prior to any drug exposure and
independent of protein expression or P-gp mediated drug resistance. We demonstrate that
topo IIα translocates to the cytoplasm in a cell-density dependent manner and that the
nuclear export of topo IIα has a role in decreased drug sensitivity to VP-16 and other topo
targeting agents, but less so with non-topoisomerase inhibitors. The cytoplasmic
localization of topoisomerase IIα has thus far been attributed only to C-terminally
truncated proteins that have lost a critical nuclear localization signal (Wessel et al., 1997).
Our data are the first to describe a nuclear export signal of topo IIα by cells expressing
full-length topo IIα-GFP. We also demonstrate that a cytoplasmic transport of
endogenous topo IIα in human myeloma cells can be abrogated in the presence of the
nuclear export inhibitor, leptomycin B. The clinical significance of these findings is the
treatment of multiple myeloma is suggested.
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Chapter Ten
Materials and Methods
10.1 Materials.
Etoposide (VP-16), phenylmethylsulphonyl fluoride (PMSF), cis-platinum,
paclitaxel (taxol), carmustine (BCNU), ara-C (cytosine 1-β-D-arabinofuranosyl
hydrochloride), dimethyl sulphoxide (DMSO), 2-mercaptoethanol, and leptomycin B,
NonidetP-40 (NP-40), phenylmethylsulphonyl (PMSF), adenosine triphosphate (ATP),
dithiothreitol (DTT), ethylenediaminetetroactetic acid (EDTA), MTT, and vincristine,
were all obtained from Sigma Chemical (St. Louis, MO). Mitoxantrone was generously
provided by Immunex Corp (Seattle, WA). Topotecan was generously provided by
SmithKline Glaxo (Philadelphia, PA).

10.2 Cell Culture.
All cells were obtained from the American Type Culture Collection (Manassas,
VA). The RPMI-8226 cell line is from the peripheral blood of a 61 year old male with
multiple myeloma and the NCI-H929 cell line is from the malignant effusion of a 62 year
old Caucasian female with myeloma. The HL-60 cell line was obtained from a 36-year
old Caucasian female with acute promyelocytic leukemia. This cell line is positive for
the myc oncogene. The KG-1a human acute myelogenous leukemia cells are a subline
variant of the KG-1 cell line. The parental KG-1 cells were obtained from a 59-year old
Caucasian male with erythroleukemia that evolved into acute myelogenous leukemia.
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After 10 passages, the KG-1 cells were split and cultured by two different
laboratories in the same department and under identical conditions. After 35 passages,
one of the cultures exhibited different morphological characteristics (reviewed in ATCC)
and were called KG-1a cells. The CCRF cell line was obtained from the peripheral blood
buffy coat of a 4-year old Caucasian female with lymphoblastic leukemia. The L1210
cells were derived from a female mouse with lymphocytic leukemia. HeLa cells are
epithelial adenocarcinoma cells that were obtained from the cervix of a 31 year old black
female.
HeLa cells were grown in Alpha Minimal Essential Media (Gibco) containing 0.1
mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml
streptomycin and 10% fetal bovine serum (FBS) (Hyclone). The HL60, KG1a, RPMI8226, and CCRF cells were grown in RPMI medium containing100 U/ml penicillin and
100 µg/ml streptomycin from Gibco BRL (Gaithersburg, MD) and 10% FBS (Hyclone).
The NCI-H929 cells were grown in RPMI medium containing 100 U/ml penicillin, 50
µM β-mercaptoethanol (Sigma) and 100 µg/ml streptomycin from Gibco BRL
(Gaithersburg, MD). The L1210 cells were grown in RPMI medium containing 100
U/ml penicillin, 100 µg/ml streptomycin from Gibco BRL (Gaithersburg, MD) and 20%
FBS. The Chinese Hamster Ovary (CHO) cells were grown in Alpha Minimal Essential
Media (Gibco) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 5% fetal calf
serum (FCS). Flow fibroblast 2000 cells were grown in Alpha Minimal Essential Media
(Gibco) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf
serum.
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10.3 Log, Plateau, and Accelerated-plateau Cell Model.
Cell density and viability were determined by staining cells in a 1:1 dilution with
trypan blue and counting them with a hemacytometer. Growth curves were performed on
all cell-lines described above (HL60, KG1a, RPMI, 8226, CCRF, L1210, CHO) to
determine log and plateau phase cell density. Log-phase was defined as 3.0 X 105 to 4.0
X 105 cells/ml with ≥ 85% viability. The log cell densities for the CHO and Flow
fibroblasts were 2.0 X 104 cells/ml for 10 ml of media in a 25-cm2 flask, whereas plateau
phase was reached at 8.0 X105 cells/ml for CHO cells and 2.0 X 105 cells/ml for the Flow
fibroblast cells.
When the log growing cells reached confluence, they were referred to as “naturalplateau”. Natural-plateau is defined as cell viability ≥ 85% (by trypan blue dye
exclusion) and no net gain in cell number. The plateau density was different for each cell
line: 9.0 X 105 cells/ml for RPMI 8226, 1.0 X 106 cells/ml for H929, 1.6 X 106 cells/ml
for HL-60, 2.0 X 106 cells/ml for CEM-CCRF and L1210, and 8.0 X106 cells/ml for KG1a cells.
For convenience, the “accelerated-plateau” model was established by
concentrating log-phase H929, 8226, HeLa, CCRF, or HL-60 cells to a super-confluent
cell density for 16 h or 24 h before experimentation (Valkov et al., 2000; Engel et al.,
2004). Log-phase cells were centrifuged at 100 x g for 5 min at room temperature and
resuspended in fresh media to obtain a superconfluent cell density and grown with 5%
CO2 at 37οC. The super-confluent cell density was between 2.0 x 106 and 2.5 x 106
cells/ml for RPMI-8226, H929, and HeLa cells. The super-confluent cell density for HL60 and CEM-CCRF was set between 3.0 X 106 cells/ml and 4.0 X 106 cells/ml. KG-1a,
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Chinese hamster ovary, and Flow Fibroblast cells were not used in the acceleratedplateau cell model.

10.4 Bone Marrow Samples.
Bone marrow samples were obtained after informed consent from patients with
multiple myeloma on a high-dose chemotherapy study, approved by the Institutional
Review Board. Approximately 5 ml of bone marrow aspirate was collected in EDTA
tubes and diluted to 30 ml with PBS. This was then layered over 15 ml of Ficoll-Paque
Plus (Pharmacia Biotech) and centrifuged at 400 x g in a swinging bucket rotor at 4°C
for 30-min. The mononuclear cell interface was collected and washed twice with cold
PBS. The cell number was determined and 105 cells were cytospun onto double
cytoslides. The cells were fixed with 4% formaldehyde and stored at -85°C. Aliquots of
cells were preserved in freezing media consisting of 40% RPMI-1640, 50% FCS, and
10% DMSO in liquid nitrogen. Where noted, samples were also obtained in a similar
manner but from two untreated myeloma patients. Mononuclear fractions of these
samples were obtained by centrifuging the bone marrow aspirates at 700 x g over a
Ficoll-Hypaque density gradient (Valkov et al., 2000).

10.5 Clonogenic Cytotoxicity Assays.
Cytotoxicity assays were performed by treating 1.0 X 105 cells from either log,
plateau, or accelerated plateau cell suspensions (Valkov et al., 2000; Engel, 2004). Drug
treatment was for 1 hour with various concentrations of etoposide, mitoxantrone,
topotecan, and cis-platinum (diluents were DMSO, water, MeOH, and DMSO,
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respectively). Cells were treated with paclitaxel for 24 hours and the drug was diluted in
DMSO. Cells were treated with carmustine for 4 hours and the drug was diluted in
ethanol. Cells were treated with ara-C (cytosine 1-β-D-arabinofuranosyl hydrochloride)
for 20 hours and the drug was diluted in water. Cells were exposed to γ-irradiation (Cs137 gamma irradiator) (0-800 rads). Controls had the same concentration of dilutent. A
total of 2500 drug-treated cells were plated in triplicate in 0.3% select agar (Gibco BRL)
in RPMI-1640 containing 15% FBS for 14-17 days at 37οC in the presence of 5% CO2.
Colonies > 50 cells were counted manually.

10.6 Flow-cytometric Cell Cycle Analysis.
The cell cycle was analyzed by measuring BrdU incorporation and total amount
of DNA by propidium iodide staining (Engel et al., 2004). To measure BrdU
incorporation, one million log and accelerated-plateau cells each were treated with 30
µg/ml BrdU (Becton Dickinson, San Jose, CA) in serum free media for 30 min. Cells
were washed twice in PBS and resuspended in 4 ml of ice cold PBS. While vortexing, 6
ml of ice cold 100% ethyl alcohol was slowly added and the cells fixed overnight at 20ºC. At least 1 X 106 cells were centrifuged at 100 x g for 5 min and resuspended in
pepsin solution (0.04% pepsin in 0.1% HCl) for 1 h at 37º C with gentle shaking. Whole
cells were pelleted at 100 x g for 5 min, resuspended in 3 ml of 2 N HCl, and then
incubated for 30 min at 37ºC. To this solution, 6 ml of 0.1M sodium borate was added,
vortexed for 20 seconds and then recentrifuged. Cells were washed once with a wash
buffer containing 0.5% BSA and 0.5% Tween-20 in PBS and brought to a final volume
of 200 µl FITC-conjugated anti-BrdU antibody (Becton Dickinson, San Jose, CA) was
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added in a 1:20 dilution and allowed to incubate in the dark for 60 min at room
temperature. These same cells were washed once with wash buffer and resuspended in
10 µg/ml PI in wash buffer to achieve 1 X 106 cells/ml. Cells were treated with 250 µg of
RNase (Sigma) from a 10 mg/ml solution in PBS for 30 min at 37ºC. The sample was
passed through an 18 G needle and transferred to a Falcon 2054 vial and read by FACSScan (Becton Dickinson, San Jose, CA). The experiment was repeated three times and
the mean values were plotted using Prism 2.01 (GraphPad Software, San Diego, CA).
In addition to the above, DNA content was also determined by measuring
propidium iodide staining alone in three separate flow cytometry experiments. To
measure DNA content by propidium iodide staining, one million log and acceleratedplateau cells each were centrifuged at 1000 r.p.m. for 5 min at 4ºC and resuspended in
100 µl of ice cold PBS. The cells were fixed with 70% ice cold ethanol by slowly
trickling the ethanol into the cell suspension with constant vortexing. The cells were
fixed overnight at -20ºC, centrifuged at 1,400 r.p.m. for 5 min at room temperature,
resuspended in 200 µl of PBS, and transferred to a 10 X 75 mm tube (Fisher Scientific,
Pittsburgh, PA). An RNase (Sigma) stock, equivalent to 100 K units/mg solid, was
diluted to 10 mg/ml in PBS and added to the cell suspension in a 1:4 dilution. A 1 mg/ml
propidium iodide stock solution was prepared in ethanol and added to the cells in a 1:10
dilution immediately before reading and DNA histograms were determined by FACSScan (Becton Dickinson, San Jose, CA). The experiment was repeated 3 times.
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10.7 Gel Electrophoresis and Immunodetection.
Log-phase H929 and 8226 cells were seeded at 2.0 X 106 cells/ml, returned to the
incubator and then lysed either 4h, 16h, or 24 h later (Engel et al., 2004). Whole cell
lysates were prepared from log and accelerated-plateau cells by centrifuging 2.0 X 106
cells at 100 x g. for 5 min at 4°C. The pellet was washed once with ice cold PBS and
then resuspended in 250 µl of H2O (pH 9.0; adjusted with 0.1 M borate buffer). Cells
were sonicated on ice with 15 pulses from a Branson sonifier (output 4.0, duty cycle
30%), and then boiled for 3 min in 1X sample buffer (2% SDS, 0.1M DTT, 10%
glycerol, and 0.025% bromphenol blue). Protein concentration was determined by using
the BCA protein assay kit (Pierce, Rockford, IL). A total of 50-100 µg of protein were
loaded onto a 7.5% SDS-page gel, electrophoresed under 7 watts and transferred at 65
volts overnight onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, CA). Membranes were blocked in 0.05% dry milk in TBST
buffer containing 0.05% Tween-20 , 0.5M NaCl, 20 mM Tris, pH 7.5. Primary
antibodies used were polyclonal antibody 454 against topo IIα diluted 1:5000
(Hochhauser et al., 1999), polyclonal antibody JB1 against topo IIβ diluted 1:5000
(Valkov et al., 2000; Austin et al., 1995), or C-21 murine monoclonal IgM antibody
directed against the C-terminus of topo I (a generous gift from Dr. Y.-C. Cheng, Yale
University Medical School, New Haven, CT) diluted 1:2500, or polyclonal anti-LDH
(Research Diagnostics, Flanders, NJ) diluted 1:500 in blocking buffer. Membranes were
blocked for 1 h, and treated with either the polyclonal antibody 454 against topo IIα or
JB1 against topo IIβ for 1 h or blocked overnight at 4°C and treated with the monoclonal
antibody C21 for 2 h. Membranes were washed in TBST every 15 min for 1 h and then
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treated with secondary antibody for 1 h at room temperature. Secondary antibodies used
were either donkey anti-rabbit (topo IIα and topo IIβ), sheep anti-mouse (topo I)
(Amersham, Arlington Heights, IL) or mouse anti-goat (LDH) (Santa Cruz
Biotechnology, Santa Cruz, CA) conjugated to horseradish peroxidase. The topo IIα and
IIβ secondary antibodies were diluted 1:3000 and the LDH secondary antibody was
diluted 1:500 in blocking buffer. The signal was detected with ECL (Amersham) and
exposed to film. The bands were quantified with Adobe PhotoShop 5.0 imaging
software. The experiment was done one time for topo IIβ and repeated 3 times for topo
IIα and topo I in NCI-H929 and RPMI-8226 cell lines (Engel et al., 2004).

10.8 Nuclear-cytoplasmic Separation.
Subcellular fractions was prepared from 1.0 X 107 cells as previously described
(Oloumi et al., 2000) with the following modifications (Engel et al., 2004; Valkov et al.,
2000). Cells were washed in PBS and resuspended into cold Buffer A (10 mM HEPES
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 300 mM sucrose, 1 mM EDTA (pH 8.0), 1 mM
DTT, 0.2% NP-40, 1 mM phenylmethylsulphonyl fluoride, 10 µg/ml protease inhibitors
mixture (Sigma), and 0.1 mM Na3VO4). The cells were incubated in Buffer A on ice for
15 min., sheared with a pipette 20 times, and then centrifuged for 10 min at 830 x g at
4°C. The supernatant was reserved and the nuclear pellet was prepared for protein
determination and gel electrophoresis as described above (refer to "Gel Electrophoresis
and Immunodetection") except that the DNA was sheared with 10 pulses from a Branson
sonifier after being resuspended in Buffer B (250 mM Tris-HCl (pH 7.9), 5 mM MgSO4,
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250 mM sucrose, 2 mM NaTT, 1% thiodiglycol, 1% NP-40, 1mM PMSF, 10µg/ml PI,
and 0.1 mM Na3VO4).

10.9 Immunofluorescence Microscopy.
Slide preparations from log and accelerated-plateau cells were immunostained as
previously described (Engel et al., 2004; Valkov et al., 2000). Log and accelerated
plateau cell suspensions were diluted to 5.0 X 104 cells/ml with PBS and cytocentrifuged
for 3 min at 500 r.p.m. onto double cytoslides (Shandon, Pittsburgh, PA). The cells were
fixed in 4% paraformaldehyde for 4 min at room temperature and permeablized with
0.5% Triton X-100 and 1% glycine in PBS overnight at 4°C. After permeablization, the
slides were washed in fresh PBS every 15 min for 1 h. The slides were treated with the
following combinations of primary antibody: either rabbit polyclonal antibody 454
against topo IIα (Hochhauser et al., 1999) was used simultaneously with a mouse
monoclonal antibody against histone (Roche Molecular Biochemicals) or a C-2 murine
monoclonal IgM antibody against topo I (a generous gift from Dr. Y.-C. Cheng, Yale
University Medical School, New Haven, CT) was used simultaneously with the
polyclonal antibody JB1 against topo IIβ (Austin et al., 1995). The primary antibodies
were diluted 1:100 with staining solution containing 0.1% NP-40 and 1% BSA in PBS
and the incubation period was for 1 h at room temperature. Slides were washed in PBS
every 10 min for 1 h and then incubated with goat anti-rabbit IgG-TRITC labeled
antibody (Sigma) diluted 1:80 and goat anti-mouse IgG FITC-labeled antibody (Sigma)
diluted 1:64 in staining solution as above for 35 min in the dark at room temperature.
The slides were washed in PBS every 15 min for 2 h, air dried and covered with
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antifade/DAPI (Vector, Burlingame, CA). Immunofluorescence was observed with a
Leitz Orthoplan 2 microscope and images were captured using a CCD camera with Smart
Capture program (Vysis, Downers Grove, IL).

10.10 Quantitative Measurement of the Immunofluorescence of Topo IIα.
Slide preparations from log and accelerated-plateau cells were immunostained as
previously described (Valkov et al., 2000; Engel et al., 2004). Topo IIα
immunofluorescence was analyzed as previously described (Valkov et al., 2000; Engel et
al., 2004) using Adobe PhotoShop 5.0 (Adobe Systems, San Jose, CA) and Prism 2.01
(GraphPad Software, San Diego, CA). The nuclear/cytoplasmic ratios were calculated
for each cell by dividing [the number of pixels X (mean intensity - background)] of the
nuclear compartment by [the number of pixels X (mean intensity – background) of the
cytoplasmic compartment. At least 50 cells per experiment were analyzed and the
experiment was repeated 3 times.

10.11 Equilibrium concentrations of [3H]-VP-16.
[3H]-VP-16 was obtained from Moravek Biochemical (Brea, CA). Equilibrium
concentrations of [3H]-VP-16 were measured as previously described (Sullivan et al.,
1986, 1987). Briefly, equal numbers of log and accelerated-plateau cells were incubated
in the presence of 5 to 50 µM of [3H]-VP-16 diluted with cold etoposide for 1 h at 37ºC.
Whole cells were centrifuged at 100 x g for 10 min and washed with cold PBS. Drug
uptake for log and accelerated-plateau cells was determined as cpm/mg of cells.

107

10.12 Band Depletion Assay.
Cleavable complex formation was measured in log and accelerated-plateau H929
cells as previously described (Engel et al., 2004) with few modifications (Kaufmann et
al., 1997). Briefly, 2.0 X 107 cells were centrifuged at 1,000 r.p.m. for 5 min in a
swinging bucket rotor. The pellet was resuspended in 10 ml of buffer A (10 mM HEPES,
pH 7.4 in serum free media). 2.0 X 106 cells were transferred to a 1.5 ml microcentrifuge
tube and treated with VP-16 in DMSO for 45 min in a 37ºC water bath and mixed by
inverting the tubes every 15 min. After the incubation period, the cells were centrifuged
at 3200 X g for 1 min. Proceeding one tube at a time, the supernatant was aspirated and 1
ml of lysis buffer (6M guanidine HCl, 0.25 M Tris, pH 8.5 with HCl, 10 mM EDTA, 1%
2-BME, and 1X protease inhibitors containing (20 mM PMSF, and 20 µg/ml each of
antipain, aprotinin, chymostatin, leupeptin, soybean trypsin inhibitor, benzamidine, and
pepstatin A) was added with brisk vortexing. The cells were incubated in lysis buffer
overnight at 20ºC. Genomic DNA was sheared with 20 pulses from a Branson sonifier
(output 4.0, duty cycle 35%). To each sample, 100 µl of 150 mM iodoacetamide in lysis
buffer without 2-BME was added and allowed to incubate in the dark for 1 h at room
temperature. After incubation, 10 µl of 2-BME was added to each sample. The samples
were dialyzed at 4ºC in the dark as follows: 3 X 90 min in 1 L of 4M Urea, 2 X 90 min in
0.1% SDS, and 1 X overnight in 0.1% SDS. Samples were lyophilized and stored at 20ºC. Immediately before gel electrophoresis, protein was solublized by heating the
samples in sample buffer (4M Urea, 2% SDS, 62.5 mM Tris-HCl, pH 6.8, 1 mM EDTA,
0.03% bromphenol blue and 1% 2-BME) for 20 min at 65-70ºC. Proteins were separated
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by gel electrophoresis on a 10% bis-acrylamide gel for western analysis. The experiment
was repeated two times.
10.13 Comet Assay.
DNA damage was analyzed by the comet assay as previously described with some
modifications (Engel et al., 2004; Kent et al., 1995). Briefly, 2.5 X 105 cells/ml were
treated with VP-16 for 1 h at 37ºC. After treatment, 5,000 cells were removed and
washed in cold PBS. The supernatant was aspirated and 1.5 ml of 1% agar (Nusieve
GTG) was added to 500 µl of PBS, mixed with the pellet, and spread onto a frosted glass
microscope slide. The slides were solidified at room temperature for 2 min and then 4
min at 4ºC. Cells were lysed for 1 h at 4ºC in batches (6-8 slides) in 200-250 ml lysis
buffer containing 0.5% SDS (w/v), 30 mM EDTA, pH 8.0, and Proteinase K was added
(375 units/100 ml) immediately before use. After 1 h, the slides were incubated in the
same lysis buffer overnight at 37ºC for 12-16 h. The lysis buffer was washed off with
200 ml of 1X TBE (pH 8) for 2 h, changing buffer every 15 min. The cells were
electrophoresed in 1X TBE under 25 volts for 20 min. The DNA was stained with a
1:10,000 dilution of Syber Green (Molecular Probes) in 1X TBE for 25 min in the dark at
room temperature. Slides were washed two times with 1X TBE for 5 min each, stored in
a dark humidified box at 4ºC, and viewed within 24 h with a Leitz Orthoplan 2
microscope. Images were captured using a CCD camera with Smart Capture program
(Vysis, Downers Grove, IL). Fifty single cells with no overlapping tails were captured
per drug dosage per condition and the experiment was repeated three times. The comet
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moments were captured and analyzed with Optimas and calculated by using the formula:
∑0→n (Intensity X Distance)/Total Intensity.

10.14 Putative NES Peptides.
The complete amino acid sequence for human topo IIα (accession number NP
001058) was downloaded from the National Center for Biotechnology Information
database and searched for matches to the NES consensus sequence from table 12 (Engel
and Turner et al., 2004). Six amino acid sequences in topo IIα matched the NES
consensus sequence (refer
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to Table 11, page 163), and
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Figure 20. Sulfosuccinimidyl 4-[N-maleimidomethyl]
cyclohexane-1-carboxylate (Sulfo-SMCC). Sulfo-SMCC is a
water soluble non-cleavable crosslinking agent.

were synthesized as native
(nt) or mutated (∆)
peptides. The mutated
peptides contained alanine

in place of those hydrophobic residues suspected of being critical for nuclear export
(leucine, isoleucine, or valine). To facilitate conjugation with preactivated
sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC-BSA)
(Pierce) (Figure 20), the NES-peptides were designed with a cysteine residue at the
amino terminus. The peptides obtained from the Biopeptide Company (San Diego,
California) were as follows: (ntNES80-91), C80GLYKIFDEILVN91; (∆NES80-91),
C∆80GAYKAFDEAAAN91; (ntNES230-241), C230SLDKDIVALMVR241; (∆NES230-241),
C∆230SADKDAAAAMAR241; (ntNES467-476), C467TLAVSGLGVVG477; (∆NES467-477),
C∆467TAAASGAGAAG477, (ntNES1017-1028), C1017DILRDFFELRLK1028; (∆NES1017-1028),
110

C∆1017CDIARDAFEARAK1028. Peptides (ntNES569-580), C569FLEEFITPIVKV580;
(∆NES569-580), C∆569AAEEAATPAAKA580; (ntNES1054-1066), C1054FILEKIDGKIIIE1066;
and (∆NES1054-1066) C∆1054FIAEKADGKAIAE1066 were obtained from the University of
Florida Protein Chemistry Core Facility (Gainesville, FL). All peptides were HPLC
purified to ≥ 95% and analyzed by mass spectroscopy. In addition, peptide sequences and
purity were confirmed by Rick Feldhoff, Ph.D at the University of Louisville, School of
Medicine (Louisville, KY).

10.15 Generation of BSA-Peptide-FITC Conjugates.
Peptides were crosslinked to BSA and FITC. Figure 21 illustrates the plausible
binding of peptides and FITC to BSA. First, a total of 2 mg Imject® Maleimide activated
sulfosuccinmidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate bovine serum
albumin (Sulfo-SMCC BSA) (Pierce, Rockford, IL) was reconstituted in 200 µl distilled
water for a final concentration of (0.1 M sodium phosphate buffer, 0.15 M NaCl, 0.1 M
EDTA, pH 7.2). Then, a molar excess (1-2 mg) of native or mutated topo IIα NES
peptide in 400 µl of conjugation buffer (83 mM sodium phosphate buffer, 0.1 M EDTA,
0.9 M NaCl, 0.002% sodium azide, pH 7.2) was mixed with the Sulfo-SMCC BSA and
reacted for 30 min at room temperature.
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The reaction was quenched by adding 40 mM cysteine solution in deionized water to the
peptide-SMCC-BSA solution to obtain a molar excess of cysteine to peptide sample
(approximately 7 nmoles cysteine/nmole of SMCC-BSA-peptide). The conjugates were
purified by size exclusion chromatography at room temperature using the Pharmacia P-
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Figure 21. An Illustration of BSA-FITC-Peptide Complexes. Multiple peptides
covalently bind BSA-SMCC ( )via disulfide bonds (red) formed by the placement
of a cysteine residue (blue) at the carboxyl terminus of the peptide. Here the peptide
is illustrated as the backbone of any amino acid residue (shown in black brackets [ ]
FITC is shown in green. FITC covalently binds to any primary amine, whether
located on the BSA or peptide molecules. Theoretically, multiple FITC and peptides
will be crosslinked per mole of BSA .
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500 FPLC system with LKB control Unit UV-1. The high resolution column (10 mm
inner diameter and 30 cm length) (Amersham Pharmacia, Piscataway, NJ) was packed at
2.0 ml/min with Superdex 200 prep grade (Amersham Pharmacia) in filtered and
degassed PBS, pH 7.4. The peptide conjugates were loaded onto the column using a 500
µl Superloop and were run at 0.5 ml/min in degassed dH2O. The 500 µl fractions were
collected with a Fraction-100 collector (Pharmacia Biotech) and stored at 4°C overnight.
Total protein was estimated in peak samples by measuring absorbance at 562 nm using
the Fisherbrand Protein Assay. Approximately 25 µg of protein from eluted fractions
were loaded onto a 10% SDS-page gel and electrophoresed with 7 watts for 2-3 h.
Peptide conjugation was confirmed by silver stain analysis. Similar fractions of
crosslinked BSA-peptide were pooled and concentrated on a microsep 30k filter (Pall
Corporation) by centrifuging at 5,000 x g in an SS-34 rotor until dry. The samples were
eluted with 400 µl of PBS, pH 7.4 to obtain approximately 2 mg/ml peptide-conjugate
solution. FITC was solubilized in DMSO to 1 mg/ml and added to the peptide sample in
four 5 µl aliquots until a total of 20 µl of FITC (Sigma) was added. FITC was reacted
with the peptides for 6 h at 4°C, and then 23 µl of 1 M NH4Cl in PBS, pH 7.4 was added
to the sample and incubated for 2 h at 4°C. FITC-BSA-peptide conjugates were
separated from unincorporated label by FPLC. The ratio of fluorescein to protein was
determined by measuring the absorbance at 495 nm and 280 nm. The nuclear control,
tetramethylrhodamine-bovine serum albumin (TRITC-BSA), was obtained from Sigma.
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10.16 Microinjection.
To promote cell adherence, Fisherbrand glass coverslips were pretreated with 1N
HCl for a minimum of 4 hours at 50°C and then rinsed extensively with deionized water.
Coverslips were washed in 100% ethanol and dried between pieces of Whatman paper.
Subconfluent HeLa cells growing in Alpha Minimal Essential Medium (Gibco)
containing 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 U/ml
penicillin, 100 µg/ml streptomycin and 10% FBS (Hyclone) were plated onto the center
of glass coverslips in NUNC brand petri dishes and incubated at 37°C for 24-48 h
preceding microinjection. Prior to microinjection, cells were gently rinsed with sterile
PBS warmed to 37°C and replaced with Leibovitz’s L-15 Medium containing no phenol
red.
FITC labeled BSA-NES peptide conjugates were centrifuged at 13,000 x g for 30
min at 4°C, and the supernatant then loaded into Eppendorf Femptotips (diameter of 0.5
µm ± 0.2 µm). All cells were injected
using the semi-automated Eppendorf
Injectman NI2 and Femtojet
microinjector on a Nikon TE 2000
inverted microscope (Figure 22) under
exactly the same conditions (injection
Figure 22. Eppendorf FemptoJet and
Micromanipulator on a Nikon TE 2000
Inverted Microscope.

pressure (Pi), 100 hPa; compensation
pressure (Pc), 30 hPa; injection time (It)

0.2 sec, atomospheric conditions). Following injection, the cells were incubated at 37°C
for up to 90 min, washed with Leibovitz’s L-15 Medium, and then fixed with 4%
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paraformaldehyde for 3 minutes at room temperature, rinsed in PBS and mounted onto
Shandon microscope slides with mounting medium containing DAPI. Fluorescence was
observed with a Leitz Orthoplan 2 microscope and images were captured using a CCD
camera with Smart Capture program (Vysis, Downers Grove, IL).

10.17 Topoisomerase IIα Cloning and Site Directed Mutagenesis.
Topo IIα primers were designed which contained the eight amino acid FLAG
peptide preceded by a start codon and a Kozak motif (5’-ATG GAC TAC AAA GAC
GAT GAC GAC AAG GAA GTG TCA CCA TTG CAG CCT GTA AAT GAA AAT
ATG-3’ forward primer, 5’-ATG CGG CCG CTT AAA ACA GAT CAT CTT CAT
CTG ACT CTT C-3’ reverse primer). Amplification was performed with an enzyme
mixture of Taq and Pyrococcus species GB-D thermostable DNA polymerases
(Elongase, Invitrogen), in 60 mM Tris-SO4 (pH 9.1), 18 mM (NH4)2SO4, 2 mM MgSO4,
200 µM dNTP mixture and 200 nM each primer. Forty cycles were performed (94°C for
30s, 60°C for 30s, and 5.5 min at 68°C), and the PCR products were agarose gel-purified
and ligated to a pcDNA3.1 vector using a TOPO-TA cloning system (Clontech). The 5’
end of the new FLAG-topo IIα fusion protein vector was sequenced to ensure that the
DNA was in-frame. Site-directed mutagenesis was performed using a Quickchange XL
site-directed mutagenesis kit (Stratagene). Briefly, 100 ng of template dsDNA were
mixed with 125 ng of each oligonucleotide primer, 2.5 units of PfuTurbo DNA
polymerase, in a reaction mixture containing 2 mM dNTPs. Eighteen cycles were
performed (95°C for 50 s, 60°C for 50s, and 68°C for 20 min), after which the parental
plasmid was digested with methylation specific enzyme Dpn-I. Ultra-competent cells
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were transformed with mutated plasmid and clones were sequenced to determine the
presence of desired mutations. DNA sequencing was performed at the H. Lee Moffitt
Cancer Center Molecular Biology Core Facility.

10.18 Transfection Protocol.
Human myeloma H929 and human leukemia HL-60 cells (ATCC) were plated at
log phase density (2x105 cells/ml) two days prior to transfection. Transfection was
performed as previously described (Van den Hoff et al., 1992). Briefly, 40 µg of wildtype or mutated topo IIα plasmid in 300 µl tris-EDTA (TE) buffer was precipitated by the
addition of 30 µl of 5 M NaCl and two volumes of 95% ethanol on ice for ten minutes.
Plasmid was pelleted by centrifugation for fifteen minutes at 20,000 x g at 4°C, washed
with 75% ethanol and re-centrifuged. All remaining ethanol was removed by pipette and
the DNA immediately resuspended in 50 µl of cytomix buffer containing 120 mM KCl,
0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM Hepes, 2 mM EGTA, 5 mM MgCl2, 2
mM ATP, and 5 mM glutathione, pH adjusted to 7.6 by the addition of KOH. ATP and
glutathione were made fresh and added prior to each transfection (26). Two days prior to
transfection, human myeloma H929 cells and leukemia HL-60 cells were placed in fresh
growth media (RPMI/10% FBS/pen-strep) at a concentration of 2 x105 cells/milliliter.
Cells were collected and 1.6x107 cells pelleted by centrifugation at 1500 x g for 5
minutes. Cell pellets were washed twice in 10 ml of sterile PBS, resuspended in 350 µl
of cytomix buffer (4°C), mixed with prepared DNA, and placed in a 4 mm
electroporation cuvettes. Electroporation was at 250V/750 capacitance, after which cells
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were split into even groups and plated at log and plateau growth conditions for twenty
hours in 5 % CO2 incubator at 37°C with RPMI medium containing a 5% FBS.

10.19 Immunofluorescence of FLAG-Topo IIα.
Twenty hours post-transfection, live cells were isolated by centrifugation for 20
minutes at 20°C on a ficoll gradient, and then washed with PBS. Transfected cells were
plated on a glass microscope slide using cytospin funnels and fixed with 4%
paraformaldehyde at 20oC for ten minutes. The fixation was stopped by washing in PBS
and cells were permeabilized for twenty-four hours in a solution containing 1% glycine
and 0.25% Triton X-100 in PBS. Slides were stained with anti-FLAG M2 monoclonal
antibody-FITC conjugate (Sigma) diluted 1:100 with 0.1% NP-40 and 1% BSA in PBS,
and incubated one hour at room temperature. Slides were washed in PBS, dried briefly
and counterstained with Vectashield mounting media antifade/DAPI (1:1) (Vector
Laboratories Inc., Burlingame, CA). Immunofluorescence was observed with a Leitz
Orthoplan 2 fluorescent microscope and images were captured by a CCD-camera with
Smart Capture program (Vysis, Downers Grove, IL). Quantitation of FITC fluorescence
was performed using the Adobe Photoshop 7.0 program.

10.20 Western Blot of FLAG-Topo IIα.
Hela cells grown in RPMI media containing 5% FBS were transfected directly on
100 cm2 tissue culture plates. Plasmid DNA (10 µg) was mixed with 60 µl of Superfect
transfection reagent (Qiagen) in 300 µl of serum-free media for 10 minutes, followed by
600 µl of serum containing media, and the entire mixture was then added directly to cell
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culture plates. Transfection was allowed to proceed for three hours at 37°C in a 5 % CO2
incubator, and terminated by the removal of transfection solution and the addition of 15
ml of 5% FBS containing RPMI media. After incubation for twenty-four hours, the cells
were harvested by the addition of 0.53 mM EDTA, washed with cold PBS, and lysed in
SDS buffer (2% SDS, 10% glycerol, 0.06 M Tris, pH 6.8). Protein from 2x105 cells per
lane was separated on an 8% SDS-PAGE gels and electrobloted (Biorad) onto
nitrocellulose membranes (Amersham). The blots were blocked for one hour at ambient
temperature in a blocking buffer containing 0.1M Tris-HCl buffered saline, 0.5% Tween20, and 5% non-fat milk. Blots were stained by the direct addition of anti-FLAG M2
(Sigma) antibody and incubated overnight at 4ºC. Membranes were washed three times
for ten min with 0.1M Tris-HCl buffered saline and incubated with anti-mouse IgG
antibody (Sigma) in blocking buffer containing 0.1M Tris-HCl buffered saline, 0.5%
Tween-20, and 5% non-fat milk for sixty minutes at room temperature. Antibody
binding was visualized by ECL (Amersham) on autoradiography film (Kodak).
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Chapter Eleven
Experimental Results
Part I: Cell density-dependent VP-16 Sensitivity of Leukemic Cells is Accompanied by
the Translocation of Topo IIα from the Nucleus to the Cytoplasm.

11.1 Preliminary Results.
The results of the data described immediately below were obtained prior to my
entering the laboratory, but are important because they established a foundation for my
doctoral work on mechanism of drug resistance to topoisomerase targeting agents. A
complete description of the data is given in Valkov et al., 2000. I became a contributing
author of Valkov et al., 2000 for my immunostaining and microscopy work on log and
plateau 8226 and CCRF cell lines, which included the development of an in vitro cell
model for investigating the nuclear-cytoplasmic distribution of topo IIα.

11.2 Drug Resistance Phenotype of Plateau-phase Tumor Cell Lines.
Most cell lines display a differential sensitivity to topo II targeting agents such
that when cells reach confluence they become drug resistant to topo II poisons (Sullivan
et al., 1987, 1986; Chow and Ross, 1987; Markovits, 1987). Drug resistance to topo II
poisons in non-transformed plateau cell lines have been attributed to attenuations in the
amount and activity of topo IIα protein. However, the transition from log to plateau cell
density does not necessarily lead to a decreased cellular content of topo IIα protein in
119

transformed cell lines (Sullivan et al., 1987). Thus, we were interested in explaining the
observed drug resistance in transformed cell lines at plateau density, which is
independent of the cellular content of topo IIα.
First, the differences in drug sensitivity between log and plateau cell densities of
several transformed and non-transformed cell lines were investigated. To do this, the
cytotoxic effects of two topoisomerase II poisons (i.e., VP-16 and MTX), one topo I
poison (TPT), and two non-topoisomerase targeting agents (i.e., cisplatin and vincristine)
in several log and plateau cell lines was determined. A comparison of the drug sensitivity
of four leukemic cell lines (CCRF, HL-60, KG-1a, L1210), one myeloma cell line
(RPMI-8226) and non-transformed human Flow 2000 fibroblasts and Chinese hamster
ovary (CHO) cells shows that, at plateau cell density, all cell lines become resistant to
VP-16 (Table 9). The magnitude of cross-resistance to another topo II inhibitor,
mitoxantrone, was uniformly less in all cell lines, but followed a similar pattern of
resistance as that observed with VP-16. The mouse leukemia L1210 and Chinese
hamster ovary (CHO) cell lines showed significant plateau phase drug resistance to the
topo I inhibitor topotecan. Resistance to drugs that act by mechanisms other than the
inhibition of topo was low, except for the resistance of human leukemia KG-1a cells to
vincristine. These data suggest that the log to plateau phase transition involves specific
changes in topo in these leukemic and non-transformed cell lines. Altered drug
sensitivity to VP-16 has been shown to result from a cell-cycle dependent degradation of
topo IIα protein. It is well established that the cellular content of topo IIα is maximal in
G2/M of the cell cycle, and thus alterations in the cell cycle can result in altered drug
sensitivity to topo II poisons. The specific contributions of topo IIβ in conferring drug
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resistance to topo II poisons are less well understood. Attenuation in the cellular content
of topo I protein, however, has also been attributed to decreased drug sensitivity to topo I
targeting agents. Furthermore, topotecan is reported to be S-phase specific cytotoxic
agent. Thus, we examined the cell cycle distribution by flow cytometric analysis and the
cellular content of topo I, topo IIα, and topo IIβ by Western blot analysis in log and
plateau cells.
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Table 7. Drug Resistance of Natural Plateau Phase Non-transformed and Tumor Cell Lines
VP-16

MTX

IC50 *

CDDP

TPT

IC50

IC50 (µmol/l)

Vincristine

IC50

IC50

(µmol/l)

Rf**

Fibroblasts

11.5±6.6a.

5.2±0.2a

17, 17.1b

2.6

2.4±0.6

3.3±0.1

ND

ND

ND

ND

CHO

4.0**

15.0d

25.0††

8.0

0.18±0.15

274±168

3.0c

1.0

ND

ND

CRRF

0.63±0.61

39.0±11.5e

1.37±0.66

7.7±3.9g

0.37±0.28

16.8±12.6

0.71±0.29

1.9±0.05

1.25±0.91

1.3±0.4

HL-60

0.55±0.04

7.6±0.3

18.0c

2.2

0.06±0.02

1.0±0

ND

ND

ND

ND

8226

0.57±0.26

10.4±2.1

8.5±0.5

2.6±0.2

0.95±0.55

2.0±1.0

1.15±0.35

1.1±0.1

1.8

1.3

7.5±0.5

4.9±0.5

0.30±0.29

282±156

0.55±0.55

1.3±0

3.55±0.05

1.3±0.1

22.3±12.2

1.1±0.1

1.25±0.75

2.5±0

3.1±0.1

1.1±0.1

1.0, 1.1b

27.5, 25.3b

L1210

1.33±0.29

17.7±6.6

KG-1a

5.67±1.7

3.5±1.4

Rf

(µmol/l)

f

*

Rf

Rf

(µmol/l)

IC50, drug concentration that inhibits growth by 50% as determined by the colony forming assay; values reported are for log phase cells
Rf, the resistance factor or ratio of IC50 values of plateau and log phase cells
a
Mean ± SEM
b
n = 2, the experiment was done two times and both values are shown
c
n = 1, the experiment was done one time and the individual value is shown
d
From Sullivan et al., 1986
e
Similar results found with MTT assay (n = 3), where Rf = 26.0 ± 4.9.
f
Similar results found with MTT assay (n = 3), where Rf = 10.5 ± 0.5
g
Similar results found with MTT assay (n = 3), where Rf = 6.0 ± 4.3
**
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Rf

(µmol/l)

11.3 Cell Cycle Distribution and [3H]-thymidine Incorporation.
The drug resistance to topotecan observed in the L1210 and CHO cell lines may
be explained in part by the decrease in the number of S-phase cells at plateau density
(Table 10), as topotecan is thought to be an S-phase specific agent. However, the
magnitude of the decrease in S-phase cells at confluence did not parallel the degree of
resistance. The fibroblast cells were only minimally resistant to topotecan, and yet had
the second greatest decrease in number of S-phase cells at confluence. Although the HL60 cells showed no decrease in the number of S-phase cells at confluence, they had 6.5
fold less [3H]-thymidine incorporation, suggesting a significant decrease in the number of
cycling cells. The sensitivity of HL-60 cells to topotecan, however, paralleled the flow
cytometry results (no apparent change in S-phase). Factors other than a simple change in
percentage of S-phase are probably involved in the sensitivity to topotecan in this log and
plateau cell model.
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Table 8. Analysis of S-phase and [3H]-thymidine Incorporation in Log and Natural Plateau Phase Cell Lines*
BrdU Incorporation
BrdU Incorporation
Log [3H] thymidine
6

Plateau [3H] thymidine

Log S (%)

Plateau S (%)

(cpm/10 cells)

(cpm/106 cells)

Flow fibroblasts

29.6 ± 6.9a

10.1 ± 10.3

NDb

ND

CHO

37.4 ± 5.1

14.9 ± 9.2

ND

ND
c

CCRF-CEM

34.7 ± 8.9

25.9 ± 8.2

20760 ± 371 (P < 0.0001)

HL-60

30.0 ± 8.9

30.5 ± 4.9

2289 ± 401 (P = 0.003)

352 ± 33

RPMI-8226

25.4 ± 7.8

15.5 ± 2.3

6819 ± 351 (P = 0.41)

6504 ± 39

L1210

37.3 ± 9.5

27.9 ± 8.1

10570 ± 750 (P = 0.0004)

2306 ± 188

KG-1a

21.6 ± 7.1

11.7 ± 7.9

2860 ± 120 (P <0.0001)

2089 ± 256

695 ± 50

*Cell cycle distribution was determined by flow cytometry of log and plateau phase cells in three to five independent experiments,
while incorporation of [3H] thymidine was measured in appropriate cells in three or four separate experiments.
a
Mean ± SEM
b
c

Not determined

P-values relative to uptake in plateau phase
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11.4 Cellular Content of Topo in Log and Plateau-phase Cell Lines.
The overall quantity of topo was determined by Western blot analysis of whole
cell lysates of log and plateau phase leukemic, myeloma and non-transformed cell lines.
A notable difference between malignant and non-transformed cell lines was the near
disappearance of topo IIα from CHO and fibroblasts cells at a time when they reach
confluency and lose their proliferative potential (Figure 23 ). In contrast, all tumor cell
lines preserved their total cellular topo IIα content, independent of cell density. Topo IIβ
did not show any substantial changes in the cell lines studied and was not downregulated
in either normal or neoplastic cells. The content of topo I was not found to be
significantly changed by the log to plateau phase transition in fibroblasts, 8226, HL-60,
KG-1a, CCRF, or L1210 cells. Furthermore, a reduction in the total cellular amount of
topo IIα could not account for the decreased sensitivity to VP-16 and mitoxantrone in
transformed cell lines. The relatively high level of resistance of plateau phase L1210 cells
to topotecan also does not appear to result from a downregulation of cellular topo I
content.
Thus far, we have been able to attribute the drug resistance to topo VP-16 and
MTX observed in non-transformed cell lines to attenuation of topo IIα protein. However,
we have not been able to fully describe the mechanism(s) of drug resistance to VP-16 or
mitoxantrone in the transformed cell lines at plateau cell density. Although alterations in
the cell cycle may have a role in the decrease drug sensitivity of L1210 cells to topotecan,
the data obtained from analysis of the cell cycle was not always consistent with the drug
sensitivity. Furthermore, there were discrepancies between the percent of S-phase cells
as determined by flow cytometric analysis and the number of cycling cells determined by
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[3H] thymidine incorporation. For example, plateau HL-60 cells have minimal resistance
to topotecan, which is consistent with the analysis of S-phase by flow cytometry.
However, HL-60 cells demonstrated relatively large decrease in the amount of [3H]
thymidine incorporation. Thus, we speculated that other cellular events must be
occurring that have a role in drug sensitivity to topoisomerase targeting agents. We
questioned whether transformed cell lines may alter their subcellular distribution of topo
IIα protein to evade drug-target interactions with VP-16 or mitoxantrone. To address this
possibility, we compared the subcellular distribution of topo IIα in 8226 and CCRF cells
at log and plateau density by immunofluorescence microscopy.
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Figure 23. Western Blot Analysis of Topo I, Topo IIα, and Topo IIβ from
Whole-cell Lysates of Cell Lines at Log and Plateau Densities. One million
cells were loaded in all lanes, and the ECL signal was quantified by
densitometry. These results are representative of experiments performed a
minimum of three times for each cell line. Lane A, log-phase cells; lane B,
plateau-phase cells.
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11.5 Subcellular Distribution of Topo in Log and Plateau-phase Cell Lines.
At log density, topo IIα was strictly nuclear, while at plateau cell density, the
tumor cell lines demonstrated an increase in topo IIα present in the cytoplasm (Figure
24). In order to evaluate the amount of topo IIα at the single cell level statistically, the
pixel intensity of nuclear and cytoplasmic topo IIα in 200 individual cells (50
cells/experiment four times) at log, midlog and plateau densities was determined
(complete data not shown here, refer to Valkov et al., 2000). CHO cells had a
proportional decrease in the nuclear/cytoplasmic ratio, such that at plateau phase the ratio
was less than one (<1). This suggested that for the remaining undegraded topo IIα there
was relatively more in the cytoplasm than in the nucleus. From early log phase to plateau
phase, there was a significant decrease in the topo IIα nuclear/cytoplasmic ratio for all
cell lines except KG-1a. Thus, at confluent densities, all cell lines (except KG-1a) had
significantly more topo IIα in the cytoplasmic compartment. The immunolabelling of
three cells lines (CCRF, L1210, and HL-60) for topo I and topo IIβ demonstrated no
significant trafficking of these topoisomerases to the cytoplasm during the transition from
log to plateau phase (data not shown).
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Figure 24. Immunofluorescent Staining and Confocal Microscopy.
Immunofluorescent staining for topo IIα (A, D, G, J, histones (B,E, H, and K), and
merged images (C, F, I,and L) in log and plateau phase CCRF and 8226 cells. Log
phase 8226 cells (A-C) were at a density of 2.0 X 105 cells/ml; plateau-phase 8226
cells (D-F) at 9.0 X 105 cells/ml; log phase CCRF cells (G-I) at 2.0 X 105 cells/ml;
and plateau phase CCRF cells (J-L) at 1.6 X 106 cells/ml. Cell viability in all
experiments was ≥ 95% and the immunofluorescence was observed with a Leitz
Orthoplan 2 microscope and captured digitally using the Smart Capture program.
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11.6 Conclusions.
The resistance of several leukemia and myeloma cell lines (CCRF, L1210, HL-60,
KG1a, and RPMI-8226) to VP-16 was found to increase with cell density and to be
maximal (3.5 to 39-fold) in plateau phase cell cultures, as measured by clonogenic and
MTT assays. Non-transformed confluent Flow 2000 human fibroblasts and Chinese
hamster ovary (CHO) cells were also five and 15-fold resistant to VP-16, respectively.
The transition from log to plateau phase was accompanied by a drastic decrease in
topoisomerase IIα content in CHO cells and human fibroblasts, while the leukemic cells
maintained constant cellular levels of topo IIα and topo IIβ. The nuclear-cytoplasmic
ratio of topo IIα may be critical in determining the sensitivity of leukemia cells to topo II
inhibitors.
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Chapte Twelve
Experimental Results
Part II: The Cytoplasmic Trafficking of DNA Topoisomerase IIα Correlates with
Etoposide Resistance in Human Myeloma Cells

12.1 Introduction.
The data described in Part I, suggests that the nuclear-cytoplasmic ratio of topo
IIα may be critical in determining the sensitivity of myeloma and leukemia cells to topo
II inhibitors. However, many questions remain. Does a nuclear-cytoplasmic trafficking
of topo IIα contribute to drug resistance in vitro? Are plateau leukemia and myeloma
cells cross-resistant to other classes of antitumor agents besides topo targeting agents?
How does a cytoplasmic topo IIα contribute to altered drug sensitivity? Is the
cytoplasmic distribution of topo IIα a result of deceased nuclear import or increased
nuclear export? Can we manipulate the nuclear-cytoplasmic trafficking of topo IIα by
either inducing its cytoplasmic location or by blocking the cytoplasmic relocation of topo
IIα in plateau cells? These question, and others established the purpose of my doctoral
work.

12.2 Accelerated-plateau Human Myeloma Cell Line Model.
To more precisely define the role that the nuclear-cytoplasmic shuttling of topo
IIα has in modulating drug sensitivity to topo inhibitors and other classes of anti-cancer
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agents, we developed a human multiple myeloma cell line model. The data presented
inthe log and plateau cell models suggest that the nuclear-cytoplasmic trafficking of topo
IIα could be cell-density dependent, and thus influenced by cell-cell contact. To exploit
cell-cell contact, log-phase (defined as 3.0 x 105 cells/ml) human myeloma cell lines
(NCI-H929 and RPMI-8226) and the human leukemia HL-60 cell line were concentrated
to a superconfluent cell density (2.0 x 106 cells/ml) and grown at this density for up to 24
h before experimentation. After growing at the superconfluent density for as long as 24
h, the accelerated-plateau cells were still > 85% viable by trypan blue exclusion.
The superconfluent cell density was initially determined by obtaining growth curves for

5

16

1 00

14

80

12
10

60

8

P la te au

6
4

40
20

2

Percent Vi ability
( )

Cell Count x 10 cells/ml
( )

NCI-H929 (Figure 25) and RPMI-8226 (data not shown) cells to establish the cell-density

Log

0

0
0

20 40 60 80 1 00 1 20 1 40 1 60 1 80 2 00 2 20

Tim e (h)

Figure 25. Growth Curves. Growth curves for human myeloma H929 and 8226
(data not shown) cells were plotted to determine log and plateau cell densities.
H929 cells enter logarithmic growth approximately 2 days after being seeded to an
initial cell density of 2.0 x 105 cells/ml in fresh media. After growing continuously
for 2 days, H929 cells reach “natural-plateau” near 1.2 x 106 cells/ml The graph
illustrates the relatively long plateau phase (~4-5 days) characteristic of these cell
lines. Cell density as cell count x 105 cells/ml (o); Percent viability, (▲).
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of “naturally-plateaued” H929 and 8226 cells. For example, after being seeded at 2.0 X
105 cells/ml, H929 cells require approximately 48 hours to reach log-phase, and then The
remain in log-phase for an additional 36-48 hours before reaching plateau phase. H929
cells remained in plateau phase for approximately 2 days. The H929 cells reach
confluence when their cell density nears 1.2 X 106 cells/ml (natural plateau). Thus, the
superconfluent or accelerated-plateau was set to approximately double the natural-plateau
cell density (2.0 x 106 -2.5 x 106 cells/ml).growth curve also illustrates the relatively long
natural plateau-phase (approximately 4-5 days) characteristic of H929 human myeloma
cells. Other cell densities were also analyzed (1.0 X 106 cells/ml, 5.0 x 106 cells/ml, and
1.0 x 107 cells/ml) however, 2.0 x 106 cells/ml was determined to be an optimal celldensity that preserved cellular viability and demonstrated topo IIα export in a measurable
period of time.

12.3 Drug Sensitivity of Human Myeloma Cell Lines in Accelerated-plateau.
To determine if topo IIα protein trafficking correlates with cellular drug resistance
to other topo targeting agents as well as other classes of antineoplastic agents, the toxic
effects of several classes of antineoplastic agents were examined in log and acceleratedplateau H929 and 8226 cells. We expanded the drug sensitivity data that was described
for log and plateau cells (in Valkov et al., 2000) to include an antimetabolite (ara-C), a
nitosourea DNA crosslinking agent (BCNU), a platinum containing DNA crosslinking
agent (cisplatin), an antimicrotubule (Paclitaxel), and γ-irradiation. A comparison of
drug sensitivity of log-phase and accelerated-plateau phase H929 and 8226 (data not
shown) cells shows that the log-phase cells are more sensitive to topo inhibitors, such as
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VP-16 and mitoxantrone, compared to cells seeded at the plateau-phase density for 16 h
or 24 h, as determined by colony forming assays (similar results were obtained with 8226
cells) (Table 11). The accelerated-plateau cells were most resistant to VP-16, 10-fold at16
h and 24-fold at 24 h). The accelerated-plateau H929 cells demonstrated less resistance to
the non-topo inhibitors such as ara-C, taxol, BCNU, and γ-irradiation, but were found to
be 3-fold resistant to topotecan. Thus, the observed drug resistance appears to be more
specific for topo inhibitors than other classes of chemotherapeutic agents. These data
suggest that the principal mechanism of drug resistance involves quantitative or
qualitative changes in topoisomerase. However, other cellular events, such as alterations
in either drug transport or cell-cycle can also contribute to a decrease in drug sensitivity
to topo poisons. To explain the mechanism(s) of observed drug resistance to topo poisons
in accelerated-plateau cells, changes in total amount of topo protein, drug uptake, cell
cycle distribution, and subcellular localization were examined.
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Table 9. Drug Sensitivity of Log and Accelerated-plateau H929 Cells to Cytotoxic
a
A
Resistance Factord (RF)
Antitumor Drugb
Log-phase IC50c
16 h
24 h
e
VP-16 (DMSO, 1 h)
0.360 ± 0.08
9.6 ± 3.3
23.5 ± 5.1
f
Mitoxantrone (water, 1 h)
0.0009 ± 0.0001
5.3 ± 0.2
5.1 ± 0.2
g
Topotecan (methanol, 1 h)
3.32 ± 1.0
3.1 ± 0.4
3.5 ± 0.3
Taxol (DMSO, 24 h)
1.40 ± 0.92
1.2 ± 0.3
2.8 ± 0.2
75 cGy ± 8.6
0.33 ± 0.2
1.3 ± 0.1
γ-Irradiation
h
Cis-platinum (DMSO, 1 h)
7.00
0.43
0.5
Ara-C (water, 20 h)
1.20h
1.3
5.0
h
BCNU (ethanol, 4 h)
1.0
1.5
1.0
a

Unless otherwise noted, three to five independent experiments were performed for each drug in triplicate.
The mean values ± SEM are shown.
b
Solvent for drug dissolution and hours of drug exposure are shown in parentheses.
c
IC50 is the concentration of drug that inhibits growth by 50% and the values reported are for log- phase cells
in µM concentrations.
d
Fold resistance (RF) is the ratio of 50% inhibition concentration values (IC50’s) obtained from
colony-forming assays.
e
Similar results were found in 8226 cells at 24 h, IC50 = 0.460 ± 0.06 (n =3), where RF = 10.3 ± 1.6.
f
Similar results were found in 8226 cells at 24 h, IC50 = 0.003 ± 0.001 (n =3), where RF = 5.0 ± 0.5.
g
Similar results were found in 8226 cells at 24 h, IC50 = 1.1 ± 0.5 (n =3), where RF = 2.0 ± 1.1.
h
The colony-forming assay was performed one time in triplicate.
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12.4 Cell-cycle Analysis.
The cellular amount and activity of topo IIα is regulated in a cell-cycle and
proliferation dependent manner, and alterations in the amount and activity of topo IIα
correlate with cellular drug resistance to topo inhibitors. Therefore, it was necessary to
separate the contributions of the cell cycle to the observed drug resistance from other
cellular events. The cell cycle was analyzed over a 24 h period for changes in the S-phase
cell population from the time that the log-phase cells were concentrated to 2.0 X 106
cells/ml (time zero) (Figure 26). Analysis of BrdU incorporation in H929 cells indicates
that 19.4% ± 5.0% of log-phase cells are in S-phase compared to 14.4% ± 1.3% of
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Figure 26. Percent of Accelerated-plateau Cells in S-phase. BrdU incorporation
was measured to determine the percent of NCI-H929 and RPMI 8226 cells in Sphase. The experiment was repeated three times and the mean values with
standard deviation are shown (o), 8226 cells; (•), H929 cells.
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accelerated-plateau cells at 16 h. These data suggest that the changes in the cell cycle
distribution that occur within 16 h of being plated at 2.0 x 106 cells/ml are not likely to be
the main mechanism contributing to the drug resistance observed to topo inhibitors. A
greater reduction in the S-phase population of accelerated-plateau cells was observed at
24 h and this difference could account for the increase in drug resistance observed with
ara-c (1.3 fold to 5.0 fold) and taxol (1.2 fold to 2.8 fold). To more specifically
determine the contribution that topo IIα trafficking plays in drug sensitivity, subsequent
experiments were performed within 16 h to minimize contributions of cell cycle changes
to drug sensitivity in the accelerated-plateau cell model.

12.5 Cellular Amount of Topoisomerase by Immunoblotting.
An attenuation of topo enzymes can contribute to drug resistance by decreasing
the amount of drug target. To determine if there are any changes in the total cellular
amount of topo protein in accelerated-plateau cells that could contribute to the observed
drug resistance, the amount of topo protein in whole cells was determined by Western
blot analysis. No significant changes in the amount of topo II protein were observed in
whole cells when compared to log-phase cells 4-24 h after seeding at the super-confluent
cell density (Figure 27). Thus a decrease in the total amount of topo II protein is unlikely
to account for the observed drug resistance in accelerated-plateau H929 and 8226 cells to
VP-16 and mitoxantrone, while a decrease in topo I (20-30%) may contribute to the
resistance to topotecan.
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Figure 27. Western blot Analysis of DNA Topoisomerase I and II. The total cellular
amount of topo I, topo IIα, and topo IIβ protein in whole cell lysates from 1.0 x 106 log
and accelerated-plateau H929 and 8226 cells was determined by Western blot analysis.
There are no significant differences in the amount of topo IIα or IIβ protein up to 24 h
by densitometry. A small decrease in topo I is seen in H929 cells ≥ 16h, while a 30%
decrease in topo I is seen in 8226 cells at times ≥ 4 h. Hours refer to the time after
concentrating log-phase cells to super-confluent densities. The expermiment was
performed one time in duplicate for topo IIβ and repeated three times each for topo I

The observed decrease in topo I may also contribute to the decrease in drug
sensitivity to ara-C because recent data shows that topo I cleavable complexes can be
trapped by ara-C incorporation into DNA (Pourquier et al., 2000). Inhibition of topo I by
ara-C is suggested to occur by structural modifications that occur in the DNA helix when
ara-CTP is incorporated. Ara-c incorporation into DNA results in structural
modifications in the DNA helix and inhibition of DNA synthesis (Pourquier et al., 2000)
Ara-c incorporation into DNA is believed to result in misalignment of the DNA 5'hydroxyl with the enzyme-DNA tyrosyl phosphodiester bond, which is necessary for
nucleophilic attack and DNA religation (Pourquier et al., 1997, 1998, 2000). Thus, it
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appears that ara-C cytotoxicity is a result of both inhibition of DNA polymerization and
topo I poisoning. Inhibition of topo I by ara-C could explain the 5-fold resistance of
plateau cells to ara-C at 24 hours because there is a concomitant decrease in the total
cellular amount of topo I protein in plateau cells. Thus, it is possible that cell death
induced by ara-C in the log growing cells was due in part to the formation of topo I
cleavable complexes in addition to cessation of DNA synthesis.

12.6 Drug Transport in Tumor Cell Lines.
Reduced drug accumulation is a major mechanism conferring drug resistance in
several drug-resistant cell lines, and many important mammalian drug transport proteins
are ATP-dependent proteins that belong to the ABC superfamily (reviewed in Leonard et
al., 2002). Under normal conditions, these pumps protect cells from accumulating toxic
substances by actively pumping out cytotoxic substances. Thus, topo I and II inhibitors
may be effectively eliminated from cells by a variety of these drug transporters. To
determine if the differences in log and accelerated-plateau cells in drug sensitivity to topo
inhibitors was a function of altered drug transport, cellular uptake of [3H]-VP-16 was
measured as described in "Materials and Methods" (Sullivan et al., 1987). Briefly, H929
cells were incubated in the presence of [3H]-VP-16 for 1 h to achieve steady state,
washed, and pelleted by centrifugation. The pelleted cells were transferred to drying
paper and dried overnight, and then weighed. After weighing, the pellets were dissolved
in a buffer, and then 3H content was determined by scintillation counting. Drug uptake
for log and accelerated-plateau cells was determined as cpm per milligram of cells. No
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considerable difference was observed in the uptake of [3H]-VP-16 between log (1.7 x 104
counts/mg of dry weight) and accelerated-plateau cells (1.8 x 104 counts/mg of dry
weight). We have previously shown that there are no differences between several log and
natural-plateau human myeloma and leukemia cell lines (Valkov et al., 2000; Sullivan et
al., 1986, 1987). Thus, an alteration in drug transport of VP-16 is not likely to be the
main mechanism conferring drug resistance to topo inhibitors in the accelerated-plateau
model.

12.7 Subcellular Distribution of Topoisomerase IIα.
Although the total amount of topo protein does not appear to change in the whole
cells, a change in the subcellular distribution of topo could alter the amount of topo
protein located in the nucleus. Therefore, we examined the subcellular distribution of
topo IIα (28 ) and topo I and topo IIβ (29) was examined by immunofluorescence
microscopy and confirmed by scanning confocal microscopy.
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Figure 28. The Subcellular Distribution of Topo IIα in Log and Accelerated-plateau H929 Cells at 16 h and
24 h. Histones are non-shuttled proteins that define the area of the nucleus. Topo IIα is nuclear in log-phase
cells and has a markedly increased cytoplasmic distribution in accelerated-plateau cells at 16 h and 24 h.
Arrows point to cells with cytoplasmic topo IIα.
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Figure 29. The Subcellular Distribution of DNA, Topo I, and Topo IIβ in Log and
Accelerated-plateau H929 Cells at 24 h. DNA was stained with DAPI which defines
the area of the nucleus. Topo I appears nuclear in log and accelerated-plateau cells.
Topo IIβ is found in the nucleus and cytoplasm of log and plateau cells.

142

A least 50 cells per experimental condition (i.e., log or plateau) were randomly picked by
4'-6-diamidino-2-phenylindole (DAPI) staining of the nucleus. Cells were numbered as
1-50 and then, analyzed for the pixel intensity of either tetramethyl rhodamine
isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) labeled antibody as
described in Figure 30. Topo IIα is predominately nuclear in log-phase cells, but there is
a time-dependent translocation of topo IIα in the accelerated-plateau cells after 16 h.
Similar results were observed in the natural plateau cells (data not shown).

Figure 30. Method for Selecting Cells by Confocal Microscopy. Cells
were selected randomly by positive DAPI staining and images captured
using a CCD camera as described in“Materials and Methods”. The cells
were numbered 1-50. Mitotic cells and cells touching the edge of the field
of vision were not included in the data. Furthermore, any cell staining
positive for DAPI but histone negative were presumed to be cell debris
and also were not included in the data.
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The subcellular distribution of topo protein was quantified in log and acceleratedplateau H929 and 8226 cells by calculating the nuclear/cytoplasmic ratio (N/C) from the
pixel intensity of the individual compartments from 50 cells per time point. The staining
for nuclear topo I and II was internally controlled in each cell by DAPI staining of DNA
and histone staining. Figure 31 illustrates the method, as described in "materials and

Figure 31. Determination of Nuclear-cytoplasmic Ratios (N/C). Using
AdobePhotoshop, we were able to zoom-in on each cell. To obtain the value of the
pixel intensity between the nuclear and cytoplasmic compartments for either TRITC or
FITC labeled antibody, the nuclear and cytoplasmic compartments were outlined using
the "lasso" feature. In the cell shown here, the cytoplasm is outlined in blue, whereas
the nucleus is outlined in yellow. The N/C ratio was determined from the following
equation: number of pixels in nucleus x (mean-background)/number of pixels in
cytoplasm x (mean - background).
methods", for analyzing the subcellular localization of topo by immunofluorescence. A
least 50 cells per experimental condition (i.e., log or plateau) were analyzed. These
experiments were performed in duplicate and repeated three times in both H929 and 8226
cells. The median N/C ratio of topo IIα is 29.9 ± 9.1 for log-phase H929 cells and
decreases to 1.3 ± 1.3 for the accelerated-plateau cells after 16 h and to 0.90 ± 1.1 after
24 h. The median N/C ratio of topo I and IIβ did not change. The median N/C ratio of
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topo I was 27.0 ± 3.2 in log-phase H929 cells and 29.2 ± 4.1 at 16 h accelerated plateau.
The median N/C ratio of topo IIβ was 10.1 ± 5.5 in log-phase and 8.9 ± 5.4 at 16 h
accelerated plateau. The subcellular distribution of histones was monitored as a nuclear
control and also does not change in the accelerated-plateau cells. Similar results were
obtained in 8226 cells (data not shown). For example, the median N/C ratio in 8226 cells
of topo IIα in log-phase was 9.5 ± 6.3 versus 2.1 ± 1.6 at 16 h accelerated plateau.
The subcellular distribution of topo IIα in H929 cells was confirmed by
biochemical separation of the nuclear and cytoplasmic compartments with subsequent
western blot analysis (Figure 32). The subcellular locations of topo I and LDH were used
as nuclear and cytoplasmic controls, respectively. The amount of topo IIα found to be
distributed to the cytoplasmic compartment in plateau-phase H929 cells varied between
25% and 50% of the total cellular amount. This experiment was repeated seven times and
the majority of the experiments demonstrated 40-50% cytoplasmic topo IIα in plateauphase cells. These results agree with the microscopy findings above, which demonstrated
a N/C ratio of 1.3 ± 1.3 for 16 h plateau-phase H929 cells. The partial degradation of
topo IIα that occurred during the nuclear-cytoplasmic separation was not observed when
cells were immediately immunoblotted, and was not prevented by the addition of several
protease inhibitors (see “Materials and Methods”). Similar immunoblot results were
obtained in HL-60 cells (data not shown) and 8226 cells. Thus, it appears that topo IIα,
but not topo I or IIβ, is shuttled to the cytosol when H929 cells are grown at a superconfluent cell density.
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Figure 32. Nuclear-cytoplasmic Separation and Western Blot Analysis of DNA
Topoisomerase I and II and LDH. Nuclear-cytoplasmic separation of log and
plateau (16h) H929 cells followed by Western blot analysis for topo IIα, topo I, and
LDH. Experiment A demonstrates that in plateau phase there is approximately onehalf of the cellular topo IIα (partially degraded) in each of the nuclear and
cytoplasmic compartments. In experiment B, the amount of total cellular topo IIα is
distributed as approximately 75% to the nucleus and 25% to the cytoplasm in
plateau phase growth (determined by densitometry). The subcellular locations of
topo I and LDH were used as nuclear and cytoplasmic controls, respectively. WC,
whole cells; N, nucleus; C, cytoplasm.

12.8 Topoisomerase II Enzyme Activity.
Although the total amount of topo IIα protein does not change between log and
accelerated-plateau cells, a redistribution of topo IIα from the nucleus to the cytoplasm
would be expected to decrease the amount of drug target in the nucleus. If the nuclearcytoplasmic trafficking of topo IIα results in attenuation of nuclear content, then there
would be less drug-induced DNA damage and fewer cleavable complexes expected.
Thus, we hypothesized that a cytoplasmic distribution of topo IIα would protect cells
from drug induced DNA damage by attenuating the amount of lethal drug-enzyme-DNA
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complexes formed. To test this hypothesis, the amount of VP-16 induced DNA damage
was compared in log and accelerated-plateau phase (16 h) H929 cells by the alkaline
comet assay (Figure 33). The mean of three experiments showed that the average comet
moment was higher in log-phase cells than accelerated-plateau cells at each drug
concentration. For example, the average comet moment for log-phase cells was 80 ± 7
and 50 ± 5 for accelerated-plateau cells in the presence of 10 µM VP-16. The results
indicate that there are less drug-induced double strand DNA breaks in cells seeded at the
super-confluent cell density.
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Figure 33 . Determination of VP-16 Induced Double-strand DNA Breaks.
Measurement of VP-16 induced double-strand DNA breaks in log and
accelerated-plateau H929 cells at 16 h using the comet assay. Cells were
treated with 0-50 µM VP-16 as described in “Materials and Methods”. The
average comet moment of 50 cells at each drug concentration was
calculated from three experiments and is shown in panel B. A
representative comet is shown in A. (o), log-phase cells; (•), acceleratedplateau cells.
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To determine if the decrease in DNA damage can be explained by a reduction in
the number of drug-induced enzyme-DNA complexes formed, the amount of topo IIα
drug-stabilized cleavable complex formation was compared in log and acceleratedplateau (16 h) cells using a modification to the band depletion assay originally described
for observing topo I cleavable complex formation in the presence of topotecan. We
adapted the same procedure to observe topo IIα cleavable complex formation in the

VP-16
Stacking gel

Trapped topo IIα
Free topo IIα

Separating gel

Figure 34 . Illustration of Band Depletion Assay. The band depletion
assay was preformed as described in "materials and methods". Briefly,
cells treated with increasing concentrations of etoposide (VP-16) are
lysed in a buffer containing guanidine hydrochloride, which acts as a
strong protein denaturant that traps preexisting covalent topo II-DNA
complexes. Cell preparations are then electrophoresed on an SDSpolyacrylamide gel. Topo IIα-DNA complexes run more slowly than
free topo IIα, which is observed as a decrease in the intensity of the topo
IIα by Western blot analysis.

presence of etoposide. This assay is based on the observation that topo II covalently
bound to DNA migrates more slowly than free topo II on sodium dodecyl sulfate (SDS)polyacrylamide gels (Figure 34). Accordingly, as topo II forms increasing amounts of
cleavable complexes in the presence etoposide, there is a corresponding decrease in the
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molecular weight signal of topo IIα by Western blot analysis (Figure 35) (Kaufmann et
al., 1997). Results from the band depletion assays showed that a 7-fold higher
concentration of etoposide was needed to deplete the topo IIα levels by 50% in
accelerated-plateau H929 cells. The drug concentration to achieve 50% band depletion is
5 µM in log-phase cells and 35 µM in accelerated-plateau cells, suggesting that there are
fewer enzyme-drug DNA complexes formed in accelerated-plateau cells relative to logphase cells. These results were further confirmed by measuring the catalytic activity
(kDNA decatenation) of topo II present in the nuclear extracts from log and acceleratedplateau H929 and HL-60 cell lines (data not shown). Approximately 4-times more
nuclear extract protein was needed to decatenate 1 µg of kDNA in either acceleratedplateau H929 or HL-60 cells than in log-phase cells.

150

Topo IIα

Figure 35. Measurement of Cleavable Complexes. Differences in the
formation of VP-16-stablized enzyme-DNA complexes were examined in
log and accelerated-plateau H929 cells using the band-depletion
assay.These results show that a 7-fold increase in VP-16 was needed to
achieve a 50% reduction in the topo IIα band in plateau-phase cells
relative to log-phase cells. (o), log-phase cells; (•), accelerated-plateau
cells. Topo IIα cleavable complexes become trapped in the stacking gel
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Collectively, these data suggest that there are significantly fewer topo catalyzed
double-strand DNA breaks in VP-16 treated accelerated-plateau cells than log H929 cells
because there are fewer drug-induced DNA-protein complexes formed. Thus, a decrease
in drug-induced DNA-protein complexes could explain in part the observed drug
resistance to topo inhibitors; attenuation in the total amount of cleavable complexes
formed can best be explained by the cytoplasmic trafficking of topo IIα enzyme. Also,
nuclear topo IIα present in plateau H929 cells appears to be less drug sensitive.

12.9 Subcellular Distribution of Topo IIα in Malignant Plasma Cells.
We next studied the distribution of topo I, topo IIα, and topo IIβ in clinical
samples: bone marrow aspirates from myeloma patients. Representative aspirates from
two out of 10 patients examined are shown in Figure 20 and figure 21. The aspirates
(both with >90% plasma cells) were obtained before high-dose chemotherapy but after
standard-dose chemotherapy. Figure 37 shows the subcellular distribution of topo IIα in
one untreated patient with multiple myeloma. In all patients, there was a considerable
proportion of topo IIα in the cytoplasmic compartment of the plasma cells. The
percentage of plasma cells that was brightly fluorescent and displayed a nuclear
distribution of topo IIα was always in the range of 10-15% and reflected cells that were
probably in the S-or G2/M-phase of the cell cycle. Topo I was found to be strictly nuclear
or nucleolar except for one patient (90% of cases). In the one patient who had relapsed
after high-dose chemotherapy, topo I was found to be exclusively cytoplasmic. The topo
IIβ subcellular distribution was mostly a mixed nuclear and cytoplasmic pattern, and in
~50% of the patients showed nucleolar staining as well. Generally, topo IIβ labeling
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demonstrated a low expression by immunofluorescence and was nearly undetectable on
Western blots. When the nuclear/cytoplasmic ratios of topoisomerases were examined in
the malignant plasma cells from 10 myeloma patients by confocal laser scanning
microscopy, only topo IIα was present with ratios below 1 in the majority of cells.
Collectively, the data in this study suggests that a correlation may exist between the
cytoplasmic location of topo IIα and decreased sensitivity of these cells to topo inhibitors.

12.10 Conclusions.

In this study, we have investigated the role of topoisomerase IIα trafficking in
cellular drug resistance. We developed a cell model (called accelerated-plateau) using
human myeloma H929 and 8226 cells that reproducibly translocates topo IIα to the
cytoplasm. It was necessary to separate the influence of the cell cycle, drug uptake, topo
protein levels, and enzyme trafficking of drug sensitivity in this cell model. Compared to
log-phase cells, the cytoplasmic redistribution of topo IIα in the accelerated-plateau cells
correlated with a 10-fold resistance to VP-16 and a 40-60% reduction in the number of
drug-induced double strand DNA breaks. In addition, 7-fold more VP-16 was necessary
to achieve 50% topo IIα band depletion, suggesting that there are fewer drug-induced
topo-DNA complexes formed in the accelerated-plateau cells than the log-phase cells.
The total cellular amount of topo IIα and topo IIβ protein in log- and accelerated-plateau
was similar as determined by Western blot analysis. There was a 25% reduction in Sphase cell number in plateau cells (determined by bromodeoxyuridine (BrdU)
incorporation).
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The data from this study support the hypothesis that the nuclear-cytoplasmic
trafficking of topo IIα mediates, at least in part, cellular drug resistance to topo inhibitors
by reducing the amount of topo IIα in the nucleus and the subsequent number of enzyme
drug-induced DNA complexes formed. Thus, we established a novel mechanism of de
novo drug resistance that is independent of drug transport and cellular quantity of topo
IIα. Furthermore, Western blot analysis demonstrates that the cytoplasmic location of
topo IIα is not likely to be a result of expression of a truncated enzyme that has lost the
C-terminal NLS (Wessel et al., 1997).
These data may have clinical implications in the treatment of human myeloma, as
immunohistochemistry (Figures 36 and 38 ) and Western Blot analysis (Figure 37)
demonstrates that topo IIα has a cytoplasmic distribution in malignant plasma cells
obtained from the bone marrow aspirates of myeloma patients before (Figure 36) and
during treatment (Figures 37 and 38). The data also suggests that topo IIβ and topo I may
be more appropriate molecular targets in multiple myeloma because neither their amount
nor their subcellular localization were found to be altered at plateau densities.
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Topo IIα

Histone

Merged

Figure 36. Subcellular Distribution of Topoisomerase IIα in Plasma Cells
from One Untreated Multiple Myeloma Patient. Immunofluroescent staining
for Topo IIα and histone. Goat anti-rabbit IgG-TRITC labeled antibody was
used for detecting topo IIα (appears red). Goat anti-mouse IgG-FITC labeled
secondary antibody was used to detect histone (appears green) as a nuclear
control. Cells were mounted on microscope slides containing Vectashield
mounting media containing DAPI, which binds DNA (appears blue).

Figure 37 . Western Blot Analyses of Topoisomerase I and Topo IIα in
Two Patients with Multiple Myeloma being Treated with Chemotherapy.
The nuclear and cytoplasmic compartments were separated as described in
"Materials and Methods" and the equivalent of 5.0 x 105 cells was loaded
in each lane. The CCRF cells were loaded as a positive control for topo I
and topo IIα immunoreactivity. WC, whole-cell lysates; nu, nuclear
fraction; cy, cytoplasmic fraction.
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Patient 1

Patient 2

Topo IIα

Histones

Topo IIβ

Topo I

Merged
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Histones

Merged

Topo I
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Topo IIβ
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Figure 38. Subcellular Distribution of Topoisomerase in Two Multiple Myeloma Patients
being Treated with Chemotherapy. Confocal microscopy was performed on plasma cells
obtained from patient 1 (A-F) and Patient 2 (M-R). Cells were stained for topo IIα (A and
M) with polyclonal antibody 454 and histones (B and N). The merged image (C and O)
demonstrates that topo IIα is nuclear ~ 10% of the cells (proliferative fraction) and
cytoplasmic or faintly nuclear in the remaining plasma cells. Histone staining was used to
define the nucleus. Patient plasma cells were also stained for topo IIβ (D and P) with the
polyclonal JB1 antibody, for topo I with the C-21 monoclonal antibody (E and Q) and the
merged images (F and R). Topo IIβ was observed in the nucleus (D), cytoplasm (F) and
nucleoli (P), but its amount was relatively low compared with topo IIα. Topo I
distribution was typically nuclear (E) or nucleolar (Q).
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Chapter Thirteen
Experimental Results
Part III: Human Topoisomerase IIα Contains Two
Leptomycin B Sensitive Nuclear Export Signals

13.1 Introduction.
Resistance to chemotherapeutic drugs is a major obstacle in the treatment of
leukemia and myeloma. We have previously found that myeloma and leukemic cells in
transition from low-density log phase conditions to high-density plasteau phase
conditions exhibit a cell density dependent translocation of topo IIα to the cytoplasm.
The determination of the mechanism of topo IIα transport across the nuclear membrane
could lead to a better understanding of how to regulate the levels of active enzyme in the
nucleus, and thus sensitize cells to topo inhibitors. We questioned whether the
cytoplasmic distribution of topo IIα was a result of decreased import or increased export.
Initially, we tried to block the import of topo IIα in log and plateau density cells by using
the general nuclear import inhibitor, lectin. Wheat germ agglutin (WGA) is a nonspecific inhibitor of general nuclear import (Duveger et al., 1995). WGA is believed to
inhibit nuclear import by binding nucleoporins and "clogging" the nuclear pore
complexes. We did not observe a difference in the nuclear-cytoplasmic distribution of
topo IIα in log or accelerated plateau 8226 or H929 cells treated with lectin as determined
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by confocal microscopy (unpublished data). One possible explanation of these results is
that in log-phase cells, topo IIα was already present in the nucleus prior to drug treatment
and does not shuttle continuously between the nucleus and cytoplasm of log-growing
cells. We also treated accelerated plateau 8226 and H929 cells with lectin to determine if
a greater percentage of topo IIα protein would become trapped in the cytoplasmic
compartment of lectin treated cells compared to untreated cells. We observed no
significant differences in the nuclear-cytoplasmic distribution of topo IIα in the presence
of lectin. These results suggest the possibility that topo IIα is exported from the nucleus
to the cytoplasm, and thus is not inhibited by lectin. Therefore, we investigated the
ability of the nuclear export inhibitor, Leptomycin B, to block the nuclear export of topo
IIα in the accelerated-plateau cells.

13.2 LMB Modulation of Topoisomerase IIα Trafficking.
To determine the mechanism by which topo IIα accumulates in the cytoplasmic
compartment, accelerated-plateau H929 cells were treated with the nuclear export
inhibitor, LMB (Figure 39). This Streptomyces metabolite has been shown to inhibit
CRM1-mediated nuclear export of proteins with leucine-rich nuclear export signals
(Engel et al., 1998; Wolff, B. et al., 1997; Nishi et al., 1994; Hamamoto et al., 1985).
Immunofluorescent microscopy demonstrates that the median N/C ratio of topo IIα is
increased 58-fold in plateau H929 cells treated with 0.5 ng/ml of LMB for 16 h when
compared to untreated cells. The median N/C ratio of untreated accelerated-plateau cells
is 0.98 ± 2.0 and increases to 57.5± 170.2 in the presence of LMB. A total of 50 cells
were examined per condition and the experiment was repeated three times. Similar results
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were obtained in HL-60 cells (data not shown). The large standard deviation observed in
the LMB-treated cells can be accounted for by the presence of several cells with N/C
ratios > 300. Therefore, the median values have been reported as a more representative
value of the true N/C ratio. These data indicate that the cytoplasmic translocation of topo
IIα can be blocked by LMB and suggests that topo IIα is exported from the nucleus as
opposed to retained in the cytoplasm in untreated cells. Furthermore, the average total
pixel density of topo IIα in whole cells decreased from 113,929 ± 51,530 in control cells
to 38, 053 ± 41, 040 in LMB-treated cells, a 67% reduction in pixel density of whole
cells. These data suggest that topo IIα may be downregulated in the presence of LMB
because there is a greater reduction in total pixel density of treated cells relative to
untreated plateau cells. The pixel density of topo IIα immunofluorescence in the nuclear
compartment is reduced from an average pixel density of 52,241 ± 21,716 to 868 ± 1226
pixels. One possible explanation is that LMB blocks the export of topo from the nucleus
and topo becomes degraded by nuclear proteasomes. The degradation of topo has been
shown to occur in the nucleus, but Western Blot analysis of topo IIα protein content in
LMB treated plateau cells would be necessary to confirm these results. These results
suggest that topo IIα trafficking in the log-plateau cell model could be a result of
increased nuclear export.
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Plateau (16 h), 0 ng/ml LMB
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Plateau (16 h), 0.5 ng/ml LMB
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Figure 39. Confocal Microscopy and Nuclear-cytoplasmic Ratios of DNA Topoisomerased IIα Immunoflurescent Staining in the Presence or
Absence of Leptomycin B. Subcellular localization of topo IIα and pan-histone in 16 h accelerated-plateau H929 cells ± 0.5 ng/ml LMB (panel A, 0
ng/ml LMB; panel B, 0.5 ng/ml LMB). The nuclear-cytoplasmic ratio per cell is shown for 50 plateau-phase cells (± LMB) in panels C and D.
tetramethylrhodamine isothiocyanate (TRITC) staining (red) is for topo IIα and FITC staining (green) is for histones, in the immunofluorescence
figures. The experiment was repeated three times in H929 cells and once in HL-60 cells (data not shown). Cytoplasm ( ■ ), nucleus (□).
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Table 10. Determination of a Consensus Sequence from Established Nuclear Export Signals (NES)
α-actin
(Wada et al., 1998)
β-actin
(Wada et al., 1998)

A

L*

P

H

A

I

M

R

L

D

L

A

A

L

P

H

A

I

L

R

L

D

L

A

P

V

L

E

N

L

T

L

TFIIIA

L

(Fridell et al., 1996)
PKIα
(Wen et al., 1995)
MAPKK
(Fukada et al., 1996)
RevHIV
(Fischer et al., 1995)

E

L

A

L

K

L

A

G

L

D

I

N

A

L

Q

K

K

L

E

E

L

E

L

D

Q

L

P

P

L

E

R

L

T

L

D

K

V

A

R

K

L

E

A

L

S

V

R

L

E

D

N

L

R

E

L

Q

I

C

L

T

M

K

E

L

E

E

L

E

L

L

S

L

S

G

D

L

S

L

A

L

C

F

R

E

L

N

E

A

E

L

K

D

Ran BP-1
(Zolotukhin and Felber,
1997)
C-Abl
(Taageoera et al., 1998)
hZyxin
(Nix and Beckerle, 1997)
MdM2
(Roth et al., 1998)
P53
(Strommel et al., 1999)
Consensus

L

HX1-4HX2-3HXH(X = Leu, Ile, Val, or Phe)

*Bold letters represent hydrophobic residues thought to be crucial for nuclear export
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13.3 Determination of Consensus Sequence for Nuclear Export Signals.
Since we observed a 58-fold increase in the nuclear-cytoplasmic ratio of topo IIα
immunofluorescence in accelerated-plateau H929 cells treated with leptomycin B when
compared to untreated cells, we hypothesized that topo IIα may contain a LMB sensitive
nuclear export signal. Thus, we aligned several proteins with established nuclear export
signals to determine a consensus sequence (table 10). We determined the consensus
sequences as HX1-4HX2-3HXH (where H represents the hydrophobic amino acids, leucine,
isoleucine, valine, or phenylalanine). The hydrophobic amino acids are separated by a
characteristic spacer region containing any amino acids (represented as the letter "X").
Using the consensus sequence we identified six matching nuclear export sequences in the
amino acid sequence for human topo IIα (Table 11 ), which was downloaded from the
National Center for Biotechnology Information database (accession number NP 001058).
We initially expected to express exogenous topo IIα in human myeloma cells to
investigate the nuclear cytoplasmic distribution between log and plateau cell-density.

13.4 Transfection of Topo IIα and Alternative Experiments.
For one year, I attempted to transfect a number of human myeloma and leukemia
cell lines with a full-length topoisomerase IIα green fluorescent (GFP-topo IIα) fusion
protein expression vector. The expression vector that I worked with was obtained from a
laboratory that described a method for cloning the GFP-topo IIα gene that produced high
levels of expression of the topo IIα-GFP chimera in the nucleus of human cells (Mo et al.,
1998). During this time, I worked with the combined efforts of Dr. Terresita Muñoz and
her laboratory personnel. However, we found that in most cases we were unable to
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obtain a positive clone. The clones that were achieved often failed to grow exponentially,
suggesting that the bacteria were resistant to the uptake of the large topo IIα gene. Thus,
many of my initial experiments resulted in a low yield of plasmid with the topo IIα gene
making subsequent transfection procedures unsuccessful. We used several different
methods for transfecting human myeloma cell lines including cationic lipids and
electroporation. We also attempted to express topo IIα-GFP under the regulation of an
inducible promoter, but also had negative results. The most successful experiments
demonstrated transient expression of the topo IIα-GFP chimera, but at very low
transfection efficiency. For example, I tried to transfect human myeloma H929 cells,
HL-60, and 8226 cells by electroporation. However, electroporation also produced
negative results that included a high rate of cell death and low transfection efficiency. Of
the cells that were transfected, I observed gross morphological changes in their
appearance. In addition, translocation of GFP-topo IIα to the cytoplasm in plateau
density cells was extremely limited when compared to endogenous topo IIα (data not
shown). I found that expression of GFP-topo IIα recombinant protein was cytotoxic,
inducing cell death in all cell lines tested (CCRF, H929, HeLa, HL-60, 8226, Flow
fibroblast 2000) within 12-16 hours after transfection. This was a significant problem
that impeded our ability to monitor the nuclear cytoplasmic trafficking of the topo IIαGFP fusion protein because according to my accelerated-plateau cell model, the
transfected cells would need to grow for 16-24 hours at a high-cell density.
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Table 11. Putative Nuclear Export Signals in Human DNA Topoisomerase IIα
Topo IIα

Consensus Sequence

Amino Acids

HX1-4HX2-3HXH(X = Leu, Ile, Val, or Phe)

80-90

G

L*

Y

K

230-241

S

L

D

K

467-476

T

L

A

569-580

F

L

E

E

1017-1028

I

L

R

I

L

E

1054-1065

F

I

F

D

E

I

L

V

I

V

A

L

M

V

R

V

S

G

L

G

V

V

I

T

P

I

V

K

V

D

F

F

E

L

R

L

K

K

I

D

G

K

I

I

I

D

F

*Bold letters represent hydrophobic residues thought to be crucial for nuclear export
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The lack of success with expressing exogenous topo IIα into human cells led us to
look for an alternative method for defining a nuclear export signal. Different methods for
defining a nuclear export signal have been described (Koster et al., 2005; Henderson and
Eleftherion, 2000; Bogerd et al., 1996). We decided to crosslink the putative nuclear
export signals found in topo IIα to bovine serum albumin (BSA), a large carrier molecule
that is unable to be transported across the nucleus, and then microinject the NES-peptide
BSA conjugates into the nucleus of cells. By labeling the NES-peptide BSA conjugates
with a fluorescent molecule (ie FITC or TRIC) we were able to visualize the subcellular
localization of the microinjected peptides. Nuclear export was observed when the NESpeptide was able to transport BSA from the nucleus to the cytoplasm. BSA is a suitable
molecule for investigating nuclear-cytoplasmic transport pathways because it does not
contain a functional NES. Therefore, putative nuclear export signals can be crosslinked
to BSA to determine if they are sufficient to transport BSA across the nuclear membrane
and into the cytoplasm. Although the objective of transfecting human myeloma cells
with topo IIα was not abandoned, my specific efforts were redirected towards the
microinjection experiments.
The six putative NES shown in table 11 were synthesized and their sequences
confirmed as described in "materials and methods". The peptides were synthesized as
native (nt) or mutated (∆) sequences. The mutated peptides contained alanine in place of
those hydrophobic residues suspected of being critical for Crm-1 mediated nuclear
export. Crm-1 is a nuclear export receptor that recognized specific types of NES
containing a characteristic spacing of hydrophobic amino acids. Although other export
receptors are likely to exist, crm-1 is the only export receptor for NES containing proteins
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that has been described to date. To facilitate conjugation with preactivated SMCC-BSA,
the NES peptides were designed with a cysteine residue at the amino terminus. In this
manner, SMCC-BSA forms a disulfide bond with the cysteine residue in the peptide
sequences. We did an initial experiment to determine the optimal duration required to
incubate the NES peptides with SMCC-BSA and the approximate quantity of total
protein needed for gel electrophoresis. Figure 40 shows that after five minutes of
reaction time, detection of NES peptides crosslinked with SMCC-BSA are noticeable as a
shift in the apparent molecular weight of SMCC-BSA (compare lanes 4 and 5). We
determined that 20-30 minutes are optimal for NES peptide crosslinking to SMCC-BSA.
Proceeding one peptide at a time, the peptides were reacted with SMCC-BSA, and then
the conjugated peptides were purified by size exclusion chromatography on a using a
Pharmacia P500 FPLC system. As peptides passed through the LKB control Unit UV-1,
the absorbance spectra was recorded. An example of the absorbance spectra obtained for
peptide containing amino acids 80-90 is shown in figure 41. Three main peaks are
evident and correspond with the size of the eluted fractions. The largest compounds elute
first, whereas the smallest molecules become impeded within Superdex gel matrix beads
and elute last. FPLC fractions 4-7 (Figure 41) are likely to be large SMCC-BSA
molecules crosslinked with each other, fractions 16-18 represent conjugated BSA
peptides, and fractions 30-32 represent unreacted peptide molecules. Peptide conjugation
was confirmed by running FPLC eluted fractions on a 10% SDS-PAGE gel, and then
visualizing the proteins by silver stain analysis (Figure 43 and 44). Similar conjugated
BSA peptide fractions were pooled and concentrated before reacting with fluorescein
isothiocyanate (FITC). FITC labeled BSA-peptides were again purified by gel filtration
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chromatography (Figure 42) and a large single peak was noticeable on the absorbance
spectra (data not shown). The type of cell to be microinjected was an additional
experimental parameter that we had to determine before beginning our experiment. We
initially wanted to microinject human myeloma or leukemia cell lines with the
crosslinked peptide, but we ran into two problems. First, the myeloma and leukemia cell
lines are suspension cells. To microinject suspension cells, they must be held in place by
suction with one capillary while being pricked with a needle with the opposite hand. The
human myeloma and leukemia cell lines proved to be too small, and instead became
trapped inside the capillary (Figure 45). So, we tried using the adherent cell lines, HeLa
and FlowFibroblasts2000. We found that pre-treating glass coverslips with HCl
optimized the adhesion of HeLa cells to the coverslips. The HeLa cells spread out across
the coverslips and gave us an easily identifiable nucleus to inject (Figure 45).
Furthermore, microinjection of the HeLa cell directly onto the glass coverslips facilitated
their visualization by fluorescence microscopy.
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Figure 40. Coomassie Blue Stain of SDS PAGE gel with NES- peptide BSA Conjugates. Lanes
1 & 2 are molecular weight markers; lane 3, bovine serum albumin; lane 4, preactivated SMCCBSA; lane 5, NES peptides incubated with SMCC-BSA for 5 minutes; lanes 6 and 7 are NES
peptides incubated with SMCC-BSA for 20 minutes; lames 8-10 are NES-peptides conjugated
with SMCC-BSA for 30 minutes; lanes 11-13 are NES peptides conjugated with SMCC-BSA
for 1 h. Approximately 25µg of protein were loaded in lanes 4-8; 50 µg were loaded into lane 9,
and 10 µg were loaded into lanes 10-13. Lane 4 represents free SMCC-BSA (lower smear) and
SMCC-BSA crosslinked with itself (upper smear). Lane 5 shows that after 5 min, some peptide
already began to crosslink with SMCC-BSA (compare lanes 4 and 5, notice upward shift).
Arrow indicates conjugated peptides. We determined that 20-30 minutes was optimal for
peptide conjugation to SMCC-BSA.
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Figure 41. Absorbance Spectra of a BSA NES-peptide Conjugate at
562 nm. Three main peaks are evident and represent elution of
different sized molecules. SMCC-BSA cross linked with itself is
likely to be the largest complex to elute first (fractions 4-7) followed
by BSA-peptide conjugates (fractions 16-18) and then unreacted
peptides (fractions 30-34). An absorbance spectra was obtained for
each BSA crosslinked peptide.

Unreacted FITC

FITC-BSA-Peptides
Figure 42. FITC-Labeled-BSA NESpeptide on Size Exlusion Coulmn. Arrows
indicate the separation of FITC-conjugates
from unreacted FITC.
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Lane 4.Peptide pre-FPLC

Lane 3. SMCC-BSA

Lane 2. Free Peptide

Lane 1. MW

FPLC Fractions
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Figure 43. Silver-stain Analyses of SDS-Page BSA-NES-Peptide FPLC
Fractions. FPLC Peptide fractions were collected and electrophoresed as
described in Materials and Methods. Gels were stained with Silver staining.
Lanes 20-28 show a shift in the apparent molecular weight of free peptide
(lane 2) and free SMCC-BSA (lane 3). Lane 3 also shows that some SMCCBSA crosslinks with itself.
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Figure 44. Silver Stain Analysis of each BSA Conjugated Peptide. SDS-PAGE gels were
scanned into AdobePhoto Shop 6.0. (1) native peptide 80-91 (2) mutated peptide 80-91 (3)
native peptide 230-241. Please note that mutated peptide 230-241 data not available because gel
was shattered during the drying process. Since the native peptide did not export, SDS-PAGE
was not repeated for the mutated peptide. (5) native pepide 569-580 (6) mutated peptide 569580. Arrows indicate FPLC fractions containing SMCC-BSA crosslinked to peptides Figure 44
continued on next page.
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Figure 44 continued. (7) native peptide 569-580 (8) mutated peptide 569-580 (9) native peptide 1018-1024
(10) mutated peptide 1018-1024 (11) native peptide 1054-1065 (12) mutated peptide 1054-1065 Arrows
indicate FPLC fractions containing SMCC-BSA crosslinked to peptides.
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Figure 45. Comparison of H929 Cells with HeLa Cells for Microinjection. (A)
H929 cells (low magnification) (B) H929 cells (High magnification) (C) HeLa
cell. H929 cells are suspension cells, whereas the HeLa cells are adherent.
The suction capillary is necessary to hold suspension cells in place while being
microinjected.
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13.5 Peptides NES1054-1066 and NES1017-1028 Signal the Nuclear Export of BSA-FITC.
The data suggest that topo IIα may be translocated from the nucleus to the
cytoplasm under specific conditions, and this may result in altered drug sensitivity. Of
the six putative NES identified in topo IIα, two peptides, NES1054-1066 and NES1017-1028,
exported BSA into the cytoplasm when microinjected into the nuclei of HeLa cells
(Figures 46). BSA-NES1054-1066 showed strong cytoplasmic staining and were seen in the
cytoplasm within 15 minutes of microinjection, as compared to TRITC-BSA alone,
(Figure 47), or the mutated BSA-NES1054-1066 conjugate. BSA-NES1017-1028 also appeared
cytoplasmic within 15 min of being microinjected into the nucleus, but complete nuclear
clearing (like the ntNES1054-1066) was not observed even after 90 min. The mutated
BSA-NES1054-1066 was nuclear in all cells observed even 90 min after microinjection.
BSA-NES80-90 (Figure 47) mutated BSA-NES80-90 (Figure 47), BSA-NES230-241, mutated
BSA-NES230-241, and BSA-NES467-476, BSA-NES569-580, and mutated BSA-NES569-580 all
remained in the nucleus even 4 h after microinjection (data not shown).
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Mutated Peptide

Native Peptide
NES 1054-1066

NES 1017-1028

NES 80-90

Figure 46. HeLa cells Microinjected with Peptide-BSA-FITC Conjugates. HeLa cells
microinjected with either wild-type (left column) peptide-BSA-FITC conjugates (green),
and then counterstained with DAPI (blue). A total of 20-50 cells were successfully
microinjected per peptide and similar results were seen in all cells.
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TRITC-BSA

DAPI

Merged

Figure 47. HeLa Cells Microinjected with TRITCBSA. HeLa Cells were microinjected with BSATRITC in the nucleus and counterstained with
DAPI.

13.6 LMB Blocks ntNES1054-1066 and ntNES1017-1028 Mediated Nuclear Export.
LMB is a specific inhibitor of Crm-1 mediated nuclear export of proteins. To
determine if the nuclear export of BSA conjugated to peptides NES1054-1066 and NES10171028

was Crm-1 dependent, LMB pretreated HeLa cells were microinjected in the

presence of 2 ng/ml LMB in ethanol. Fluorescence microscopy demonstrated that LMB
blocked the export of BSA conjugated to peptides NES1054-1066 and NES1017-1028 (Figure
48). Peptide NES1054-1066 had a strong perinuclear staining, suggesting that the protein
cargo is docking at the NPC. Although the NES defined by microinjection are sufficient
to transport a non-shuttling protein to the cytoplasm, these leucine rich sequences may or
may not serve a role in exporting topo IIα.
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LMB NES 1054-1066

LMB NES 1017-1028

Figure 48. HeLa Cells were microinjected with wild-type peptide-BSA-FITC
conjugates in the presence of 2 ng/ml LMB (leptomycin B).
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13.7 Topoisomerase IIα Cloning, Site Directed Mutagenesis, and Gene Expression.
While obtaining results from the microinjection of the BSA-peptides, we began to
obtain promising results with the transfection of a FLAG-epitope tagged topo IIα in HeLa
cell lines. Although my focus in the laboratory was concerned with the microinjection of
conjugated BSA-peptides, I had a vested interest in the project and maintained a
significant involvement with the transfection studies. As such, I shared responsibility for
certain experimental procedures such as, design of the experiments, selection of the
mutated nucleotides (Table 12), and immunostaining of the FLAG-topo IIα chimeras. In
the earlier stages of the work, I transformed bacteria and performed a number of plasmid
preparations.
FLAG peptide is an eight amino acid protein (NYKNNNNK) that does not occur
in nature. FLAG does not contain any putative nuclear export signal and its small size
limits any secondary protein structure problems. Hela cells transfected with a FLAGtopo IIα plasmid vector expressed a full-length (170 kDa) topo IIα recombinant protein
(Figure 49 ) Using a specific transfection protocol previously described by VandenHoff
et al., 1992, we were able to transfect H929 and HL-60 cells by electroporation with a
high degree of efficiency for these cell lines (2-20%). The success of the transfection
experiments is attributed to the buffer described by Van den Hoff et al., 1992. The buffer
contains ATP and glutathione to promote the rapid repair of cellular membranes.
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Figure 49. Western blot of full-length FLAG-topo IIα. HeLa cells were transfected with plasmid
containing FLAG-topo IIα plasmid via cationic lipid, and harvested after 20 hours. Protein
extracts from 2.0 x 106 cells per lane were separated on SDA-PAGE gel, blotted onto
nitrocellulose and probed with FLAG M2 antibody. Lane A is protein from cells transfected
with non-mutated FLAG-topo IIα plasmid, lane B is FLAG-topo IIα 1054-1066, lane C
transfected with FLAG-topo IIα plasmid 1017-1028, and lane D is a non-transfected control.

13.8 FLAG-topoisomerase IIα Immunofluorescence.
BSA-peptide microinjection data indicated that the putative nuclear export sites at
1017-1028 and 1054-1066 may function to signal export of topo IIα. To confirm these
data with a full- length topo IIα protein, H929 human myeloma cells were transfected
with FLAG-topo IIα expression vectors possessing mutated hydrophobic residues in the
nuclear export sites at 1017-1028 and 1054-1066 (Table 14). Twenty hours posttransfection, live cells were isolated by centrifugation on a ficoll-paque gradient and
plated on glass microscope slides using cytospin funnels. After fixing and
permeabilization, slides were stained with anti-FLAG M2 monoclonal antibody-FITC
conjugate and counterstained with mounting media containing DAPI to show the location
of the nuclei. Images were acquired using a fluorescent microscope (Figure 50), with
quantitation of FITC fluorescence using Adobe Photoshop 7.0 (data expressed in Figure
51). Figure 50 establishes that the wild-type (non-mutated) FLAG-topo IIα protein is
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present in the nucleus of the cells plated at log density, whereas FLAG-topo IIα protein is
located in the cytoplasm in cells plated at plateau density. Quantitation of fluorescence
revealed a statistically significant shift (P=0.00001) for log cells with a
nuclear:cytoplasmic ratio of 5.9:1, to a ratio of 0.42:1 in plateau cells (Figure 51) when
using the wild-type FLAG-topoIIα plasmid.
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Table 12. Wild-type and Mutated Nucleotide Sequences of Putative Nuclear Export Signals.
Wild-type sequence 1017-1028
TTG

GAT

ATT

CTA

AGA

GAC

TTT

TTT

GAA

CTC

AGA

CTT

AAA

TAT

TAT

L

D

I

L

R

D

F

F

E

L

R

L

K

Y

Y

Mutated sequence 1017-1028
AGC

CTG

GAC

AAA

GAT

GCT

GTT

GCA

GCA

ATG

GTC

AGA

AGA

GCA

D

I

L

R

D

A

F

E

A

R

L

K

Y

Y

Wild-type sequence 1054-1065
CGC

TTT

ATC

TTA

GAG

AAA

ATA

GAT

GGC

AAA

ATA

ATC

ATT

GAA

R

F

I

L

E

K

I

D

G

K

I

I

I

E

AAT
N

Mutated sequence 1054-1065
CGC

TTT

ATC

TTA

GAG

AAA

GCA

GAT

GGC

AAA

GCA

ATC

ATT

GAA

AAT

R

F

I

L

E

K

A

D

G

K

A

I

I

E

N
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FITC

Log
DAPI

Merged

FITC

Plateau
DAPI

Merged

Wild-type

Wild-type

Mutated 1017-1028

Mutated 1017-1028

Mutated 1054-1066

Mutated 1054-1066

Figure 50. FLAG-topo IIα Immunofluorescence. Human multiple myeloma H929 cells
were transfected by electroporation with full-length wild-type and mutated toto IIα and
plated for 20 hours at log and plateau cell densities. Cytospins containing fixed cells
were stained with FITC-labeled anti-FLAG M2 antibody (green), counterstained with
DAPI for nuclear staining, and assayed by immunofluroescent microscopy..
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1053-1066 plateau
Nucleus
1053-1066 log

Cytoplasm

1016-1027 plateau
1016-1027 log
Wild-type plateau

*p = 0.00001
Wild-type log

Figure 51. Quantitation of FLAG-topo IIα Immunofluoresence. Human myeloma H929
transfected cells (n = 20) stained with anti-FLAG M2 monoclonal antibody-FITC
conjugate were assayed for nuclear and cytoplasmic immunofluorescence. Quantitation
of FITC fluorescence was performed using Adobe Photshop 7.0 program. Wild-type
FLAG-topo IIα was export to the cytoplasm in cells at plateau density (P = 0.00001),
whereas topo IIα mutated at the putative export sites, 1016-1027 and 1053-1066, did not
demonstrate statistically significant levels of export to the cytoplasm.
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13.9 Peptide ntNES1054-1066 and ntNES1017-1028 are Conserved.
To determine if peptides NES1054-1066 and NES1017-1028 are conserved, a BLAST
search of the SWISS PROT database was performed to identify homologous sequences in
topo IIα. Tables 15 and 16 summarize a list of representative species containing
homologous topo IIα sequences. The data show that the characteristic spacing of
hydrophobic residues in peptides NES1054-1066 and NES1017-1028 are highly conserved in a
broad range of species. For example, leucine residues appearing in human topo IIα NES
are often substituted with the hydrophobic amino acids isoleucine or valine.
Furthermore, Phe1054 and Ile1055 in peptide NES1054-1066 are highly conserved from
mammals to the most primitive eukaryotic organism, Giardia lamblia, unlike Leu1056.
This suggests that the presence of phenylalanine and isoleucine are critical for nuclear
export of this peptide, and thus an omission of these two hydrophobic amino acids from
the peptide sequence could explain why a previous report failed to identify NES1054-1066
as the dominant nuclear export signal (Mirski et al., 2003) .
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Table 13. Sequence Alignment of DNA Topoisomerase IIα NES1017-1028
Homo sapiens (human) NES1017-1028

D

I*

L

R

D

F

F

E

L

R

L

K

Sus scrofa (pig), Mus musculus (mouse),

D

I

L

R

D

F

F

E

L

R

L

K

Cricetulus griseus (Chinese hamster)

D

I

L

D

F

F

E

L

R

L

K

Gallus gallus (chicken)

D

I

L

F

F

E

L

R

L

I

L

F

V

R

L

D

I

L

F

L

R

L

D

I

L

F

V

R

L

Encephalitozoon cuniculi (protozoan)

I

L

F

L

R

L

Bombyx mori (silkmoth)

I

L

F

L

R

L

Rattus norvegicus (rat)

Saccharomyces cerevisia (yeast)
Aspergillus niger (fungus), Penicillium
citrinum (fungus)
Nicotiana tabacum (tobacco)

R

*Bold letters represent hydrophobic residues thought to be crucial for nuclear export.
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F

Table 14. Sequence Alignment of DNA topo IIα NES1054-1066
Homo sapiens (human) NES 1054-1066

F

I

L

E

K

I

D

G

K

I

I

I

E

Cricetulus griseus (Chinese hamster),
Mus musculus (mouse), Rattus
norvegicus (Rat)

F

I

L

E

K

I

D

G

K

I

I

I

E

Caenorhabditis elegans (nematode)

F

I

L

E

K

I

D

G

K

I

V

I

E

Saccharomyces cerevisiae (yeast)

F

I

L

K

I

I

V

I

E

Candida glabrata (yeast)

F

I

K

I

L

Aspergillus candidus (fungus)

F

I

K

I

L

I

I

Trichophyton rubrum (fungus)

F

I

K

I

I

V

I

Giardia lamblia (protist)

F

I

K

I

Bold letters represent hydrophobic residues thought to be crucial for nuclear export.
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G

I

I

I

13.10 NES1054-1066 and NES1017-1028 Reside within a Putative Coiled-coil Domain
We were interested in predicting the structural features of the region containing
NES1054-1066 and NES1017-1028. Each topo II monomer can be divided into three domains,
an N-terminal domain that contains the ATP-binding region, the central domain
containing the active site tyrosine residue, and the C-terminal domain that contains the
nuclear localization sequences. Both of the NES are situated upstream of the bipartite
NLS (Figure 52) and downstream of the active-site tyrosine residue (Tyr805).
Furthermore, several CK-2 phosphorylation sites downstream of both NES have been
identified in vitro and could be important for regulating the subcellular localization of
topo IIα. Although NES1017-1028 alone is predicted to form an α-helix, we were interested
in predicting the motif of the complete amino acid sequence stretching from NES1017-1028
to NES1054-1066. According to EMBOSS and Predict Protein, two programs designed to
predict protein motifs, amino acids 1017-1066 are characterized by a high potential to
form α -helices and also contain five 4-3 hydrophobic repeats, a typical feature of a
coiled-coil motif. Such a repeating pattern of hydrophobic amino acids has been shown to
form a hydrophobic core, which is critical for dimerization. In this manner, the
hydrophobic amino acids are predicted to align on the same interface which facilitates
DNA binding or protein-protein interactions. Interestingly, amino acids 1014-1057 in
topo IIα have previously been shown to form a stable two-stranded α -helical coiled-coil
in solution. Furthermore, the Advanced Chemistry Development ChemSketch 5.12
software was used to predict the 3-D structure of native and mutate peptides 1054-1066
and 1017-1028. The secondary structures of each peptide sequence was cleaned and
then, visualized with the 3-D viewer. Although each mutated peptide differed from their
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native peptides by just two amino acids, figure 53 establishes that each mutated peptide
appears more globular than the native peptide. These results suggest that the native
peptides may have more accessible binding sites available to bind CRM-1, whereas the
mutated peptides are more compact with fewer extensions for CRM-1 binding. These
results, however, are limited to the microinjection data and do not necessarily reflect the
tertiary structure of full-length topo IIα in living cells. However, the results suggest that
the larger amino acids such as isoleucine, leucine, and phenylalanine, have the potential
to form extensions that would facilitate CRM-1 binding.

13.11 Conclusions.
In order for topoisomerase targeted chemotherapy to function, the topoisomerase
target must have access to the nuclear DNA. Therefore, the nuclear export of
topoisomerase IIα may contribute to drug resistance, and defining this mechanism may
lead to methods to preclude this avenue of resistance. We have identified nuclear export
signals for topo IIα at amino acids 101701028 and 1054-1066 using FITC-labeled BSAexport signal peptide conjugates microinjected into the nuclei of HeLa cells. Functional
confirmation of both signals was provided by transfectin of human myeloma cells with
plasmids containing the gene for a full-length human FLAG-topoiosmerase fusion
protein. We futher showed that export by both signals was blocked by treatment of cells
with leptomycin B, indicating that a CRM-1 dependent pathway mediates export.
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MEVSPLQPVN ENMQVNKIKK NEDAKKRLSV ERIYQKKTQL EHILLRPDTY IGSVELVTQQ
61 MWVYDEDVGI NYREVTFVPG LYKIFDEILV NAADNKQRDP KMSCIRVTID PENNLISIWN
121 NGKGIPVVEH KVEKMYVPAL IFGQLLTSSN YDDDEKKVTG GRNGYGAKLC NIFSTKFTVE
181 TASREYKKMF KQTWMDNMGR AGEMELKPFN GEDYTCITFQ PDLSKFKMQS LDKDIVALMV
241 RRAYDIAGST KDVKVFLNGN KLPVKGFRSY VDMYLKDKLD ETGNSLKVIH EQVNHRWEVC
301 LTMSEKGFQQ ISFVNSIATS KGGRHVDYVA DQIVTKLVDV VKKKNKGGVA VKAHQVKNHM
361 WIFVNALIEN PTFDSQTKEN MTLQPKSFGS TCQLSEKFIK AAIGCGIVES ILNWVKFKAQ
421 VQLNKKCSAV KHNRIKGIPK LDDANDAGGR NSTECTLILT EGDSAKTLAV SGLGVVGRDK
481 YGVFPLRGKI LNVREASHKQ IMENAEINNI IKIVGLQYKK NYEDEDSLKT LRYGKIMIMT
541 DQDQDGSHIK GLLINFIHHN WPSLLRHRFL EEFITPIVKV SKNKQEMAFY SLPEFEEWKS
601 STPNHKKWKV KYYKGLGTST SKEAKEYFAD MKRHRIQFKY SGPEDDAAIS LAFSKKQIDD
661 RKEWLTNFME DRRQRKLLGL PEDYLYGQTT TYLTYNDFIN KELILFSNSD NERSIPSMVD
721 GLKPGQRKVL FTCFKRNDKR EVKVAQLAGS VAEMSSYHHG EMSLMMTIIN LAQNFVGSNN
781 LNLLQPIGQF GTRLHGGKDS ASPRYIFTML SSLARLLFPP KDDHTLKFLY DDNQRVEPEW
841 YIPIIPMVLI NGAEGIGTGW SCKIPNFDVR EIVNNIRRLM DGEEPLPMLP SYKNFKGTIE
901 ELAPNQYVIS GEVAILNSTT IEISELPVRT WTQTYKEQVL EPMLNGTEKT PPLITDYREY
961 HTDTTVKFVV KMTEEKLAEA ERVGLHKVFK LQTSLTCNSM VLFDHVGCLK KYDTVLDILR
1021 DFFELRLKYY GLRKEWLLGM LGAESAKLNN QARFILEKID GKIIIENKPK KELIKVLIQR
1081 GYDSDPVKAW KEAQQKVPDE EENEESDNEK ETEKSDSVTD SGPTFNYLLD MPLWYLTKEK
1141 KDELCRLRNE KEQELDTLKR KSPSDLWKED LATFIEELEA VEAKEKQDEQ VGLPGKGGKA
1201 KGKKTQMAEV LPSPRGQRVI PRITIEMKAE AEKKNKKKIK NENTEGSPQE DGVELEGLKQ
1261 RLEKKQKREP GTKTKKQTTL AFKPIKKGKK RNPWSDSESD RSSDESNFDV PPRETEPRRA
1321 ATKTKFTMDL DSDEDFSDFD EKTDDEDFVP SDASPPKTKT SPKLSNKELK PQKSVVSDLE
1381 ADDVKGSVPL SSSPPATHFP DETEITNPVP KKNVTVKKTA AKSQSSTSTT GAKKRAAPKG
1441 TKRDPALNSG VSQKPDPAKT KNRRKRKPST SDDSDSNFEK IVSKAVTSKK SKGESDDFHM
1501

DFDSAVAPRA KSVRAKKPIK YLEESDEDDL

Figure 52.The Complete Amino Acid Sequence of Human DNA Topo IIα (accession
number NP 001058). The active-site tyrosine resiude (805) is indicated (*). NES10171017
DILRDFFELRLK1028 and NES1054-1066 1054FILEKIDGKIIIE1066 are shaded;
1028.
bipartite NLS is single underscored; Ser/Thr phosphorylation sites are bold and
underscored ; the predicted coiled-coil region is double underscored; the active-site
tyrosine residue is indicated with a star, ( ).
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Wildtype sequence (1054-1066)
RFILEKIDGKIIIE

Mutant sequence (1054-1065)
RFILEKADGKAIIE
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Figure 53. Predicted Tertiary Structure of Wild-type and Mutant Peptides. The 3-D
structure of the wild-type and mutant peptides was determined using the Chem-Sketch 5.12
3-D viewer. Arrows indicated amino acids protruding at or away from the viewer. Figure
53 continue on next page.
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Wildtype sequence (1017-1028)
LDILRDFFELRLK

Mutant sequence (1017-1028)
LDILRDAFEARLK

OH

O

O

O
CH3

NH
H3C
NH

O

OH
H2N

NH
CH3

O

O
H3C

O
CH3

H3C
CH3
CH3

CH3

O

O

NH

NH

O NH

HN
HN
H2N

NH

NH

NH2

NH2

OH
NH

H3C

CH3

O

NH NH

O
O NH

OO

O
O

CH3

HN

O

O

NH
OH

NH O
O

O
NH

H3C

NH2
O

CH3
O NH
NH O

CH3

O CH3
HO

NH

NH

NH2
CH3

O

NH

OH O
O NH

OH

O

HO
O

HN

O

NH NH

NH

CH3

H3C

CH3

HN
HN

NH2

HN

HN

NH2

Figure 53. Continued. The 3-D structure of the wild-type and mutant peptides was determined
using the Chem-Sketch 5.12 3-D viewer. Arrows indicated amino acids protruding at or away from
the viewer.
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Chapter Fourteen
Discussion
14.1 Previous Findings.
It is well established that most cell lines display a differential sensitivity to topo II
inhibitors, which depends on cell density (Sullivan 1986, 1987; Chow and Ross, 1987,
Markovits, 1987). When non-transformed cell-lines reach confluence there is a
concomitant decrease in drug sensitivity to topo targeting cytotoxic agents that has been
attributed to an attenuation in the amount of topo IIα content (Sullivan, 1987). However,
in the tumor cell lines studied, confluence does not necessarily lead to a decrease in
cellular topo II content, yet the cells are resistant (Sullivan 1986, 1987). We investigated
several possible mechanisms of drug resistance in human myeloma and leukemia cell
lines to explain the discrepancy in the cellular content of topo enzymes in transformed
and non-transformed cell lines.

14.2 Log and Plateau Cell Lines Drug Sensitivity Phenotype.
Findings from this laboratory suggest that there are two general types of growthdependent mechanisms of drug resistance that are unrelated to prior drug exposure. The
first is demonstrated by non-transformed Chinese hamster ovary and human Flow 2000
fibroblasts cells lines which are 5-15 fold resistant to VP-16 in plateau-phase relative to
log-phase cells (Table 7, page 122). This is due to an 80-90% reduction in total cellular
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topo IIα protein (Figure 23, page 127), with a concomitant decrease in enzyme activity
(data not shown). The second mechanism is seen in several hematological cell lines
(mouse leukemia L1210, human myeloma RPMI-8226, human leukemia HL-60, human
leukemia KG-1a, and human lymphoblastic leukemia CCRF cells), which show
significant resistance to VP-16 at plateau phase (7.3-55-fold) (Table 7), but show no
decrease in total cellular amounts of topo I, IIα, or IIβ protein when compared to logphase cells (Figure 23).
Immunochemistry experiments demonstrated that in these cells, topo IIα is found
in the nucleus of log-phase cells, but had a significant cytoplasmic distribution in plateauphase cells (Figure 24, page 129). It appeared from this data that altered
nucleocytoplasmic trafficking of topo IIα, but not topo I or topo IIβ, occurs in
transformed cell lines at plateau-density. This was in contrast to other non-transformed
cell lines that degrade topo IIα at plateau phase.

14.3 Novel Human Myeloma Cell Line Models.
We questioned whether the nuclear-cytoplasmic trafficking of topo IIα had a role
in conferring altered drug sensitivity to topo targeting agents as well as cross-resistance
to other non-topoisomerase associated cytotoxic agents. Alterations in the subcellular
localization of topo enzymes have been previously associated with a decrease in drug
sensitivity, but the weight of the data describe alterations in the amount of activity of
drug resistant cell lines as a result of a truncated enzyme that has lost its C-terminal NLS
(Wessel et al., 1997). There are two notable exceptions that correlate altered subcellular
distribution of topo enzymes with altered drug sensitivity. First, multicellular spheroids
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and Xenograft tumor cells are protected from etoposide-mediated DNA damage due to
the cytoplasmic distribution of topo IIα (Oloumi et al., 2000). Secondly, adhesion of
human myelomonocytoid U937 cells to fibronectin by means of β1 integrins protects
cells against mitoxantrone and etoposide mediated DNA damage and is accompanied by
an altered sub-nuclear relocalization of topo IIβ to the nucleolus. Thus, changes in the
nuclear localization or binding properties of the nuclear pool of topo IIβ protein is
suggested to have a role in cellular drug resistance to etoposide and mitoxantrone in these
cells (Hazlehurst et al., 2001).
The lack of data to describe the subcellular distribution of topo IIα, especially the
nuclear export of the enzyme, as a predictor of drug responsiveness could be attributed to
the unavailability of in vitro cell models to study the nucleo-cytoplasmic distribution of
topo enzymes, that would otherwise make it possible to thoroughly investigate the role of
topo trafficking in drug sensitivity. Molecular analysis of the topo gene has been largely
unachievable because overexpression of topo IIα is lethal to cells, as well as topo IIα
gene knockouts. Most reports are successful at transfecting cells with truncated topo or
topo peptides (Ernst et al., 2000). In either case, the exogenous full-length topo is not
expressed in the nucleus because of a missing C-terminal NLS. These experiments fail to
correlate a cytoplasmic distribution of topo IIα with drug resistance because endogenous
topo is still present in the nucleus to cause drug-induced DNA damage. Furthermore, the
expression of an exogenous cytoplasmic topo makes it ineffectual at studying the nuclear
export of the protein (since it never enters the nucleus). In addition to these laboratory
complications, it has proved very difficult to culture cells from a plasma cell dyscrasia,
such as multiple myeloma. Much of our understanding of the biology of multiple
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myeloma has been obtained by studying multiple myeloma derived cell lines.
Unfortunately, human myeloma cell lines have proven difficult to transfect (refer to page
162).
We established an in vitro cell model system, referred to as accelerated-plateau,
using established human myeloma cell-lines and overcame many of the experimental
complications described above. Since log and plateau-phase cells represent low and high
cell densities relative to one another, we postulated that cell-cell contacts may trigger a
cytoplasmic relocation of topo enzymes. This model was used to describe the mechanism
of growth dependent drug resistance described above (Table 9, page 135), and ultimately,
to better characterize the mechanism of the nucleo-cytoplasmic trafficking of topo IIα
(Figure 39, page 160).
We realize that the plateau density of cell cultures is far below the cell density
existing in the tissues and biological fluids of patients. However, we consider that the
changes that occur in the transition from the proliferative state in log culture to quiescent
plateau densities are a reasonable model system to study the molecular mechanisms of
acquiring drug resistance without a drug selection pressure.
14.4 Log and Accelerated-plateau Drug Sensitivity Phenotype.
Accelerated-plateau cells had a similar drug resistance phenotype as the naturalplateau cells described above, but the accelerated-plateau cells were also analyzed for
cross-resistance to a range of drugs with different mechanisms of cytotoxicity (Figure 5
Table 11). The accelerated-plateau cells were 10-fold resistant to VP-16, but less than
1.5 fold resistant to Ara-c, taxol, BCNU, cis-platinum, and γ-irradiation. Similar results
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were obtained in human myeloma RPMI-8226 cells. These data area not consistent with
the multidrug resistance phenotype, but instead suggests that the observed drug resistance
is specific for topo II interacting agents. Furthermore, drug resistance to DNA
crosslinking agents, such as cisplatinum and γ-irradiation, has been found to be inversely
proportional (Gornati, 1997; Barret et al., 1994) to topo II amount as a result of enhanced
DNA repair processes by topo II. The drug resistance observed here, in the human
myeloma cells, is not likely to be a result of enhanced DNA repair because there was
minimal resistance to cisplatinum and γ-irradiation. Furthermore, cells were
hypersensitive to both cisplatinum and γ-irradiation at 16 h, suggesting that there was a
decrease in the total cellular content of topo II enzyme. However, Western blot analysis
demonstrated minimal changes in the levels of topo protein after 16 hours, suggesting
another mechanism exists for the observed hypersensitivity to the DNA crosslinking
agents. The cells grown at plateau-phase for 24 h continued to be hypersensitive to
cisplatinum but, there was a 4-fold decrease in sensitivity to γ-irradiation. Cell lines
resistant to CDDP have not been found to be crossresistant to γ-irradiation, suggesting
that there are different mechanism of resistance to γ-irradiation and cisplatinum (Caney et
al., 2004). For example, there may be different DNA repair processes for radiation
induced DNA damage as compared CDDP induced DNA damage (Caney et al., 1999;
Wilkins et al., 1996). Furthermore, an association between the acetylation status of DNA
histones and sensitivity to radiation has been previously reported (Zhang et al., 2004;
Camphausen et al., 2004; Paoluzzi and Fig, 2004). This suggests that histones may be
hypoacetlyated in plateau-phase myeloma cells as compared to the log-growing cells.
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Exposure to an HDAC inhibitor could sensitize the plateau-cells to γ-irradiation, by
maintaining the acetylation of histone proteins.
To elucidate other mechanisms conferring drug resistance to VP-16 and
mitoxantrone, log and accelerated-plateau cells were examined for differences in cell
cycle distribution, drug uptake, and subcellular distribution of topo protein. No
considerable difference was observed in the uptake of [3H-VP-16] between log and
accelerated-plateau cells, suggesting that altered drug transport is unlikely to account for
the observed drug resistance. Furthermore, cross-resistance to non-topoisomerase
targeting agents would be expected, if plateau-phase human myeloma cells overexpressed
MRP2 or MRP3 because both VP-16 and CDDP are substrates for MRP2 and MRP3.
However, accelerated-plateau cells were not cross-resistant to CDDP. Plateau-phase cells
were minimally resistant to the non-topoisomerase targeting agents, providing additional
support of the results from the drug uptake studies. Since flow cytometric analysis
indicate that there are minimal changes in the levels of topo protein and in the number of
cells in S-phase after 16 hours respectively, these cellular events are also not likely to be
the principle mechanisms of drug resistance.

14.5 Subcellular Distribution of Topo IIα.
Immunofluorescence microscopy demonstrated that topo IIα was nuclear in logphase cells but had a cytoplasmic distribution in the accelerated-plateau cells at 16 h or
24 h. Cytoplasmic topo IIα was not a result of a C-terminally truncated protein that has
lost the NLS, since there were single bands at the expected molecular weights for both
topo IIα and topo IIβ by Western blot analysis. The cytoplasmic distribution of topo IIα
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observed in the accelerated-plateau cell model was similar to that observed in the naturalplateau cells, but was observed in a shorter period of time (16 h for accelerated-plateau
versus 4-5 days in natural-plateau cells). This suggests that the nuclear-cytoplasmic
trafficking of topo IIα is a function of time and stimulated by cell-cell contact. The ratio
of topo I and II β did not change over the same period of time. Topo I remained nuclear
in log, plateau, and accelerated-plateau cells. Since Western blot analysis demonstrated a
reduction of topo I content in the both 8226 and H929 accelerated-plateau cells (16-34%
reduction; Figure 27, page 138), this suggests that topo I may be degraded by nuclear
proteasomes or that its degradation in the cytoplasm is rapid, and thus its cytoplasmic
location is below the threshold of immunofluorescence detection. Topo IIβ was
distributed approximately equally between the nuclear and cytoplasmic compartments in
log and plateau cells. Therefore, the subcellular distribution of topo I or topo IIβ did not
correlate with drug responsiveness. Rather, it appeared that an alteration in the
subcellular localization of topo IIα could be the principle mechanism contributing to the
decrease in drug sensitivity to topo II inhibitors.
While it may appear unusual that DNA replication continues despite having a
significant proportion of topo IIα in the cytoplasm, cells can survive with a
predominantly cytoplasmic form of a catalytically active enzyme, which exists in several
drug resistant cell lines. For example, in the drug resistant human small cell lung
carcinoma H69-VP cell line, a catalytically active yet truncated topo IIα enzyme is
located in the cytoplasm while topo IIβ is expressed in the nucleus (Grue et al., 1998). In
these cells, chromosomal formation is dependent on cytosolic topo IIα entering the
chromatin during mitosis when the nuclear membrane disappears rather than nuclear topo
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IIβ performing the mitotic functions of topo IIα (Grue et al., 1998). Similar findings have
been reported in drug resistant Chinese Hamster V511 cells that show minor alterations
in cell growth despite having drastic reductions in the total amount topo IIα protein in
both log growth and quiescence (Hashimoto et al., 1995). The expression of topo IIβ
remained constant and topo IIβ was presumed to compensate for topo IIα activity in the
V511 cells. This is supported by recent findings of HeLa cells transiently transfected
with topo IIα or topo IIβ siRNA, which demonstrated that topo IIβ can partially substitute
for topo IIα condensation and segregation in HeLa cells (Sakaguchi and Kikuchi, 2004).
These findings could explain why there was only a minimal change in S-phase population
of cells, but not a complete cessation of DNA replication. Western blot analysis of topo
IIα protein in the nuclear and cytoplasmic compartments of log and accelerated-plateau
H929 cells indicates that topo IIα was reduced by 25-50% (by densitometry) compared to
the log cells (Figure 32, page 146). Part of the topo IIα content appears to be degraded in
both the nuclear and cytoplasmic compartments and was attributed to experimental
artifacts. Topo IIα degradation was likely to occur during the shearing of the nucleus
from the cytoplasm as a similar degradation does not occur in the whole cells. Results of
the comet assay confirmed that seeding cells at plateau density for 16 hours protects them
from etoposide induced DNA damage and additional experiments demonstrated that
etoposide treatment resulted in less DNA damage because there are fewer protein-drugDNA complexes in the cells seeded at plateau density than log-phase cells. The data
establishes that the nuclear-cytoplasmic trafficking of topo IIα mediates cellular drug
resistance to topo inhibitors by reducing the amount of topo II in the nucleus and thus,
reduces the number of enzyme-drug-DNA complexes formed. A redistribution of a
199

population of topo IIα to the cytoplasmic compartment would have a similar effect as to
drug sensitivity as an overall decrease in topo IIα content, by decreasing the amount of
drug target in the nucleus. Furthermore, these results may partially explain the
hypersensitivity of accelerated-plateau cells to CDDP and γ-irradiation observed at 16 h.
As previously mentioned, drug sensitivity to DNA crosslinking agents is inversely
proportional to topo protein levels (Gornati, 1997; Barret et al., 1994). Although, the total
cellular amount of topo IIα is not reduced, a shift from the nucleus to the cytoplasm could
account for the observed drug sensitivity.
Several mechanisms of drug resistance to topo inhibitors have been defined in
vitro and include: (1) over expression of drug transport proteins (P-glycoprotein,
multidrug resistance-associated protein, lung resistance-related protein, or breast cancer
resistance protein), that result in either increased drug efflux or decreased drug uptake
(Shustik et al., 1995), (2) a cell-cycle-dependent decrease in the amount of topo II protein
(Sullivan et al., 1986, 1987), (3) the expression of a truncated protein that has lost its Cterminal nuclear localization signal such that it remains in the cytoplasm (Wessel et al.,
1997), and (4) mutations in the topo gene that result in an enzyme with altered catalytic
or cleavage activity (Matsumoto et al., 2001). The data presented here demonstrates a
fifth mechanism of drug resistance in vitro: (5) nucleocytoplasmic-trafficking of topo IIα
is a mechanism of de novo drug resistance to topo inhibitors in human multiple myeloma
cell lines (Engel and Turner et al., 2004; Engel et al., 2004; Valkov et al., 2000).
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14.6 Clinical Relevance.
The data establishes that a measurable difference in the nuclear and cytoplasmic
distribution of topo IIα, a chief molecular target of commonly used anti-cancer therapy,
occurs in human myeloma cell-lines at plateau densities. The nuclear content of topo IIα
is critical for topo targeting agents to be effective as cytotoxic agents because topo
cleavage activity is necessary for drug-induced DNA damage to occur. The data
presented here indicate that a cytoplasmic pool of topo IIα correlates with cellular drug
resistance to etoposide (Engel et al., 2004; Valkov et al., 2000). This is also supported by
evidence that multicell spheroids and xenograft tumor cells are protected from etoposidemediated DNA damage due to the cytoplasmic distribution of topo IIα (Oloumi et al.,
2000). These findings have potential clinical implications in the treatment of human
myeloma as immunohistochemistry demonstrated that topo IIα has a cytoplasmic
distribution in the malignant plasma cells obtained from the bone marrow aspirates of
some multiple myeloma patients (Figure 36 and 38).
The magnitude of cytoplasmic immunofluorescent staining of topo IIα was
significantly more pronounced in the malignant plasma cells found in the clinical
preparation than that observed in the human myeloma cells lines at plateau density.
Many of the tumor cells demonstrated complete nuclear clearing of topo IIα that was less
frequently observed in the cell lines. The plateau and accelerated-plateau cell models
showed a shift (decrease) in the nuclear: cytoplasmic ratio of topo IIα
immunofluorescence in most cells, rather than complete nuclear clearing (ratios below
1.0). The data suggest that other physiological conditions besides cell-cell contact are
involved in topo IIα trafficking that exist in the tumor microenvironment of the bone
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marrow. For example, the cell line models demonstrate a cytoplasmic distribution of
topo IIα de novo, but the cytoplasmic distribution observed in the clinical preparations
could be influenced by prior exposure to DNA damaging agents. Multiple myeloma is
characterized by karyotypic instability and many chromosomal aberrations are acquired
after exposure to DNA damaging agents (refer to Appendix C on page 269 for a summary
of hematological related chromosomal aberrations). The amount of chromosomal
aberrations correlates with disease stage and prognosis. It is possible that certain
chromosomes are susceptible to genetic translocations. For example, many chromosomal
gene translocations that are observed in hematological malignancies involve the
nucleoporins (Nup) (Arai et al., 2000, 1997; Nakamura et al., 1996; Boer et al., 1998). I
have summarized a list of gene mutations that have been described in nucleoporins (refer
to Table 8 on page 217 and all reference contained therein). Thus, exposure to various
chemotherapeutic agents could somehow disrupt the homeostasis of nucleo-cytoplasmic
protein trafficking. This is supported by evidence that multiple gene aberrations in
Nup98 occur in some hematological disorders. For example, Nup98 gene translocations
have been reported in treatment related AML and myelodysplastic syndrome (MDS).
Also, the chromosomal translocation t(11;20)(p15;q11) results in a Nup98/Topo I fusion
protein in de novo acute myeloid leukemia (AML) (Potenza et al., 2004; Iwase et al.,
2003; Chen et al., 2003). These observations establish that a significant modulation
occurs in topo I, which could theoretically alter topo enzyme stability, enzyme activity,
and subcellular distribution. Similar chromosomal translocations involving topo II have
not been found. Additional studies to analyze the subcellular distribution of topo II in
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untreated patients compared to treated or relapsed patients combined with cytogenetic
analysis are needed

14.7 Topoisomerase IIβ as an Alternative Molecular Target in Human Myeloma.
Another interpretation of the data is that topo IIβ could be an alternative
molecular target in the treatment of human multiple myeloma. It is well documented that
topo IIβ protein expression is rather constant over the cell cycle and less influenced by
cell-cycle changes than topo IIα. Western blot analysis demonstrated no reduction in the
total cellular content of topo IIβ in plateau-cells or accelerated-plateau phase cells when
compared to log-phase cells. Topo IIβ was detectable in both the nuclear and cytoplasmic
compartments of the plasma cell in clinical samples as well as, in the human myeloma
cells lines. However, there was no measurable difference or shift in the amount of topo
IIβ immunofluorescence detected in the cytoplasm at plateau density as compared to log
density. This suggests that the balance of topo IIβ nuclear import is influenced in the
same manner or by cell-cell contact as observed with topo IIα. Recently, microinjection
studies identified an NES in topo IIβ (Mirski et al., 2003) and the data presented here
demonstrates a possible shuttling of topo IIβ between the nucleus and cytoplasm. A
determination of whether leptomycin B can shift the nuclear:cytoplasmic ratio of IIβ
toward to the nucleus in plateau-phase cells could address the mechanism of topo IIβ
trafficking. Nevertheless, the data suggests the factors resulting in cytoplasmic
distribution of topo IIα in tumor cells do not alter topo IIβ net trafficking in the same
manner.
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Several new cytotoxic agents that are specific for topo IIβ are being investigated
for the effectiveness in the treatment of solid tumors that are refractory to topo II
containing therapy (Hazeldine et al., 2005, 2002; Barthelmes et al., 2001; Gao et al.,
1999) Many of these drugs are still in development and are derivatives of XK469, a
topoisomerase IIβ selective poison that is reaching phase I clinical trials (Gatto and Leo,
2003). Tumors with large populations of cells in the G0/G1 phase are believed to be more
sensitive to topo IIβ specific inhibitors because, unlike topo IIα, topo IIβ protein
expression is not cell-cycle dependent. Thus, the low proliferative index of malignant
plasma cells observed in multiple myeloma makes topo IIβ an attractive molecular target.
Furthermore, XK469 results in upregulation of the topo IIα protein (Mensah-Osman et
al., 2002). Based on these findings a plausible regimen for multiple myeloma patients
would contain a topo IIβ specific cytotoxic agent (ex. XK469) combined with a nuclear
export inhibitor (leptomycin B) followed by a topo II targeting cytotoxic agent (i.e...,
etoposide). Theoretically, the topo IIβ specific cytotoxic agent would induce cell death
via topo IIβ activity while also elevating the cellular content of topo IIα protein. A
nuclear export inhibitor would be necessary to inhibit the export of topo IIα from the
nucleus and thus, provide a molecular target in the nucleus for etoposide mediated DNA
damage to occur. This sequence could only be effective if topo IIα activity and levels
remained sufficient to induce DNA damage. Inhibitors of the proteasome represent a
new class of cytotoxic agents with promising results in the treatment of hematological
malignancies. A proteasome inhibitor may be useful for maintaining the total cellular
content of topo protein.
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Sequestering proteins in the nucleus is gaining acceptance as a potential
mechanism for inducing apoptosis in cancer cells (Yashiroda and Yoshida, 2003). One
recent study treated human chronic myelogenous leukemia cells with a tyrosine kinase
inhibitor (STI571) to induce the nuclear import of BCR-Abl, a chimeric oncoprotein that
activates mitogenic and anti-apoptotic cell signaling pathways when it is in the cytoplasm
of cells (Vigneri and Wang, 2001). The cells were then exposed to leptomycin B to block
the export of BCR-Abl into the cytoplasm, thus trapping the protein in the nucleus. A
general weakness of this drug combination is that leptomycin B inhibits all CRM-1
mediated nuclear protein trafficking, but in vitro the drug combination selectively killed
transformed cells expressing BCR-Abl chimera. Furthermore, a phase I clinical trial of
LMB demonstrated that the drug caused profound anorexia and malaise in patients
(Newlands et al., 1996). The clinical trials with LMB were discontinued but, the
discovery that CRM is the molecular target of LMB instigated new efforts to reevaluate
LMB for potential use in chemotherapy. Safer leptomycin B analogues are currently
being developed and investigated for their antitumor activity (Kau and Silver, 2003).
Further investigations into the mechanisms of topo trafficking are needed to develop
drugs specific for topo that may be less toxic in humans.

14.8 Nuclear Content of Topo IIα is a Determinate of Topo II Drug Cytotoxicity.
There has been one report to describe the role of the nuclear-cytoplasmic
trafficking of topo IIα in de novo drug resistance (Oloumi et al., 2000). The weight of
the data has been limited to measuring the total cellular content of topo protein found
either in drug-resistant cell lines (Mirski et al., 2000’ Davis et al., 1998; Kusumoto et al.,
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1996; Chen and Beck, 1995;) or in clinical specimens (Bauman et al., 1997). Traditional
practice has relied heavily on in vivo topo quantification as a prognostic indicator
(Schrader et al., 2004; Lohri et al., 1997). As such, there have been numerous reports to
describe a correlation between topo protein expression with a positive response to topo
inhibitors (Lohri et al., 1997; Kaufmann, et al., 1994). However, there is a growing
awareness in both scientific and clinical forums that monitoring the subcellular
distribution of topo is also important when predicting drug responsiveness (Oloumi et al.,
1993). This is supported by several reports unable to explain alterations in drug
sensitivity to topo targeting agents with alterations in either topo mRNA, topo protein
expression or activity, or P-gp expression (Yamazaki et al., 1997; Davis et al., 1998;
Yamazaki et al., 1997; Boege et al., 1993). For example, eight breast epithelial cell lines,
including six derived from breast cancers, were analyzed for mechanisms of drug
resistance to camptothecin and etoposide (Davis et al., 1998). Drug resistance to
camptothecin was attributed to low levels of topoisomerase I and activity. However, topo
II levels and activity did not correlate with drug sensitivity or resistance to etoposide.
These cells were analyzed for alterations in S-phase, doubling time, expression of mdr-1,
p53, Bcl-2 and Bax proteins, but none of these parameters correlated with drug resistance
to etoposide (Davis et al., 1998). Only one cell line (BT47 cells) exhibited a high bcl2/Bax ratio and mutant p53 protein that was believed to contribute to decreased
sensitivity to etoposide. The BT47 cells also displayed slow growth characteristics
similar to that observed in the human myeloma cell line models, but the subcellular
distribution of topo enzyme was not investigated in any of the cells explored. A shift
toward the cytoplasm in the nucleo-cytoplasmic shuttling of topo II could have similar
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effects as an overall decrease in protein levels, by decreasing the amount of active
enzyme in the nucleus. A similar study was performed that analyzed 14 unselected
human lung cancer cell lines, including small-cell lung cancer and non-small cell lung
cancer, for drug sensitivity to doxorubicin and etoposide, two topo II targeting agents
(Yamazaki et al., 1997). There was variation in drug sensitivity to etoposide and
doxorubicin in all cell lines, but neither topo IIα content nor enzyme activity correlated
with observed drug resistance. Other cellular parameters were not investigated, including
the subcellular distribution of topo IIα. This could be significant because a shift in the
subcellular distribution of topo IIα would not be detectable by Western blot of topo II
protein in whole cells. Furthermore, the observation of cytoplasmic topo IIα in patient
samples described here suggests that there is a clinical role for the nucleo-cytoplasmic
trafficking of topo that could explain de novo drug resistance previously described in
other tumor types. Thus, examining the nuclear and cytoplasmic content of topo protein
by immunocytochemistry, especially topo IIα, is an important factor to consider when
attempting to explain cellular drug resistance in the laboratory and clinical preparations.

14.9 Possible Roles of Cytoplasmic Topo II.
One of the potential consequences of exporting a pool of topo IIα to the
cytoplasm is a decrease in sensitivity to topo inhibitors. This could result from
cytoplasmic topo IIα serving as a drug sink by trapping VP-16 in this compartment. This
is supported by data demonstrating that the binding of VP-16 to topo II can occur in the
absence of DNA (Burden et al., 1996). For this to occur, the amount of drug binding to
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topo IIα would need to be sufficient to result in a decrease in drug- induced DNA
damage.
One question that has not been addressed is whether topo IIα is recruited to the
cytoplasm to perform a specific function. If topo II were acting on cytoplasmic
substrates, there are at least two theoretical possibilities. First, topo II could be involved
in maintaining the secondary structure of RNA or be involved in splicing RNA. To date,
there has been no direct evidence of topo II binding RNA. A second possibility is that
topo IIα could be recruited to the cytoplasm as an early apoptotic event. I have
hypothesized that a link exists between the calcium/calmodulin pathway and nuclearcytoplasmic trafficking of topoisomerase IIα during apoptosis in chapter 15, page 220..

14.10 Topoisomerase IIα Contains Two Functional Nuclear Export Signals.
One question that we addressed was whether the cytoplasmic distribution of topo
IIα was a result of increased nuclear export or decreased nuclear import. Identification of
the direction and mechanism of transport across the nuclear membrane could lead to a
better understanding of how to regulate the levels of active enzyme in the nucleus and
thus, sensitize cells to topo inhibitors. Human topo I (Mo et al., 2000), IIα (Mirski, et al.,
1999), and IIβ (Mirski, et al., 1999) have NLS that target them into the nucleus, but only
recently has the mechanism of nuclear-export of these proteins been investigated (Mirski
et al., 2003). Sumoylation followed by redistribution of topo I from the nucleoli to the
nucleoplasm in response to topotecan or camptothecin exposure has been reported (Mo et
al., 2002; Rallabhandi et al., 2002). The lack of data describing the shuttling of topo
enzymes may be because topo is usually reported to occur in the nucleus of cells and a
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cytoplasmic distribution of topo IIα has usually been ascribed to the expression of a
truncated protein that has lost its C-terminal NLS (Mirski, et al., 2000). However,
proteins that appear predominately nuclear may still shuttle between the nucleus and the
cytoplasm if the rate of nuclear import is greater than the rate of nuclear export. Thus,
demonstrating that a protein shuttles between the nucleus and cytoplasm requires
defining the specific conditions that will shift the steady state kinetics toward nuclear
export (Table 15). Many conditions have been shown in vitro to alter the shuttling of
proteins between the nucleus and cytoplasm, including changes in the cell-cycle and
oxidative stress (Miyamoto et al., 2004; Kodiha et al., 2004; Greber and Gerace, 1995). I
have created a list of molecular and biochemical agents that have been demonstrated to
alter specific transport pathways for different proteins. This table demonstrates that
certain cellular conditions or exogenous agents can induce a shift in the nuclearcytoplasmic trafficking of specific proteins. In the accelerated-plateau cell model used in
these experiments, it is likely that intensive cell-cell contact initiates a signal that induces
the export of topo IIα to the cytoplasm. This is supported by the findings of others that a
cytoplasmic distribution of topo IIα occurs in the outer-proliferating cells of multicell
spheroids in Xenograft tumors when compared to monolayers formed by the same cells
(Oloumi et al., 2000).
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Table 15. Inhibitors of the Nuclear-cytoplasmic Transport Pathway
Biochemical Agent or MolecularFactor
Target
N-Acetylglucosamine
Wheat germ aggultinin
moieties expressed on
(Duverger et al., 1995)
nucleoporins
Anti-FG repeat antibodies
Importins/Nucleoporins
(Snow et al., 1987)
Trichostatin A
NF-kB
(Chen et al., 2001)
Cyclosporin A
(Liu et al., 1991)
3, 5–Bistrifluoromethyl pyrazoles
(Trevillyan et al., 2001)
Leptomycin B
(Wolff et al., 1997)
Myxobacterial cytotoxins (Ratjadones)
(Koster et al., 2003)
Arylene bis(methylketone) compounds
(Dubrovsky et al., 1995)
Arginine-rich RNA molecules (ARM)
(Fineberg et al., 2003)
Transfected importin-β binding domain
(Kutay et al., 1997); importin-β P446L
mutant protein (Timinszky et al., 2002)
Cellular Stress: UV radiation
Oxidative stress
Heat shock
(Miyamoto et al., 2004; Kodiha et al.,
2004)

Cyclophilin, NFAT
NFAT
Chromosome region
maintenance protein 1 (Crm1)
Pre-integration complex
(PIC)
HIV-1 Rev
Importin-β

Mechanism
Non-specifically blocks protein
import by binding sugar moieties
on nucleoporins
Blocks importins from docking to
the NPC
Blocks NF-kB import
Blocks NFAT import;
cyclosporin-cyclophilin complex
binds calcinuerin and inhibits
dephosphorylation of NFAT
Blocks NFAT import
independently of calcinuerin
Blocks CRM1 mediated nuclear
export
Blocks import of HIV viral
genome
BSA molecules with ARM
peptides block HIV-1 Rev protein
import
Dominant negative competitive
inhibitor of importin α/β mediated
import

Ran gradient

Blocks nuclear export of
importin-α

Wortmannin
(Arcaro and Wymann, 1993)

Phosphatidylinositl-3 kinas
(PI3 kinase)

Blocks nuclear-cytoplasmic
trafficking regulated by PI3kinase
phosphorylation

Okadaic acid
Calyculin A
(Elrick and Docherty, 2001)

Phosphatase inhibitors

Blocks some phosphorylation
dependent trafficking. .

Peptide Aptamers
(Colas et al., 2000)

Peptide containing a NLS or
NES directed against any
protein; may also contain
ubiquitin.

Redirects protein to the nucleus
(NLS) or cytoplasm (NES);
modify any protein with
ubiquitin.

Ran gradient

Energy source for continued
nuclear-cytoplasmic shuttling.

Calcium pump inhibitor

Blocks signal-mediated protein
import

Energy Regenerating System and
Ran Mix
(Timinszky et al., 2002)
Thapsigargin
(Greber and Gerace, 1995)
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14.11 Nuclear Transport and Oncogenesis.
Alterations in nucleo-cytoplasmic protein transport are strongly implicated in a
number of human diseases that include several autoimmune disorders (Wesierska-Gadek
et al., 1996) and human cancers (Kau et al., 2004). The data presented in this
investigation describes a mechanism of drug resistance observed in human myeloma and
leukemia cell lines that involves alterations in the subcellular distribution of topo IIα.
The data presented herein suggests that alterations in the nuclear-cytoplasmic trafficking
of topo IIα may have a role in cellular drug resistance in human myeloma and leukemia
cell lines. Several genetic abberations in the nuclear-cytolasmic transport machinery
have been described in human leukemia and myeloma cells to date (Lam and Aplan,
2001). At least 17 chromosomal rearrangements in acute and chronic leukemia involve
nucleoporin genes (Table 16) (Cronshaw and Matunis, 2004). Nucleoporin 98 (Nup98) is
implicated in 15 of those chromosomal rearrangements (Slape and Aplan, 2004;
Takeshita, et al., 2004). Furthermore, chromosomal translocations involving Nup98 and
DNA topo I have been observed in some patients with therapy related acute myeloid
leukemia, and in one patient with de novo AML (Iwase et al., 2003; Chen et al., 2003).
Leukemias associated with nucleoporin gene rearrangements have been reported to be
more refractory to therapeutic intervention. (Kakazu et al., 2001) suggesting that these
gene rearrangements are involved in drug sensitivity. Nup98 gene rearrangements have
also been implicated in therapy related myelodysplasia (MDS) (Ahuja, et al., 1999), a
group of bone marrow disorders that resemble hematologic malignancies. MDS is
characterized by the clonal expansion of stem cells and is most prevalent in individuals
over 60 years of age. Nup gene rearrangements in multiple myeloma have not been
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reported. In addition to the Nup family of proteins, the major vault protein (MVP)
referred to as the lung resistance related protein (LRP), has been associated with
decreased sensitivity to chemotherapy in multiple myeloma. The MVP is a
ribonucleoprotein complex that localizes to the nuclear pore complexes (Chugani et al.,
1993). Results of a clinical study showed that expression of MVP in myeloma patients
was associated with the multidrug resistance phenotype not mediated by MDR-1/P-gp
(Rimsza et al., 1999). Collectively, these studies illustrate the underlying role of nucleocytoplasmic trafficking and the NPC in oncogenesis. Furthermore, the significance of
Nup98/topo I fusion proteins in conferring altered drug sensitivity represent one area of
research yet to be explored

212

Table 16. Nucleoporin (NUP) Gene Rearrangements Associated with Hematological Malignancies*
Nucleoporin Gene
Protein
FUSION GENE
Disease
References
Rearrangement
Characteristics
t(7;11)(p15;p15)

NUP98/HOXA9

Homeodomain
transcription factor

AML, CML,
MDS

Nakamura et al.,
1996

t(2;11)(q31;p15)

NUP98/HOXD13

Homeodomain
transcription factor

AML

Arai et al., 2000

t(1;11)(q23;p15)

NUP98/PMX1

Homeodomain
transcription factor

MDS/AML

Nakamura et al.,
1999

t(7;11)(p15;p15)

NUP98/HOXA11

Homeodomain
transcription factor

CML, AML

Suzuki et al., 2002

t(11;12(p15;q13)

NUP98/HOXC11

Homeodomain
transcription factor

AML

Gu et al., 2003

t(7;11)(p15;p15)

NUP98/HOXA13

Homeodomain
transcription factor

AML

Taketani et al.,
2002

t(2;11)(q31;p15)

NUP98/HOXD11

Homeodomain
transcription factor

AML

Terui et al., 2003

t(11;12)(p15;q13)

NUP98/HOXC13

Homeodomain
transcription factor

AML

Panagopoulos et
al., 2003

inv11(p15;q22)

NUP98/DDX10

RNA helicases

AML, MDS

Arai et al., 1997
Potenza et al.,
2004
Iwase et al., 2003
Chen et al., 2003

t(11;20)(p15;q11)

NUP98/TOP1

DNA topo I

de novo AML;
t-AML, tMDS;
polycethemia
vera

t(10;20;11)(q24;q11;p15)

NUP98/TOP1

DNA topo I

t-MDS

Panagopoulos et
al., 2002

t(4;11)(q21;p15)

NUP98/RAP1GDS1

Nucleotide
exchange factor

T-ALL

Hussey et al., 1999

t(10;11)(q25;p15)

NUP98/ADD3

Membranecytoskeleton

T-ALL

Lahortiga et al.,
2003

t(5;11)(q35;p15)

NUP98/NSD1

SET domain

AML

La Starza et al.,
2004

t(8;11)(p11.2;p15)

NUP98/NSD3

SET domain

AML

Rosati et al., 2002

t(6;9)(p23;q34)

NUP214/DEK

DNA binding

AML, MDS

Boer et al., 1998

t(6;9)(p23;q34)

NUP214/SET

Nucleosome
assembly protein
family

AML

Saito et al., 2004

*Reviewed in reference Lam and Aplan, 2001.
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Chapter Fifteen
Future Considerations

15.1 Phosphorylation
Phosphorylation has also been shown to be important in regulating the
subcellular localization of many proteins and could have a role in topo IIα trafficking
(Harreman et al., 2004). This is suggested by the finding that the outer proliferating cells
of multi-cell spheroids contain a cytoplasmic pool of topo IIα and have a 10-fold
decrease in the phosphorylation state of the enzyme when compared to monolayers
containing nuclear topo IIα (Oloumie et al., 2000). Phosphorylation has been extensively
investigated for yeast DNA topo IIα and to a lesser extent in topo IIβ. Phosphorylation
Table 17. Phosphorylation Sites in DNA Topoisomerase IIα Established In vitro
Kinase
PKC
Presumed to be
Casein Kinase 1 or 2

Residue

Reference

Serine 29

Wells et al., 1995

Serine 1106

Chikamori et al., 2003

Casein Kinase 2

Serine 1377
Serine 1525

Wells et al., 1994

Casein Kinase 2

Threonine 1343

Daum and Gorbsky, 1998
Ishida et al., 1996

Casein Kinase 2

Serine 1469

Escarguiel et al., 2000

Serine 1213
Serine 1247
Serine 1354
Serine 1361
Serine 1393

Wells and Hickson, 1995

One or more proline
directed kinases
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events in topo II in human cells is less well characterized (Austin and Marsh, 1998)
Several serine residues in topo IIα are phosphorylated in vitro by CK2 and PKC (Table
17). Many of the phosphorylation sites are located near the NLS in the carboxyl terminus
(Figure 52, page 192). For topo IIα, the phosphorylation status at S29, S1213, S1247,
S1354, S1361, S1393 vary throughout the cell cycle. In contrast, phosphorylation at
S1377, S1525, and T1343 remains constant throughout the cell cycle (Austin and Marsh,
1998). To predict additional protein kinase recognition motifs, the complete amino acid
sequence was entered into Scansite, a computer algorithm developed at Massachusetts
Institute of Technology. Scansite 2.0 uses a library of phosphorylation data to predict
phosphorylation sites and protein-protein binding domains in any protein (Obenauer et
al., 2003).

Table 18. Predicted Phosphorylation Sites in DNA Topoisomerase IIα
Kinase Group

Amino Acid Residue

Recognition Sequence

Src SH3

Proline 887

MDGEEPLPMLPSYKN

Protein kinase C

Serine 1426

TAAKSQSSTSTTGAK

Protein kinase C

Threonine 193

YKKMFKQTWMDNMGR

Calmodulin dependent kinase IIγ

Serine 230

LSKFKMQSLDKDIVA

Calmodulin dependent kinase IIγ

Threonine1279

TKTKKQTTLAFKPIK

Casein kinase 2

Serine 1337

LDSDEDFSDFDEKTD

Casein kinase 2

Serine 1106

DEEENEESDNEKETE
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The computer program can recognize 62 protein kinase or protein binding motifs that
includes Ser/Thr or Tyr kinases and SH2 and SH3 binding domains. Figure 32 is the
graphical output showing predicted phosphorylation sites that have not been reported in
the literature. Table 18 summarizes the protein kinase recognition sequences identified
under high stringency. As expected, topo IIα has recognition motifs for protein kinase C,
casein kinase 2 and proline dependent Ser/Thr kinases. Several in vitro studies have
reported similar phosphorylation occurrences by these kinases, albeit different amino acid
residues

15.2 Calmodulin Dependent Kinases
Calmodulin dependent kinase-IIγ (CaMK-IIγ) is one unexpected result in the
Scansite report. CamK-IIγ belongs to the family of calmodulin dependent kinases
(CaMK). Calmodulin is a cytosolic protein that responds to intracellular calcium levels
by activating various calcium-calmodulin dependent enzymes, such as calmodulin
dependent kinases (CaMK) (Tombes et al., 1995). There are six different CaM kinases
but, only CaMK I and CaMK II are consistently expressed in proliferative cells (Tombes
and Krystal, 1997). CaMK II was originally believed to be encoded by a single gene.
For example, CaMK-IIγ has for different isozymes, IIγB, IIγC, IIγG, and IIγH, generated
by alternative splice sites. In one study, panels of human tumor and non-tumor cell lines
were examined for expression of all CaMK-II protein isoforms (Tombes and Krystal,
1997). The tumor cell lines included several human breast cancer cell lines, colon
adenocarcinoma, human neuroblastoma, and CCRF-CEM lymphoblastic leukemia cells,
whereas NIH 3T3 mouse fibroblasts, mammary epithelia, and mouse embryo fibroblasts
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were the non transformed cell lines examined. The tumor cell lines expressed an entirely
different spectrum of CaMK-II isozymes than adult neuronal tissue. All tumor cell lines
(including the neural derived cells) lacked CamK-IIα and expressed several alternative
splice variants. CaMK- IIγG and IIγH were preferentially expressed in tumor cell lines
as compared to undifferentiated fibroblasts. This data establishes that CaMK-IIγ is
expressed in a variety of human cancer cell lines, including the hematological cell line,
CCRF-CEM. Thus, it is possible that CaMK-IIγ is expressed in other hematological cell
lines such as, human myeloma H929 cells. Expression of CaMK-IIγ in H929 cells would
be significant if, topo IIα is regulated by CaMK-IIγ phosphorylation.
Identification of a CaMK phosphorylation site in topo IIα could be significant
factor in regulating topo IIα subcellular distribution for several reasons. First, topo IIα
has been shown to be hypophosphorylated in drug resistant cell lines in a calcium
dependent manner (Grabowski et al., 1998; Aoyama et al., 1998; Ganapathi et al., 1996).
Secondly, the complete amino acid sequence for topo IIβ was entered into Scansite but,
does not have a calmodulin dependent kinase recognition motif even when the protein
was scanned under low stringency. This is significant because topo IIβ subcellular
localization is not altered by cell-density in the same manner as topo IIα suggesting that
different cellular conditions can regulate the differential localization of the two enzymes.
Thirdly, calcium levels present in the ER cisternae have been reported to regulate
nuclear-cytoplasmic trafficking of proteins such that, when calcium levels are low, the
NPC restricts the nuclear cytoplasmic trafficking of proteins (Greber and Gerace, 1995).
It has been suggested that calcium stores signal the NPC when the cell senses stress such
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as, oxidative stress, DNA damage, or proteins unfolding in the ER. Thus, there could be
a link between NPC trafficking and early apoptotic events.
There is increasing evidence that calcium signaling pathways are intimately
involved with apoptotic regulatory pathways. BCL-2, Bax, Bak, and Bid are apoptotic
regulatory proteins that exert their effect in part by regulating calcium mobilization
between the ER and mitochondria. Bax, Bid, and Bcl-2 localize in the ER, the central
intracellular calcium stores of the cells. BCL-2 mediates the release of ER calcium pools,
which results in a concomitant increase in mitochondrial calcium uptake (Oakes et al.,
2003; Foyouzi-Youssefi et al., 2000). Bax and Bak, promote apoptosis in part by
increasing calcium transfer from the ER to the mitochondria, which results in cytochrome
c release during apoptosis (Nutt et al., 2002). Bax and Bid have also been shown to
localize on the nuclear envelope and move from the cytoplasm to the mitochondria in
response to camptothecin exposure (Gajkowska et al., 2004). This data suggests that
camptothecin may initiate apoptosis in a via Bax and Bid in a calcium dependent manner.
Calcium release from the ER may be linked with oxidative stress, which has been
one physiological condition demonstrated to modulate NPC mediated protein trafficking.
This is significant because the tumor microenvironment can contribute to hypoxia. For
example, solid tumors that are resistant to topo II containing chemotherapy usually have
regions of low oxygen, which are not observed in normal tissue (Tomida and Tsuruo,
1999). Although multiple myeloma is not considered a solid tumor, the disease is
characterized by anemia, which has been shown to induce or hasten hypoxia (Sordet et
al., 2004; Mittelma, 2003). Furthermore, when Bid is expressed in hypoxic cells, it
results in increased sensitivity to the topoisomerase II inhibitor etoposide (Erler et al.,
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2004). Downregulation of Bid was attributed to the decrease sensitivity to etoposide;
however, the subcellular localization of topo II enzymes was not investigated. Likewise,
the total amount of Bcl2, Bid and Bax were not investigated in the natural-plateau or
accelerated-plateau human myeloma cell line models. Thus, topo IIα could be regulated
by calmodulin dependent kinase activity such that, when calcium is released from the ER
under conditions of stress, topo becomes phosphorylated and degraded. In another study,
proteasomes were found to accumulate in the nucleus of cells grown under stress
conditions (glucose starvation) (Ogiso et al., 2002). This could partially explain how
tumor cells evade etoposide toxicity and yet, maintain topo II content for cell division- by
sequestering topo IIα in the cytoplasm away from the nuclear proteasomes.
Furthermore, repetitive hypoxia, which could be prevalent in multiple myeloma patients
who are chronically exposed to DNA damaging agents, could select for drug resistant
cells (Weinmann et al., 2004).
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Chapter Sixteen
Concluding Remarks

Resistance to chemotherapeutic drugs is a major obstacle in the treatment of
leukemia and myeloma. We have reported that resistance to topo IIα poisons, such as VP16 is found to increase dramatically with concurrent increases in cell density. The highcell density of myeloma cells in the bone marrow may mimic the high-density plateau
phase conditions that we established in vitro, and thus these cells may export
endogenous topo IIα. from the nucleus to the cytoplasm in vivo. In order for topo targeted
chemotherapy to function, topoisomerase must have access to the nuclear DNA. Thus,
the nuclear export of topo IIα must be added to the list of potential mechanisms of
resistance to topo poisons. It is unique in that it does not require drug exposure and may
mimic the high cell density microenvironment seen in the bone marrow of patients with
multiple myeloma. Further defining this mechanism, and possibly modulating export,
may lead to methods to preclude this avenue of resistance. Clinical drug resistance is
likely to be a multifactorial phenomeon and enhancing drug activity of available agents
will likely require a multifaceted approach.
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Appendix A: The Complete Amino Acid Sequence for Human DNA Topoisomerase I
1 MSGDHLHNDS QIEADFRLND SHKHKDKHKD REHRHKEHKK EKDREKSKHS NSEHKDSEKK
61 HKEKEKTKHK DGSSEKHKDK HKDRDKEKRK EEKVRASGDA KIKKEKENGF SSPPQIKDEP
121 EDDGYFVPPK EDIKPLKRPR DEDDADYKPK KIKTEDTKKE KKRKLEEEED GKLKKPKNKD
181 KDKKVPEPDN KKKKPKKEEE QKWKWWEEER YPEGIKWKFL EHKGPVFAPP YEPLPENVKF
241 YYDGKVMKLS PKAEEVATFF AKMLDHEYTT KEIFRKNFFK DWRKEMTNEE KNIITNLSKC
301 DFTQMSQYFK AQTEARKQMS KEEKLKIKEE NEKLLKEYGF CIMDNHKERI ANFKIEPPGL
361 FRGRGNHPKM GMLKRRIMPE DIIINCSKDA KVPSPPPGHK WKEVRHDNKV TWLVSWTENI
421 QGSIKYIMLN PSSRIKGEKD WQKYETARRL KKCVDKIRNQ YREDWKSKEM KVRQRAVALY
481 FIDKLALRAG NEKEEGETAD TVGCCSLRVE HINLHPELDG QEYVVEFDFL GKDSIRYYNK
541 VPVEKRVFKN LQLFMENKQP EDDLFDRLNT GILNKHLQDL MEGLTAKVFR TYNASITLQQ
601 QLKELTAPDE NIPAKILSYN RANRAVAILC NHQRAPPKTF EKSMMNLQTK IDAKKEQLAD
661 ARRDLKSAKA DAKVMKDAKT KKVVESKKKA VQRLEEQLMK LEVQATDREE NKQIALGTSK
721 LNYLDPRITV AWCKKWGVPI EKIYNKTQRE KFAWAIDMAD EDYEF

Figure 54. The Complete Amino Acid Sequence for Human DNA Topoisomerase I.
(accession number NP 001059). The NLS is underlined.
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Appendix B: The Complete Amino Acid Sequence for Human DNA Topoisomerase IIβ
1 MAKSGGCGAG AGVGGGNGAL TWVNNAAKKE ESETANKNDS SKKLSVERVY QKKTQLEHIL
61 LRPDTYIGSV EPLTQFMWVY DEDVGMNCRE VTFVPGLYKI FDEILVNAAD NKQRDKNMTC
121 IKVSIDPESN IISIWNNGKG IPVVEHKVEK VYVPALIFGQ LLTSSNYDDD EKKVTGGRNG
181 YGAKLCNIFS TKFTVETACK EYKHSFKQTW MNNMMKTSEA KIKHFDGEDY TCITFQPDLS
241 KFKMEKLDKD IVALMTRRAY DLAGSCRGVK VMFNGKKLPV NGFRSYVDLY VKDKLDETGV
301 ALKVIHELAN ERWDVCLTLS EKGFQQISFV NSIATTKGGR HVDYVVDQVV GKLIEVVKKK
361 NKAGVSVKPF QVKNHIWVFI NCLIENPTFD SQTKENMTLQ PKSFGSKCQL SEKFFKAASN
421 CGIVESILNW VKFKAQTQLN KKCSSVKYSK IKGIPKLDDA NDAGGKHSLE CTLILTEGDS
481 AKSLAVSGLG VIGRDRYGVF PLRGKILNVR EASHKQIMEN AEINNIIKIV GLQYKKSYDD
541 AESLKTLRYG KIMIMTDQDQ DGSHIKGLLI NFIHHNWPSL LKHGFLEEFI TPIVKASKNK
601 QELSFYSIPE FDEWKKHIEN QKAWKIKYYK GLGTSTAKEA KEYFADMERH RILFRYAGPE
661 DDAAITLAFS KKKIDDRKEW LTNFMEDRRQ RRLHGLPEQF LYGTATKHLT YNDFINKELI
721 LFSNSDNERS IPSLVDGFKP GQRKVLFTCF KRNDKREVKV AQLAGSVAEM SAYHHGEQAL
781 MMTIVNLAQN FVGSNNINLL QPIGQFGTRL HGGKDAASPR YIFTMLSTLA RLLFPAVDDN
841 LLKFLYDDNQ RVEPEWYIPI IPMVLINGAE GIGTGWACKL PNYDAREIVN NVRRMLDGLD
901 PHPMLPNYKN FKGTIQELGQ NQYAVSGEIF VVDRNTVEIT ELPVRTWTQV YKEQVLEPML
961 NGTDKTPALI SDYKEYHTDT TVKFVVKMTE EKLAQAEAAG LHKVFKLQTT LTCNSMVLFD
1021 HMGCLKKYET VQDILKEFFD LRLSYYGLRK EWLVGMLGAE STKLNNQARF ILEKIQGKIT
1081 IENRSKKDLI QMLVQRGYES DPVKAWKEAQ EKAAEEDETQ NQHDDSSSDS GTPSGPDFNY
1141 ILNMSLWSLT KEKVEELIKQ RDAKGREVND LKRKSPSDLW KEDLAAFVEE LDKVESQERE
1201 DVLAGMSGKA IKGKVGKPKV KKLQLEETMP SPYGRRIIPE ITAMKADASK KLLKKKKGDL
1261 DTAAVKVEFD EEFSGAPVEG AGEEALTPSV PINKGPKPKR EKKEPGTRVR KTPTSSGKPS
1321 AKKVKKRNPW SDDESKSESD LEETEPVVIP RDSLLRRAAA ERPKYTFDFS EEEDDDADDD
1381 DDDNNDLEEL KVKASPITND GEDEFVPSDG LDKDEYTFSP GKSKATPEKS LHDKKSQDFG
1441 NLFSFPSYSQ KSEDDSAKFD SNEEDSASVF SPSFGLKQTD KVPSKTVAAK KGKPSSDTVP
1501 KPKRAPKQKK VVEAVNSDSD SEFGIPKKTT TPKGKGRGAK KRKASGSENE GDYNPGRKTS
1561 KTTSKKPKKT SFDQDSDVDI FPSDFPTEPP SLPRTGRARK EVKYFAESDE EEDDVDFAMF
1621 N

Figure 55. The Complete Amino Acid Sequence for Human DNA Topoisomerase IIβ
(accession Number NP 001059). Nuclear export signal (NES) is double-underscored. A
specific nuclear localization signal has not been identified in topo IIβ, but the C-terminus
is important for targeting the enzyme to the nucleus (Mirski e al., 2003).
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Appendix C: Gene Rearrangements in Hematological Malignancies
Table 19.Oncogenes and Fusion Proteins in Hematological Malignacies*
Oncogene

Symbol

Abelson Murine Leukemia
Viral Oncogene Homolog 1

ABL1

Acute Myeloid Leukemia-1

AML-1

Acute Myeloid Leukemia-1 /
Myeloid Translocation Gene 8

AML1/MTG8

Receptor Tyrosine Kinase

AXL

Receptor tyrosine kinase.

B-cell CLL / Lymphoma 2

BCL2

B-cell leukemia/lymphoma protein is localized
in the inner mitochondrial membrane. Blocks
programmed cell death.

Breakpoint Cluster Region

BCR

GTPase activating protein for RAC1 and
CDC42; exhibits serine/threonine kinase
activity

Breakpoint Cluster Region /
Abelson Murine Leukemia
Viral Oncogene Homolog 1

Functional Product
A nuclear and cytoplasmic non-receptor
tyrosine kinase activity implicated in cell
differentiation, cell division, and cell adhesion.
Transcription factor (activator) for various
hematopoietic specific genes. Expressed during
differentiation and hematopoesis.
Fusion protein as a result of t(8;21). Proposed
role in preventing cell differentiation and thus,
propagating leukemic blast cells

Fusion protein with constitutive tyrosine kinas
activity as a result of 9:22 chromosomal
translocation.
Important for cell cycle regulation;
Cyclin D1
CCND1
Dysregulation of cyclin D1 associated with
t(11;14)
*Huret, J.-L. et al., 2003. Atlas of Genetics and Cytogenetics in Oncology and Haematology. [online]
http://www.infobiogen.fr/services/chromcancer/ (accessed 2004).
BCR/ABL
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Diseases
When expressed as Philadelphia
translocation its activity is
associated with CML
Associated with acute nonlymphocytic leukemia.
Associated with de novo acute
myeloid leukemias
Hematopoietic cancers
Associated with leukemias;
linked with follicular lymphoma
when overexpressed as a result
of the t(14;18) translocation.
Translocations t(9;22) BCRABL and
t(4;22) PDGFRA-BCR
associated with CML
CML, ALL
Multiple myeloma

Appendix C: (Continued)
Table 19 continued.
DEK Oncogene / Nucleoporin
214D

DEK/CAN

DEK is ubiquitous protein expressed in the
nucleus of cells and interacts with histones.;
fusion protein formed as a result of t(6;9)
translocation.
Chimeric transcription factor (activator)
resulting from t(1;19) chromosomal
translocation.
Transcription factor involved in extracellular
matrix remodeling; cell migration; tumor
invasion

Associated with poor prognosis
in AML.

Transcription Factor 3 / pre-Bcell leukemia transcription
factor 1

E2a/Pbx1

Erythroblastosis Virus E26
Homolog

ETS-1

Fibroblast Growth Factor 3

FGFR3

Receptor for acidic and basic fibroblast growth
factors.

Homeobox-11

HOX-11

Homeobox protein; DNA binding protein

Interluekin-3

IL-3

Cytokine involved in cell survival, proliferation,
and differentiation.

Lymphoid Blast Crisis

LBC

guanine nucleotide exchange factor

Myeloid leukemias

Lymphocyte Specific Kinase

LCK

src family tyrosine kinase critical for T-cell
development and activation

T-cell lymphoma
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pre-B-cell Acute Lymphoblastic
Leukemia
Lymphomas
Monocytic leukemia
Chromosomal translocation
t(4;14) implicated in multiple
myeloma
Found to be deregulated in acute
lymphoblastic T-cell leukemia
Overexpression of protein
associated with acute pre B-cell
leukemia

Appendix C (Continued)
Table 19 continued.
Lymphoblastic Leukemia
Derived Sequence 1

Lyl-1

Basic helix-loop-helix protein.

Involved in T-cell ALL through
t(7:19) which involves Lyl-1 and
T-cell receptor beta chain genes.

Mixed Lineage Leukemia

MLL

Transcription factor involved in maintenance of
HOX gene expression by hematopoietic stem
and progenitor cells

Associated with poor prognosis
in acute myeloid leukemia

Fusion protein resulting from t(4;11)
translocation.

70-80% of all ALL and 50-60%
of AML infants; Reported in
secondary leukemias after topo II
inhibitors; poor prognosis

Mixed Lineage Leukemia /
Lymphoid Nuclear Protein 4
Musculoaponeurotic
Fibrosarcoma
Myeloblastosis

Myeloctyomatosis
Myosin, heavy polypeptide 11,
smooth muscle / Core-binding
factor beta subunit

MLL/LAF4

MAF
Myb

c-Myc

MYH11/CBFB

Transcription factor; overexpression implicated
in cell proliferation and pathological
interactions with bone marrow stroma.
A family of DNA binding proteins containing
tandem repeats of a helix-turn-helix motif.
Expression in hematopoietic cells is necessary
fo proliferation.
Transcription factor involved in cell cycle
regulation, apoptosis, metabolism, cell
differentiation, and cell adhesion.

Multiple myeloma
Chromosomal aberrations at the
6q breakpoint linked with colon
carcinoma, leukemias, and
lymphomas
Overexpressed in most
hematogenic malignancies. Most
well characterized in Burkitts
lymphoma.

CBFB is a transcription factor which masterregulates a host of genes specific to hemtopoesis
Acute Myeloid Leukemia
and osteogenesis. Pericentric inversion
Inv(16)(p13;q22) fuses CBFB with MYH11
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Appendix C (Continued)
Table 19 continued.
Nucleophosmin1 /
Anaplasticlymphoma kinase

NPM/ALK

pre-B cell Leukemia
Transcription Factor 3

Pbx1/E2A

PIM1 Oncogene

PIM-1

Promyelocytic Leukemia /
Retinoic Acid Receptor alpha

PML/RAR

Reticuloendotheliosis

REL

Suppressor of variegation,
Enhancer of zeste and Trithroax
/ Nucleoporin 214

SET/CAN

Stem Cell Leukemia

SCL

Transforming Acidic Coiledcoil Containing Gene 3

TACC3

ALK is a receptor tyrosine kinase; The t(2;5)
translocation results in a fusion protein with
NPM; accumulates in the nucleoli of neoplastic
cells.
fusion protein that activates WNT-16
expression. WNT-16 expression contributes to
t(1;19) pre-B ALL
serine/threonine kinase
PML is a RING finger and nuclear matrix
associated phosphoprotein. Functions in growth,
transformation and tumor suppressor activity.
Fusion with RAR may abrogate the corepressor
function.
Transcription factor; role in differentiation and
lymphopoiesis.
CAN is a nucleoporin that may serve as a
docking site in receptor mediated nuclear
import; Fusion protein resulting from t(6;9)
translocation.
Transcription factor; t(1:14) in leukemia cell
lines results in deletion between delta chain
diversity regions
Centrosomal proteins that can interact with
microtubules.
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Non-Hodgkin’s lymphomas;
Anaplastic lymphoma; Large cell
lymphomas
Acute pre B-cell leukemia
T-cell lymphoma

Acute premyelocytic leukemia
Gene amplification associated
with Hodgkin’s lymphoma
Acute myeloid leukemia

Acute T-cell leukemia
t(4;14) implicated in Multiple
myeloma.
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